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Abstract
The thesis describes experimental work undertaken to develop novel avian 
pneumovirus (APV) ELISAs using subtype A recombinant viral proteins as 
antigen. It also investigates regions within the fusion protein (F) that may be 
important in the protective immune response to the virus.
Some potentially antigenic APV proteins, namely the F protein, the nucleocapsid 
protein (N) and the phosphoprotein (P) were selected for expression in E.coli and 
baculovirus systems. In addition to APV proteins the green fluorescent protein 
(GFP) was used as a direct visual reporter of expression. Initially an in house 
expression vector (p18smahis) was developed for use in E.coli and although 
cloning of selected genes into this vector was successful overall expression of 
them was low. Expression of these proteins and new GFP-APV fusion proteins 
was significantly improved when a commercial E.coli expression vector p-ET30 
was used in replacement for p18smahis. Purification of these proteins was 
through Ni2+ capture of designed 6 x his tag regions placed at either or both the 
N and C terminal of each protein. Only GFP was successfully purified as native 
protein although, purification of native N and P was successful after the proteins 
had been linearised using 8M urea. This highlighted problems with concealment 
of his tag regions within the proteins themselves which rendered them 
inaccessible for capture. In addition, GFP-APV fusion proteins indicated 
problems with toxicity as E.coli cells expressing them appeared to lose structural 
integrity as early as 1 hour post induction. As a result six regions of the F gene 
were individually cloned into the same expression vector. Hydrophobic regions 
were excluded in the design of these new sections in the attempt to eliminate 
toxic effects and reduce size of proteins to minimize concealment issues. Each 
new F section was expressed as a his tagged recombinant protein. These were 
detected using an anti his tag monoclonal antibody. Five of the six F sections 
consistently produced higher absorbance readings with subtype A, B and C APV- 
positive antisera and lower readings with specific pathogen free (SPF) serum 
from 12 week old chickens, when compared with a Liverpool-developed whole 
virus antigen ELISA. Tests suggest that subtype A F antigens 1 -  5 (amino acids 
25-70, 77-96, 146-199, 211-310 and 336-479 respectively) and in particular 4 F 
protein are strong universal antigen candidates for APV ELISAs.
In addition to their use in ELISAs, a study of F protein fragments enabled the 
identification of two regions targeted by neutralizing antibodies, one of which is 
also within an equivalent region identified for respiratory syncytial virus (RSV) F 
protein, suggesting that the equivalent regions of the F proteins in the two related 
viruses share similar functions.
A baculovirus expression system was also used to express a region of the F 
protein and GFP. In accordance with E.coli expressed proteins these were 6 x 
his tagged for purification. Generation of plaque purified F2 and GFP 
recombinant baculovirus was successful and a good level of expression was 
observed, as was best demonstrated by GFP using ultraviolet (UV) microscopy. 
However, F2 protein could only be purified from insoluble material. Unfortunately 
this made it unsuitable as an ELISA antigen due to destruction of its 
conformational epitopes.
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Diagnostic techniques used to identify the causal agents of economically 
important virus diseases of domestic poultry need to be rapid, sensitive and 
specific so that appropriate methods of control can be implemented. There is a 
wide range of tests available to detect viral antigens such as immunofluorescent 
staining, virus isolation and the polymerase chain reaction (PCR).
For detection of specific antibodies in serum enzyme-linked immunosorbent 
assays (ELISAs) are the method of choice, since these tests are rapid, specific, 
require only small volumes of serum and are able to process many samples at 
the same time. Most are also commercially available. The sensitivity and 
specificity of these tests are continuously under scrutiny. Traditionally most 
ELISAs use antigens prepared from virus-infected cell cultures and these 
generally work well, but have some disadvantages. These assays require virus 
that can easily be cultured in vitro and this can sometimes make it difficult to 
respond quickly to the emergence of new field strains. Furthermore, preparation 
methods of the whole virus often contain unwanted cellular proteins, which can 
lead to non-specific binding, which in turn reduces the specificity of the test.
Novel ELISAs have been developed to combat this, and one approach has been 
to use recombinant proteins [1-8] This enables the expression of individual 
epitopes that may be group or subtype-specific. Each of these authors reported 
increased or equal sensitivity and specificity of recombinant ELISAs with 
conventional ELISAs. Furthermore Chen et al. [8] highlighted some important
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advantages of using recombinant proteins over whole virus-infected cell extracts 
as antigen. These include safety (being non infectious) and having the potential 
to be modified rapidly in respond to new viral strains
The present study has been concentrated around avian pneumovirus (APV), 
initially named turkey rhinotracheitis virus (TRTV). Turkey rhinotracheitis was 
first described in South Africa in 1978 [9] and was later detected in Europe [10]. 
Here, the virus was isolated and identified as the primary agent [11-13] then 
characterized as a pneumovirus [14-16], APV is now known to exist in four 
subtypes A, B, C and D. This virus has been the major respiratory pathogen of 
turkeys in several countries for the last 20 years. Although its role as a primary 
pathogen in chickens is not clearly defined, it is known to be involved in 
respiratory disease. [17-19]. The initial viral infection is often complicated by 
secondary bacterial infections, which results in high morbidity and variable 
mortality [20]. In turkey hens, APV infection can induce reductions in egg 
production, and infection of birds of any age can result in serious economic 
losses [21, 22],
Initially the detection of APV was through immunofluorescent staining of infected 
material and isolation techniques, of which the most commonly used was tracheal 
organ culture (TOC). However, advances in molecular techniques have allowed 
faster detection of viral particles through the development of reverse 
transcriptase polymerase chain reactions (RT-PCR). Although RT-PCRs allow 
rapid detection they require careful handling and expertise as their high sensitivity 
means that contamination with extraneous DNA is a consistent threat. In some 
cases it is necessary to use all the available detection methods.
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Virus neutralization and indirect fluorescent assays were the initial methods used 
for detecting APV antibodies, however progress in culturing APV lead to 
developments in ELISA assays with more efficient and rapid detections of 
antibodies. These assays are now the method of choice for antibody detection 
although for reasons outlined above improvements are required.
1.2 Aim
It has been shown that ELISAs which use an empirical sub-type A antigen do not 
detect antibodies to sub-type B with the same sensitivity, and vice versa [23], 
Thus the use of a heterologous antigen in an ELISA may lead to false negatives, 
which, in turn could be interpreted as apparent vaccine failure or as absence of 
APV infection. By using individual APV viral proteins as antigen it may be 
possible to detect antibodies to epitopes that are equally sensitive across 
subtypes or be subtype-specific. Our approach has been to attempt to express 
important viral genes of subtype A APV encoding the fusion protein (F), the 
nucleocapsid protein (N) and the phosphoprotein (P), in both prokaryotic and 
eukaryotic systems, namely E.coli and insect cells respectively. These 
recombinant proteins have been purified using nickel column purification. 
Purified proteins were tested both for suitability as candidate antigens against a 
range of APV antisera and to investigate regions within individual proteins 
important in the protective immune response.
In addition to APV genes, a gene encoding the green fluorescent protein (GFP) of 
the pacific jellyfish Aequorea victoria was expressed. This protein was invaluable 
in both prokaryotic and eukaryotic systems when evaluating the steps throughout
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expression and purification, as its inherent fluorescence allowed simple 













(i) + (ii) Attachment and penetration
(iii) Transcription
(iv) Replication






2.3.4 Effects of age and breed
2.3.5 Pathogenesis




(i) Humoral immune responses
(ii) Maternal antibodies
(iii) Local immune responses








(i) Isolation and demonstration of viral antigen




2.6 Expression and use of recombinant viral proteins 36
2.6.1 Recombinant proteins in vaccine development
2.6.2 Protein folding, transcription and replication
2.6.3 Characterization of monoclonal antibodies and studies 
on immunity
2.6.4 Applications in ELISA development
2.7 Control







Avian pneumovirus (APV) initially named turkey rhinotracheitis virus (TRT) is 
recognised as a major respiratory pathogen of turkeys and chickens around the 
world. In chickens, the role of the virus as a primary pathogen is less clearly 
defined as in the turkey, although it is commonly, but not always associated with 
swollen head syndrome (SHS) in broiler breeders [24], The disease was first 
described in turkeys in South Africa in 1978 [9] and was later detected in 
Western Europe [10], Here, the virus was isolated and identified as the primary 
agent [11-13] and subsequently characterized as a pneumovirus [14-16]. It has 
now been classified in the new genus Metapneumovirus based on the absence of 
two genes found in pneumoviruses proper that code for non-structural proteins 
NS1 and NS2 [25, 26], The avian viruses were the only members of this new 
genus until studies in Holland showed that metapnumoviruses exist in humans 
and had been present for at least 50 years [27].
There are different sub-types of APV. A and B are present in Western Europe 
and most other countries around the world with sub-type C only present in the 
USA and to a limited degree in France. Furthermore there has been a recent 
report from France of an APV strain isolated from turkeys that is genetically 
different from A, B and C, this is referred to as subtype D [28]. Varying degrees 
of nucleotide and amino acid (aa) sequence heterology exist between these 
subtypes and these can be used for differentiation. Serological differences not 
seen between subtypes A and B have now been demonstrated for subtype C
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through the use of monospecific antisera and monoclonal antibodies (MAbs) in 
neutralization tests. It has therefore been suggested that this virus could 
represent the first isolate of a second serotype of APV. [29].
There have been reports of APV infection in species other than the turkey and 
the chicken some of which have been incriminated in the spread of infection such 
as wild or feral birds [30] [31]. However conflicting reports about APV infection of 
wild birds could suggest that they are susceptible to APV infection but may not 
play a role in transmission of infection. This notion is supported by the apparent 
absence of APV in Australia [32] which receives migratory birds from countries 
infected with APV in South East Asia and by the absence of subtype C in Central 
and South America although it is present in North America which shares 
migratory routes. The reverse applies when considering the absence of subtype 
A and B in North America.
2.2 The Virus
2.2.1 Taxonomy
Based on the morphology of viral particles, polypeptide analysis, RNA 
sequencing and mRNA analysis, APV has been placed in the family 
Paramyoxoviridae, genus Metapneumovirus in which it is now the type species 
[13-16, 25, 26, 33]. APV was initially grouped in the genus Pneumovirus 
because of its close genetic homology with human and bovine respiratory 
syncytial viruses (hRSV and bRSV respectively) as well as other mammalian 
pneumoviruses. However it has now been moved to the new genus
Metapneumovirus together with human metapneumovirus (HMPV) based on the
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différences in gene order after the M gene and on the absence of two genes that 
code for the non-structural proteins NS1 and NS2 [25, 26] (Figure 1)
3’ N P M F M2SH G L 5’ APV
3’ NS N P M SH G F M2 L 5’ RSV
1 2
Figure 1. Comparison of genes and gene order between Metapneumovirus APV and 
Pneumovirus RSV both of which belong to the family Pneumoviridae.
2.2.2 Morphology
Studies of APV by negative staining electron microscopy (EM) show the virus in 
pleomorphic, often bizarre shapes that are enveloped and covered with a fringe 
of projections approximately 15 nanometre (nm) in length (Figure 2). The virus 
particles have a size range of 50nm to more than 200nm in diameter and 
although these are often spherical they can exist in long filamentous forms of 
over 1000nm in length. The helical nucleocapsid which contains the viral 
genome is 14nm in diameter with a 7nm pitch [10, 11, 13, 14, 33-36].
Figure 2. Electron micrograph of negatively stained APV, showing 
its pleomorphic nature and surface projections (R. C. Jones)
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2.2.3 Physiochemical properties
APV has a buoyant density of 1.21g/ ml in sucrose gradients [14]. It is stable 
between pH 3.0 to 9.0, inactivated at 56°C after 30minutes and does not possess 
heamaggluting properties [13, 35].
2.2.4 Nucleic acids
APV has a single-stranded negative-sense RNA genome [37]. Sub-type A 
genes have all been sequenced [38-45] giving a final genome length of 13,373 
nucleotides (nt) [42]. All of the genes of sub-type B have now been sequenced 
[38, 41, 46-48] except for the L gene (currently being addressed at Liverpool), 
therefore the total length has not yet been reported. All genes of subtype C have 
also been sequenced [49-56], however there is some debate over its total length 
[57, 58], This is a result of discrepancies in the length of the G gene and the 
presence or absence of the SH gene [46, 50, 53, 54, 59]. Only the G gene of 
sub-type D has been sequenced in its entirety with partial sequencing of the F 
and L genes [28], Lwamba et at.., 2005 state that European viruses share 97- 
99% nt sequence identities within a subtype but only 56-61 % across subtypes. 
Isolates from the USA demonstrated nt identities between 62 and 65% with 
subtype A, 60-63% with subtype B and 89-94% within a subtype [60], This type 
of data has not yet been reported for subtype D. However the full G gene shares 
56.6% nt identity with subtypes A and B, the partial F gene shares 73.7, 80.5 and 
70% nt identity with A, B and C respectively and the partial L gene shares 
between 75.8 and 76.1 % nt identity with subtype A [28].
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2.2.5 Polypeptides
The genome of APV is transcribed into eight mRNAs encoding eight proteins. 
The genome order (designated according to the proteins) is as shown in Figure 3. 
These proteins are organized into the packaged virus as shown in diagrammatic 
form in Figure 4.
Before it was appreciated that different sub-types existed, three groups reported 
the sizes of the individual APV polypeptides. Sizes ranged from 14-200 
kilodalton (kDa) [14-16, 61] and later studies confirmed these isolates to be of an 
A subtype [47]. These were summarised by Cavanagh and Barrett [16] giving the 
following; L: 200kDa, G: 82-84kDa, F0: 68kDa dissociating into F1: 53-54 kDa 
and F2: 14-15kDa (in reducing conditions), N: 38-43kDa, P: 35-40kDa, M: 30- 
35kDa and 19-22kDa unidentified. The G and F proteins were found to be 
glycosylated. Differences in the nt length of each gene between subtypes A and 
B are minimal, with C only differing substantially in its G gene. Therefore, the 
molecular masses of each polypeptide should remain faithful to the published 
sizes with the exception of protein G of subtype C.
Three proteins distinguish APV from the closely related family members 
morbilliviruses and paramyxoviruses which initially grouped it with other 
pneumoviruses such as RSV. However, the absence of two non-structural 
proteins N1 and N2 found in other pneumoviruses is the basis for classification of 
the new genus Metapneumovirus [25, 26], The N and P proteins of 
pneumoviruses are smaller than those found in morbilliviruses or 
paramyxoviruses and the small polypeptide of 22kDa termed the M2 protein [62] 
is not found in either of those genera.
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The SH and G proteins of subtypes A and B share 47 % and 38% aa identity 
respectively [46, 47] and aa identities for N, P, F, M and M2 range between 83- 
91% [38, 41, 48, 60]. Identities between the L proteins of A and B are 
unavailable. Subtype C proteins; N, P, F, M and M2 have 53%-78% aa 
identities with those of subtype A viruses and 52%-77% with those of subtype B 
viruses [51, 52, 60], The G and SH proteins of subtype C share only 14 and 
19.5% aa identity with subtype A respectively and only 14 and 17.7% respectively 
with subtype B [50, 63], The G protein of subtype D shares 29.5% aa identity 
with subtype A and 31.2% with subtype B and 16-21% with subtype C. Partial 
sequencing and deduced aa sequence of the F protein when compared with 
homologous regions in subtypes A, B and C gave aa identities of 89.7, 97.2 and 
77.6% respectively. Partial L aa sequences yielded identities between 85.3 and 
84.3% with subtype A [28, 50].
3’ N P M F M2 SH G L 5’
Fig 3 .APV genome order, designated according to the proteins. N (nucleocapsid protein) 
P (phosphoprotein) L (polymerase protein) are the nucleocapsid proteins. M2 appears to 
play a regulatory role in RNA synthesis. M is the matrix protein. SH (small hydrophobic 










P and L 
proteins
Figure 4. Diagrammatic representation of a pneumovirus kindly provided 
by Andrew Easton University of Warwick
2.2.6 Replication
Very little is known about the mechanisms of: (i) cell attachment, (ii) penetration, 
(iii) transcription, (iv) replication and (v) assembly and release of APV. However, 
there are some published models for pneumoviruses in general.
(i) & (ii) Attachment and penetration
Conventional models for attachment suggest that G proteins interact with 
glycosaminoglycans or heparin-like molecules [64-68] on the target cell surface
[69] , It is proposed that after attachment, the F glycoprotein promotes a pH- 
independent fusion between the virus envelope and the target cell membrane
[70] . This introduces the individual viral components to the cytoplasm of the cell 
where replication can take place. Some questions have been raised about the 
conventional model for attachment, suggesting that the process may be more
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complex. Heminway et al. [71] suggested that the hRSV fusion event required 
all the surface proteins F, G and SH. However, recent reverse genetic 
approaches for pneumoviruses have produced several viral mutants that lack 
either the SH, G or both which are still able to infect cells in vitro. Naylor et al. 
[72] in developing such a system for APV, produced a virus that lacked both the 
SH gene and the G gene. This virus grew more slowly than its wild type 
progenitor and produced atypical cytopathic effect (CPE) with much larger 
syncytia. This work confirms that the SH and G proteins are not essential for 
virus viability but are essential for normal growth characteristics in vitro. Studies 
on RSV have shown similar results [73-75]. These findings imply that like RSV, 
APV has an auxiliary attachment function, probably linked with the F protein. It 
has been suggested that the enveloped glycoproteins also play a role in 
assembly through their potential to bind viral components within the host cell [76].
(iii) Transcription
The transcription and replication models of pneumovirus genomes are consistent 
with those of all nonsegmented negative-sense RNA viruses.
Transcription begins at a single polymerase entry site (termed the leader 
sequence) that is located at the 3’ end of the genome. The polymerase complex 
now moves along the gene until it reaches a region that marks a point for 
termination. During the transcriptional process the mRNA is methylated, 
producing a capped structure that prevents degradation and ensures translation 
on host cell ribosomes. Termination signals of pneumoviruses consist of a small 
run of uracil (U) residues, these also mark the position where the polyadenylated 
tail is added. Once these processes have been completed the mature mRNA is
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released for translation on free or membrane bound ribosomes. It has been
suggested that only about 50% of the polymerase molecules are able to continue 
moving along the genome to transcribe the next gene [70]. The remaining, 
dissociated polymerases, translocate to the 3’ terminal leader sequence to begin 
transcription at the first gene. This dissociation versus continuation process 
continues down the genome. Thus genes that are closer to the 3’ leader 
sequence are more abundant as mRNA molecules than those closer to the 5’ 
end. However, it has been shown that all eight RSV genes direct the production 
of more read through mRNAs in the presence of the M2-1 protein [77], Krempl 
et al. [78] demonstrated the increase of expression of genes closer to the 3’ 
leader sequence, by shifting the G and F proteins of hRSV to its promoter- 
proximal positions. In doing this these authors increased the mRNA expression 
by 2.4 and 7.8 fold respectively. Protein expression was increased by 
approximately 2.5 fold.
(iv) Replication
The model of replication of pneumoviruses is similar to that of other non- 
segmented negative sense RNA viruses and it is proposed that the nucleocapsid 
complex is the functional unit and that the N, P and L proteins are involved. 
Replication begins with the polymerase protein binding to a replication promoter 
sequence at the 3’ end of the genome. These regions are similar but not 
identical to the transcription promoters with which they overlap [79]. Unlike 
transcription, the polymerase is now committed to continue to the end of the 
genome generating an antigenome template. This template is then used for 
continued copying. The presence of increased N expression has been shown to 
stimulate replication of hRSV suggesting that replication is dependant on RNA
16
encapsidation [80], However, Bermingham et al. [81] have also shown that the 
M2-2 protein of the same virus plays a regulatory role in the balance between 
replication and transcription.
(v) Assembly and release
The M protein is assumed to play a major role in virus assembly as are the 
enveloped glycoproteins. It is thought that a series of interactions between the 
cytoplasmic domains of the enveloped glycoproteins and M protein, which acts as 
a bridge to the neucleocapsid complex, results in progeny virons budding from 
the cell surface. Roles of the glycoproteins in virus assembly have been 
established for several members of the paramyxoviridae family such as: (i) the 
fusion protein of Newcastle disease virus (NDV) [82] (ii) the heamagglutinin- 
neuraminidase protein of Sendai virus [83] (iii) the haemagglutanin and 
neuraminidase proteins of influenza virus [84] (iv)the G protein of vesicular 
stomatitis virus [85], (v) the E2 protein of Semliki Forest and Sindbis virus [86] 
and (vi) the G protein of RSV [76]
The M protein of RSV has also been shown to interact with the membranes of 
infected cells as well as with various viral components [87, 88]
2.2.7 Antigenicity
Early studies on three UK isolates and one French isolate of APV using double 
immuno-diffusion, indirect immunofluorescence (IIF), serum neutralization tests 
(SN) and ELISA using polyclonal sera, showed that all four were antigenically 
similar [34, 89]. Later studies using monoclonal MAbs [90, 91] indicated that 
isolates collected between 1985 and 1990 from the UK, were themselves closely
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related and that they were very similar to a strain isolated in South Africa in 1978. 
Conversely, the UK isolates were shown to be somewhat different from isolates 
from France, Hungary, Italy, Spain and Holland [91]. In agreement with this, was 
the work of Collins et al. [90], they found that the French Isolate 1556 [10] was 
very similar to isolates made in the UK prior to 1990. These data showed that the 
different isolates were clearly related but could be separated into two distinct 
groups. Juhasz and Easton [47], in a landmark paper, confirmed this by 
demonstrating extensive sequence variation in the attachment G proteins of 
these isolates and subsequently named the two groups subtypes A and B. In 
that study, isolates of subtype A comprised UK and French strains and isolates of 
subtype B were formed from the other continental European strains.
Isolates of APV from the USA have demonstrated antigenic differences from both 
A and B subtypes and have subsequently been designated as subtype C. 
Preliminary neutralization tests using mono-specific polyclonal antisera to A or B 
demonstrated a failure of these sera to neutralize the first US isolate from 
Colorado and vice versa. Likewise MAbs that neutralized A and B also failed to 
neutralize C [29]. However, Cook et al. [29] did show a partial neutralization of 
subtype C with subtype A hyperimmune serum.
The differences seen antigenically can be explained by the low aa identities of 
subtype C proteins with subtypes A and B proteins, especially in the highly 
antigenic surface proteins (see section on polypeptides). The use of recombinant 




The natural host of APV is the turkey and to some degree the chicken although 
the role of the virus as a primary pathogen in the latter species is less clearly 
defined. Evidence of infection with subtypes A and B has been reported in a 
number of other species including ducks [93]. Susceptibility to APV infection has 
been demonstrated serologically in pheasants by ELISA and virus neutralization 
(VN) [94, 95], in guinea fowl by ELISA and VN [95, 96], in ostriches from 
Zimbabwe by ELISA [97] and in herring gulls from the Baltic Coast, Germany by 
VN [98]. Subtype C APV in the USA has been detected in wild Canada geese 
and the blue-winged teal [99] house sparrows, ring-billed gulls and snow geese 
[100] Turpin [101] Detected subtype C antibodies to APV in five of fifteen different 
species of wild bird.
2.3.2 Geographical distribution
APV has now been detected globally with few exceptions. The only large land 
mass where it remains undetected is Australia [32] and there are no reports from 
Canada. It was first detected in South Africa in turkeys [9] and subsequently in 
the UK [102]. Other countries include, France [10], Spain [102], Italy [102], Israel 
[103], Germany [104] Hungary [105], Taiwan [106] Japan [107], South and 
Central America [19, 108 ] the Dominican Republic [109] and North America 
[110]. Subtype distribution is as follows. It appears infections in the UK, Europe, 
Africa, Central and South America and Asia have been of the A and/or B 
subtypes with C subtype infections, until recently, have been found only in the 
USA. However, a Colorado-like APV virus was isolated from ducks in France 
[93], This was confirmed as a European C strain of APV but has been shown to
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have a different genetic lineage [111], Two more French isolates Fr/85/1 and 
Fr/85/2 were shown to differ from A, B and C through sequence analysis of their 
F, G and L genes and thus a fourth subtype, labelled D, has been identified here 
[28] [111].
2.3.3 Clinical disease
In general, the severity of the disease is greater in the field than under 
experimental conditions [21]. Typically, in experimental conditions in turkeys, the 
characteristic clinical signs of APV infection begin with clear nasal discharge, 
which later becomes mucopurulent. 5 days post infection (pi) there is an 
increase in ocular discharge which frequently becomes frothy. During this period 
there are also signs of depression, head shaking, coughing, sneezing and a 
swelling of the infraorbital sinuses [112]. Within 10 -1 2  days full recovery maybe 
observed [11, 13, 35, 36], Importantly Naylor, Jones and Williams observed that 
in isolation conditions the housing of turkeys even on clean litter as apposed to 
wire resulted in more consistent and severe clinical signs (unpublished 
observations).
Naylor and Jones 1993 [112] reported that the severity of clinical sings varies 
depending on environmental and management factors such as ventilation, 
hygiene and stocking densities. In the field, other adverse effects are seen. 
There is poor feed conversion in growing birds, and in layers there is a drop in 
egg production down to 40% of the expected levels and in worst cases as low as 
2% [112]. Recovery has been shown to take approximately three weeks [21, 
102]. Mortality is variable but in cases of poor management conditions and the 
resulting invasion of secondary agents, it has been shown to reach up to 30% or 
even over 50% [21, 102], The role of secondary agents in disease severity has
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been demonstrated in experimental conditions. Bordetella avium, Pasteurella- 
like organisms [113] and Mycoplasma gallisepticum (Mg) [114] (all of which are 
commonly associated with secondary infections in the field) have been shown to 
exacerbate and prolong the clinical disease. It has been suggested that the 
failure to develop severe clinical disease in experimental conditions is due, in 
part, to insufficient numbers of these secondary pathogens at critical times and 
the different management conditions [112].
Experimental infection of chickens with APV has produced milder clinical signs 
than in turkeys [115-117]. However, SHS is a pathological condition that affects 
all types of chickens and sometimes follows APV infection in broiler-type birds. 
Morley and Thomson [118] reported that broilers were affected at 4 to 6 weeks of 
age while Pattison et al. 1989 and O’brien 1985 [24, 119] reported that broiler 
breeder birds were affected from peak of lay, at about 30 weeks to 52 weeks. 
Clinical signs include depression, lack of locomotion, sneezing, coughing, head 
shaking and scratching. The most striking feature is subcutaneous oedema 
around the eyes [24, 118, 119]. Often this extends over the whole area of the 
head giving the face a swollen appearance, hence the name. Ear and eye 
discharge, red conjunctivitis, foul smelling green diarrhoea and severe tracheitis 
due to secondary E.coli pathogens have also been observed [118, 119],
SHS has never been reported following experimental infection with APV alone.
2.3.4 Effects of age and breed
Turkeys of all ages are susceptible to APV however the severity of the disease is 
more pronounced in younger poults [21, 120], In experimental conditions
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Williams et al. 1991 [121] had to increase the effective dose of 4.7 Iog10 for birds 
of 12 weeks to 5.2 Iog10 for birds of 22 weeks of age to induce similar clinical 
signs. There is no evidence to link differences in breeds with differences in APV 
susceptibility.
2.3.5 Pathogenesis
(i) Replication and persistence in the tissues
APV predominantly infects the upper respiratory tract of turkeys and chickens. 
Experimental infections by eyedrop or intranasal inoculation, have shown the 
virus replicating in epithelial cells of the nasal turbinates, trachea and sometimes 
lungs [35, 113, 116, 122-124], Viral particles have been demonstrated in the 
trachea from days 1 -  7 post experimental infection (pi) and in the turbinates from 
days 2 - 6  using immunofluorescence staining (IF) or immunoperoxidase (IP) 
staining [122, 123], Viral replication has also been demonstrated in the ciliated 
epithelial cells of the bronchus on days 4 and 5 pi [123],
In mature turkey hens, the virus has been detected in the reproductive tract after 
infection via the respiratory route. Jones et al. [122] detected viral replication in 
the epithelium of the uterus on day 7 pi and in all regions of the oviduct on day 
9pi using IF staining. However, virus was only isolated from the middle magnum 
and vagina on day 9 pi. O’loan and Allan, [124] also detected virus in the 
surface epithelial cells of the uterus using IP staining.
The increasing use of RT- PCR as a diagnostic tool has also lead to improved 
sensitivity for virus detection. As a result, detection of virus from 17 to 19 days pi
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[125] and as late as 28 pi [126] have been recorded in turkeys and chickens 
respectively under experimental conditions. However, isolation of virus is usually 
possible only between days 2 and 7 pi. Whether there is a low level of virus 
replication during these later stages, or indeed if the birds are still harboring 
infectious virus which becomes reactivated is unknown.
Dual infection of turkeys with bacterial pathogens commonly associated with field 
disease, lead to increased invasiveness of APV with virus being recovered from 
heart, liver, spleen, kidney and caecal tonsil [113]. Conversely, dual infection of 
APV and Mg did not increase the invasiveness of APV but did increase the 
invasiveness of Mg [114]. A recent paper on dual infection with vaccine strains of 
APV and NDV using one-day old specific pathogen free (SPF) White Leghorn 
chicks, showed APV detection, via RT-PCR for almost twice as long in dual 
vaccinates than in single vaccinates [127], These authors suggest that after 
simultaneous vaccination of chicks with live APV and NDV vaccines there is a 
temporary suppression of APV vaccine proliferation.
In SPF chicks the virus has been isolated for 6 days pi from nasal secretions 
after experimental infection at one day of age with a turkey strain (BUT# 8544) 
[117]. Jones et al. [128] have also reported isolation of virus from the trachea on 
day 6 pi in chickens infected with a chicken strain. Cook et al. [116] 
demonstrated some different biological properties between two APV isolates, one 
of which was from turkeys and the other from chickens. These authors reported 
that both viruses principally replicated in the upper respiratory tact. However, the 
chicken isolate replicated to very high titre in the nasal tissue of both species, 
approximately log10 6.0 median ciliostatic doses of virus per g (CD50), whilst the 
turkey isolate only reached the same level in its host species. It is worth
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emphasizing that chickens and turkeys can each be infected with viruses from 
either species.
The demonstration of virus in the reproductive tract of chickens has only been 
possible after experimental inoculation, via the unnatural, intravenous route [129]. 
These authors refer to a paper by Catelli et al. [130] and suggest that their failure 
to detect virus in the reproductive tract might be explained by the difference in 
age of birds used in the experiments, and relating it to the immaturity of the 
oviduct. However, it is important to note that Catelli et al. [130] inoculated birds 
via the oculonasal route only.
(ii) Macroscopic lesions
Experimental infection of day old poults with a virulent or non virulent strain of 
APV did not result in any abnormalities on postmortem examination. However, 
thickened air sacs were observed in poults infected with the virulent strain of APV 
together with bacteria. This thickening of the air sacs became severe between 
days 7 and 14 pi [113].
Following experimental infection of 30 week old laying turkeys with APV alone, 
Jones et al. [122] initially found clear, watery exudate in the turbinates, which 
later became mucoid and greyish in colour between days 1 to 9 pi. Excess 
mucus was found in the trachea between days 1 to 7 pi. The same paper reports 
several reproductive tract abnormalities in mature female turkeys including ovary 
regression, folded shell membrane in the oviduct, egg peritonitis, misshapen 
eggs and deposits of solid yolk material scattered throughout the abdomen. The
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most common finding was the presence of whitish masses of inspissated albumin 
scattered throughout the organ.
Following natural APV infection together with secondary bacterial infection in the 
field, pericarditis, perihepatitis, air-sacculitis, pneumonia and adhesions between 
the pericardial sac and the epicardium have been described [21, 102],
In APV infected chickens, the only significant lesions noted are those associated 
with SHS in broilers or broiler breeders. These include extensive yellow 
gelatinous to purulent odema in the subcutaneous tissue of the head, wattles and 
neck. Swelling of the infraorbital sinuses has also been seen [104, 106, 107, 
131]. Simmilar lesions have been seen in commercially raised pheasant poults 
in Japan [132],
(iii) Histopathology
Histopathological changes have been observed in the trachea [36, 96, 123], 
turbinates [96, 123] and less frequently the lungs [123], After experimental 
infection of seven week old turkeys, Jones et al. [36] were able to demonstrate a 
loss of cilia and extrusion of the epithelial cells from the mucosal surface in the 
trachea by day 4 pi. These authors also showed an infiltration of inflammatory 
cells in the mucosa and submucosa of the trachea by day 4 pi.
Workers in France [96] repoted histopathological changes in the larynx, nasal 
cavities and trachea of both chickens and turkeys that had been experimentally 
infected at 4 weeks of age. However, changes were of a lesser degree in the 
trachea. They also reported acidophilic cytoplasmic inclusions in the ciliated
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cells of the turbinates and the trachea, a finding that has not been reported by 
any other workers.
Majo et al. [123] observed changes in the mucosa and submucosa of the bronchi 
subsequent to experimental infection of chickens and turkeys. These consisted 
of inflammatory exudate in the brochial lumen, an increase in glandular activity, 
hyperplasia of the bronchial epithelium and the presence of an abundant 
mononuclear inflammatory infiltrate in the submucosa of the bronchi.
Following experimental infection of 3-week-old commercial broiler chickens with a 
turkey isolate, Jones et al. [117] demonstrated either focal heterophil leucocyte 
infiltration of the congested nasal epithelium or focal karyorrhexis of the tracheal 
epithelium in a small number of birds at day 4 pi. In uncomplicated APV 
infections the respiratory tissues usually return to normal after about ten days.
2.3.6 Immunity
(i) Humoral immune responses
ELISA, SN tests and IIF methods have been used to detect humoral antibody 
responses of turkeys or chickens to APV [133-140]. Following natural infection 
of APV in turkeys, Baxter-Jones et al. [134] in using three antibody detection 
methods demonstrated VN antibodies as early as 5 days after the initial 
appearance of clinical signs. These antibodies reached peak levels at this time 
as did IIF antibodies. However neutralising antibodies were decreasing by day 
13. Conversely, ELISA antibodies had reached their peak on day 13. 
Antibodies were detected by all methods up to 34 days although serum titres 
were generally decreasing. Jones et al. [122] using experimental APV infection
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of laying turkeys demonstrated ELISA and neutralising antibodies at high levels 
throughout their observation period of 89 days. Again in this study neutralising 
antibodies were detected before ELISA antibodies.
The inoculation of poults with attenuated strains of APV has also resulted in 
seroconversion and protection against virulent challenge [121, 141]. Despite the 
humoral response following APV infection, the role of these antibodies in 
protection of the respiratory tact is unclear. Jones et al. [142] produced evidence 
that would suggest that the cellular response provides the main resistance to the 
virus in the upper respiratory tract. These authors demonstrated protection 
against APV challenge in turkey poults that were unable to seroconvert. These 
birds had been chemically bursectomised using cyclophosphamide (at a dose 
that had been shown to cause only B cell immunosuppression) yet they were 
equally resistant to clinical disease. However, it is likely that in laying turkey 
hens, the presence of neutralizing antibody in the blood is important for protection 
of the reproductive tract from viraemic viruses which may affect egg production 
[19].
Specific antibody responses to the fusion protein of APV have been 
demonstrated by Yu et al. [143]. These authors constructed a fowlpox 
recombinant virus that expressed the fusion protein of APV. After turkey poults 
were vaccinated twice with this recombinant, antibodies were detectable by 
ELISA and SN tests. In addition, partial protection from challenge with a virulent 
strain, two weeks after the second vaccination was observed. This work 
highlights the importance of the fusion protein for protective immune responses. 
The importance of a second surface glycoprotein for stimulating protective 
antibody production has been demonstrated by Cook et al. [91]. Although this
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work was carried out in vitro it demonstrates the neutralising capacity of Mabs 
that recognize the G glycoprotein. Protection has also been demonstrated 
following intramuscular inoculation with recombinant N and M proteins however 
the mechanism of protection was not determined [144],
Work by Munir et al. [145] has provided key insights into many individual genes 
and pathways that constitute the host cells response to infection and highlight the 
complexities of host-virus interactions and resulting defense measures.
(ii) Maternal antibodies
Maternal antibody titres that have been vertically transmitted via the yolk sac will 
be directly related to the levels of circulating antibody in the parent bird. The 
presence of these antibodies does not interfere with live APV vaccination of 
turkey poults at a young age [141]. In addition maternal antibodies in turkey 
poults have failed to protect against virulent APV challenge [146], These results 
also highlight the importance of the local and cell mediated responses in the role 
of protection.
(iii) Local immune responses
It appears that local immune responses in turkeys and chickens are important for 
protection against APV, since the virus replicates primarily in the upper 
respiratory tract. Following APV vaccination of day old chicks, local APV specific 
IgA antibodies in the lachrymal fluids have been demonstrated [127], Khehra et 
al. [147] have also showed local, APV-specific IgA antibodies, in both lachrymal 
and tracheal washes of chickens and turkeys [147],
(iv) Cell mediated immunity
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Jones et al. [142] demonstrated protection against an APV virulent challenge in 
turkey poults that were unable to seroconvert due to b-cell immunosuppression. 
This suggests that the cell mediated immune response provides the main 
resistance to infection of the respiratory tract with APV. Work of Ganapathy et al. 
[127] concurs with the suggestions of Jones et al. [142], Following dual 
vaccination of SPF chickens with live APV and live NDV, birds were still protected 
from challenge with a virulent strain of APV irrespective of the levels of circulating 
APV antibodies (personal communication).
Murin & Kapur [145] have provided key insights into individual genes and 
pathways that constitute the host cells response to APV infection. They identified 
many genes in chicken embryo cells that were differentially regulated following in 
vitro infection with a subtype C virus and showed the transcriptional change in the 
interferon (IFN)-regulated class of antiviral genes to be the most striking. The 
induction of many IFN-stimulated genes (ISGs) increased as early as 2.5 hours pi 
and increased over a period of 96 hours. Increases in induction ranged from 2- 
61 fold. One of the most strongly induced proteins was the Mx protein. These 
proteins constitute a group of large antiviral GTPases which mediate their effect 
by sequestering viral nucleocapsids, therefore rendering them inaccessible for 
replication [148], It is not known if the avian Mx protein has an antiviral effect 
towards APV or other avian respiratory viruses but activity against 
orthomyxoviruses, paramxyoviruses, rhabdoviruses, bunyaviruses and 
togaviruses have been shown using human MxA and mouse Mx1 proteins [149].
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2.3.7 Transmission
When APV was first encountered its rapid spread among turkey flocks in England 
and Wales lead to initial assumptions that transmission must be airborne [102], 
However, Cook et al. [113] reported that experimentally, virus did not transfer 
from infected poults to non-infected poults that were placed in the same room but 
in a different pen, even though air flow was favorable. Similar results have been 
reported by Alkhalaf et al. [150] using a subtype C APV. Conversely contact 
transmission has been demonstrated from affected to susceptible turkey poults, 
and by inoculation with filtered or unfiltered mucus, nasal washings or other 
material from the respiratory tract of infected birds [11, 151]. Cook et al [113] 
have demonstrated that APV was transmissible from infected to susceptible 
turkey poults that were in direct contact for a period of 9 days pi. There are 
reports of susceptibility to the virus in many other species including ducks [93], 
pheasants [94, 95], guinea fowl [95], ostrich [97] and herring gulls [98] and it has 
been suggested that the aquatic bird could be a possible carrier species. This is 
strengthened by similar studies on APV subtype C were it was found in domestic 
waterfowl [152] although in an Italian study of wild aquatic birds, APV was not 
detected [153]. The conflicting reports about APV infection in wild birds could 
suggest that they are susceptible to APV infection but may not play a role in 
transmission of infection.
No published evidence is available on vertical transmission even though high 




Because the clinical signs of APV are not pathognomonic, demonstration of the 
virus or a rise in APV antibody titre is required for definitive diagnosis.
2.4.2 Viral antigen
(i) Isolation and demonstration of viral antigen
It is important to note that APV virus isolation is difficult from field samples. This 
is partly due its relatively poor replication characteristics in laboratory host 
systems, the frequency with which secondary organisms are isolated and the 
timing of isolation attempts [19, 155], It is also laborious, time consuming and 
expensive. However, it may still be required for epidemiological studies, further 
characterization of a particular isolate or for use in collaboration with other 
diagnostic tests. Since replication is primarily confined to the upper respiratory 
tract, turbinates and trachea then samples from this area are preferred when 
attempting APV isolation. As mentioned, the timing of the isolation attempt is 
also important. Samples should be taken as early as possible after the initial 
stages of clinical disease. Experimentally both the chicken and the turkey have 
been shown to shed the most virus between 3 and 5 days pi [11, 12, 35, 113, 
116, 122], The systems of choice for primary isolation of APV from field material 
are either embryonated eggs inoculated via the yolk sac [35, 156] or chicken or 
turkey embryo TOC [11, 13, 35, 36]. The preferred method of choice is TOC, 
although no comparison between the two methods has been made. Cook and 
Cavanagh [157] suggest that the method of choice is likely to depend on the 
personal preference of the individual laboratories. However, for isolation of 
subtype C an important factor to consider is the inability of this virus to cause
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ciliostasis [29] which means that the use of TOC is inappropriate for primary 
isolation. This may explain why attempts to isolate APV in the USA were initially 
unsuccessful.
After primary isolation the virus can be adapted to grow in a variety of cell 
cultures, including chick embryo fibroblasts (CEF) [137, 156], chick embryo liver 
(CELi) [140], and vero cells [35, 140]. However, it has been shown that multiple 
passages in tissue culture systems can quickly lead to attenuation of the virus 
[140], Conversely up to 98 passages of virus in TOC did not result in any loss of 
virulence [140],
Recently two cell lines derived from grivet monkey kidney and foetal rhesus 
monkey kidney, have showed promise for growth of a subtype C vaccine strain 
[158], although the authors state that the CPE was not as clear as that observed 
in Vero cells and end points could only be determined after IF using 
hyperimmune anti-APV serum.
There are a number of techniques that can be used for demonstration of viral 
antigen in fixed and unfixed tissues and smears. However, these techniques 
have limited use for diagnostic purposes. The most widely used are IP, IF and 
less commonly immunogold staining [33, 36, 122-124, 133], These techniques 
have generally been applied for replication and pathogenesis studies in both the 
turkey and the chicken. For the demonstration of viral particles EM has been 
used [10, 11, 13, 35] but usually to confirm the morphology of isolated virus. 
More recently molecular techniques have been developed to detect the virus. 
The most widely used of these techniques is the RT-PCR.
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Although RT-PCRs are significantly more sensitive and rapid than conventional 
virus isolation methods [20, 157, 159] there are important things to consider. The 
durability of DNA, the powerful amplification procedure and high sensitivity of 
these tests means that there is a high risk of contamination. Moreover, the 
decision of whether to use a subtype specific or a generic-type PCR has to be 
made. Evidence that supports a subtype specific approach to PCR diagnosis of 
APV is that of a retrospective study [160]. This indicated that subtype A virus, 
previously only detected in South Africa and the UK had also been present in 
Germany in the late 1980s. However, to use a subtype specific approach would 
be to run the risk of overlooking new subtypes for which the chosen 
oligonucleotides would not detect. Therefore, the strategy suggested by Bayon- 
Auboyer et al. [161] to first use an N gene sequence-based RT-PCR for initial 
detection, followed in positive cases by a G gene sequence-based subtype 
specific RT-PCR for initial characterization would be more appropriate.
Cook and Cavanagh [157] suggest that the large L gene may also be a useful 
target for designing general PCR primers due to its conserved nature. A variety 




SN tests have been shown to have similar sensitivity to ELISAs [134] although 
their use is less frequent for general detection of APV antibodies. The SN test 
may be performed in a number of systems, including TOC [91] and cell cultures 
such as CEF, CEL, Vero and MA104 [10, 134, 138, 140, 165, 166] of which the
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most commonly used is TOC. TOC which uses ciliostasis as an indicator of 
infection has the advantage that the virus requires no adaptation before it can be 
used in SN. However, this system is inappropriate for SN tests with subtype C as 
this virus does not cause ciliostasis. The indicator used in cell culture systems is 
the characteristic CPE that develops upon infection. Therefore, this system is 
useful for all known APV subtypes but the virus needs to be adapted to grow in 
the chosen cell line prior to SN.
2.5.2 Immunofluorescence
Baxter-Jones et al. [133, 134] used IIF, using APV infected TOCs, on serum 
samples from both experimentally and naturally infected turkeys. The results 
showed the test to be both sensitive and specific. Although these tests are useful 
for applications in research they are limited when testing large numbers of poultry 
sera for APV antibodies. For this reason these tests do not appear to have found 
favour in diagnostic laboratories. More recently an IF test with a 96 well, flat- 
bottomed microplate was developed to detect APV antigen in Vero cells [167], 
Although in this test, the authors were looking for a method that would allow rapid 
detection of APV antigen, it may also provide a method for screening large 
numbers of serum samples, by IF, for APV antibodies.
2.5.3 ELISA
ELISAs have become, by far, the most commonly used serological method for 
detection of APV antibodies [23, 135, 137, 138, 152, 168, 169] and there are 
many commercial and in-house ELISAs that have been developed [10, 135-138, 
170, 171], Antigens for use in APV ELISAs have been prepared on different 
substrates such as TOC, CEF and Vero [10, 135-137], Baxter-Jones et al. [34]
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demonstrated similar antibody profiles when testing turkey sera using two 
different ELISA protocols and antigen that had been prepared in both TOC and 
CEF. It has been suggested that the choice of substrate for antigen growth 
appears to be a matter of personal preference [157]. However, higher virus titre 
can be achieved when using cell cultures; therefore, it may be preferential to use 
this method.
Although there are several substrates that can be used for antigen production, 
the choice of APV strain to be used in the ELISA is important. Eterradossi et al. 
[172] used two isolates of APV; a UK, subtype A isolate and a French, subtype B 
isolate as antigen in their ELISAs. Each antigen was tested against known 
positive sera from the UK (subtype A) and from France (subtype B). The results 
showed that each antigen was more efficient in detecting antibodies in sera that 
originated from the same country as the antigen; thus the authors suggest the 
importance of using viral antigens that have been prepared from strains 
originating in different geographical areas. Eterradossi et al. [23] also suggested 
that the choice of an inappropriate ELISA antigen could lead to a false diagnosis 
that indicates vaccine failure, or hinder early diagnosis of APV infection in both 
vaccinated and un-vaccinated turkeys. Moreover, it has been shown that 
vaccinal antibodies may not be detected if a heterologous APV strain is used as 
the coating ELISA antigen [23], Therefore, it has been suggested that 
homologous antigens should be used in such circumstances.
A further important point is that ELISAs which incorporate either subtype A or B 
antigens have been found to detect subtype C antibodies very poorly [29]; again 
it was suggested that the homologous strain be used as coating antigen when 
testing sera by ELISA for antibodies to subtype C [29]. Such ELISAs have now
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been developed [169, 170, 173], Antigens for these ELISAs were prepared from 
both Colorado and Minnesota isolates.
A comparative study of commercially available ELISA kits also revealed 
considerable variation in sensitivity. Mekkes and De Wit [174] in testing three kits 
from different manufacturers, showed that while two detected an antibody 
response to live vaccination with both French and UK vaccines, one failed to do 
so. McFarlane-Toms & Jackson [175] found similar results. For reasons outlined 
above it is clearly desirable to develop ELISAs that are suitable for all purposes. 
One approach has been to develop novel ELISAs using recombinant proteins as 
antigen. Literature relating to this is discussed in section 2.6 below
2.6 Expression and use of recombinant viral proteins
An extensive variety of viral proteins, have been expressed in and from a range 
of prokaryotic and eukaryotic expression systems. These proteins have been 
used in a variety of studies including those directed at vaccine development 
(2.6.1), protein folding, transcription and replication (2.6.2), characterization of 
monoclonal antibodies and studies on immunity (2.6.3) and applications in ELISA 
development (2.6.4).
2.6.1 Recombinant proteins in vaccine development
Delivery of APV subtype A fusion protein to turkeys has been achieved using 
fowlpox recombinant virus Qingzhong et al [143] resulting in partial protective 
immune response and induction of antibodies detectable by ELISA and virus 
neutralization.
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For APV subtype C, antibody responses to the fusion protein have also been 
demonstrated in turkeys Tarpey et al [176] following two intramuscular injections 
with DNA plasmids carrying the encoding gene. Although the authors reported 
no clinical protection following homologous challenge, they demonstrate cross 
reaction of antiserum to both A and B subtype APV’s. Therefore, although not 
discussed by the authors, they might have inadvertently identified the fusion 
protein as a useful antigen candidate for single recombinant ELISAs that detect 
antibodies against A, B and C subtypes. Similar DNA vaccine studies have been 
undertaken using both the fusion and the nucleocapsid genes of subtype C [177], 
In contrast to the findings of Tarpy et al [176] the authors reported significant 
homologous protection against challenge in turkeys that received DNA plasmids 
containing the fusion gene. These discrepancies might be explained by 
differences in the virulence of challenge virus. However, Kapczynski et al [177] 
made no reference to, or discussion of the work of Tarpy et al [176] which had 
been undertaken two years previous.
2.6.2 Protein folding, transcription and replication
Nucleocapsid proteins of paramyxoviruses have been the focus of many studies 
due to their importance during replication [178-181], Interestingly Kho et al [182] 
demonstrated the ability of E.coli-expressed Newcastle disease virus N protein to 
self-assemble into the herringbone-like structure which morphologically 
resembled the authentic structures described by Alexander et al [183]. Later Kho 
et al [181] produced several deletion variants in E.coli, which helped to identify 
amino acids important for proper formation. Prior to this study much structural 
and functional information on this particular protein had been derived from other 
members of the paramyxovirus family in similar studies. These authors also
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demonstrated that deletions further from the c’ terminal end tended to form longer 
particles.
Fearns et al [184] also used the nucleocapsid protein in conjunction with the 
phosphoprotein of respiratory syncytial virus to investigate a current model for 
RNA synthesis of nonsegmented negative-strand viruses. These authors 
expressed nucleocapsid and phosphoproteins from transfected plasmids carrying 
the genes and evaluated their effects on the replication of RSV minireplicons. 
Essentially the authors demonstrated that the nucleocapsid protein was required 
for RNA replication and that replication was stimulated by increased levels of 
nucleocapsid protein.
2.6.3 Characterization of monoclonal antibodies and studies on 
immunity
N protein of subtype C APV expressed from a transfected plasmid in HEp-2 cells 
[185] helped to characterize six monoclonal antibodies prepared against this 
virus. Yu et al [185] showed that although none of these antibodies neutralized 
APV infectivity at a detectable level, they all recognized both denatured and 
nondenatured forms of the N protein, thus suggesting that these antibodies 
recognized structurally independent epitopes. A similar study characterizing 
monoclonal antibodies against avian reovirus (ARV) with a baculovirus- 
expressed recombinant ARV sigma C protein was recently undertaken by Hsu et 
al [186], These authors also demonstrated conformation-independent binding of 
the monoclonal antibodies to the recombinant protein.
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Analysis of immune responses to baculovirus and vaccinia virus-expressed RSV 
surface proteins F and G has been undertaken [187, 188]. Werle et al [188] 
using baculovirus-expressed full length F protein or a fragment of RSV F protein 
were able to identify at least two neutralizing epitopes within this region. Olmsted 
et al [187] reported that immunization of cotton rats with vaccinia-expressed F 
protein stimulated almost complete resistance to replication of RSV upon 
challenge and that resistance offered by F exceeded that induced by vaccinia- 
expressed G protein.
2.6.4 Applications in ELISA development
Recently, individual, recombinant viral proteins have been tested for their 
suitability as ELISA antigen candidates for APV subtype C [2, 3, 63]. Both 
sandwich and indirect ELISAs using subtype C nucleocapsid and matrix proteins 
respectively, provided more specific and sensitive tests compared with routine 
ELISAs [2, 3], Lou et al. used the SH protein of the same subtype and developed 
an ELISA that was suitable for detecting subgroup-specific antibodies in turkeys. 
They suggested that this test could be used for serologically-based differential 
diagnosis of APV and hMPV infections. The authors state that the SH protein 
was chosen as a likely candidate for a subgroup-specific sérodiagnostic reagent 
because it demonstrated extensive amino acid variation between subtypes A, B 
and C and hMPV. Other APV proteins or regions of proteins share the same 
properties or conversely, maintain conserved sequences between subtypes. This 
means that theoretically, different recombinant proteins have the potential to 
detect subtype specific antibodies or antibodies common to all subtypes, when 
used as antigen in ELISAs. Such ELISAs have also been developed and tested 
for other members of the paramyxoviridae family [1, 4-7] each demonstrating
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increased or equal sensitivity and specificity with conventional ELISAs. Chen et 
al [8] highlighted some important advantages of using recombinant proteins over 
whole virus-infected cell extracts as antigen. These include safety (being non 
infectious) and having the potential to be modified rapidly in respond to new viral 
strains. In this study, the authors compared sensitivities of infectious bronchitis 
virus ELISAs using baculovirus and £co//-expressed nucleocapsid protein as 
antigen. Surprisingly, they found that N protein purified from E.coli was more 
sensitive to anti-IBV serum than that purified from insect cells even though E.coli 
expressed N protein lacked phosphorylation. This may suggest that IBV 
antibodies detected in the ELISAs recognized structurally independent epitopes, 
such as described by both Yu et al and Hsu et al [185, 186] following their studies 
on APV and ARV respectively. However, it could also suggest that epitopes 
reacting in the ELISAs of Chen et al [8] are not dependent on phosphorylation for 
their formation.
2.7 Control
2.7.1 Management and treatment
Management factors play an important role in the severity of clinical signs and 
therefore the severity of APV infection in commercial poultry, especially turkeys. 
Conditions such as high stocking densities, poor litter quality, inadequate 
ventilation and temperature control, multi-age stock and secondary pathogens all 
exacerbate infection [21, 131, 154, 189]. In general, any procedure that causes 
stress to the birds can influence the severity of infection. Gough and Jones [190] 
suggest that disinfection of delivery and catching crews, equipment and feed 
trucks should also be routine practice to reduce the introduction and spread of 
APV onto poultry farms.
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Problems of secondary infections can be reduced through the use of antibiotics. 
Initially medications aimed at alleviating secondary infections had only limited 
success [21] but later, Hafez et al. reported success in using enrofloxacin [191]. 
Most recently Munir et al [192] have provided interesting results that could lead to 
the development of novel RNA interference (RNAi) based antiviral prophylactic 
treatments. These authors showed that double stranded short interfering RNA 
(siRNA) molecules that corresponded to a subtype C, APV P gene broadly 
reduced the expression of P and other viral proteins and also led to the inhibition 
of subtype C virus replication in vitro. Moreover, this technique is being 
increasingly utilized to inhibit the replication of other viral pathogens, including 
HIV-1 [193], influenza [194, 195], hepatitis B & C [196, 197], poliomyelitis [198], 
foot and mouth disease [199] and severe acute respiratory syndrome [200]. It is 
important to note that efficient means for in vivo APV P siRNA delivery have not 
yet been developed.
2.7.2 Vaccines
The main approach for control of APV infection is through the use of both live- 
attenuated and killed vaccines [35, 140, 141, 201-204], both of which are 
available commercially. Live attenuated vaccines have been successfully 
produced in a variety of cell cultures and have been reported to confer protection 
against experimental infection [35, 140, 141, 201]. In the field, the results have 
been generally good following spray, aerosol or drinking water administration 
although problems have arisen possibly due to a lack of control over 
simultaneous exposure of the entire flock to the vaccine via these methods. 
Moreover, because of the genetic instability of RNA viruses, live vaccines that 
have been attenuated through minimal coding sequence changes after multiple
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cell culture passages have a tendency to revert to virulence. Therefore if birds 
only become exposed to the vaccine following several back-passages, then 
exposure may be to a virulent revertant or possibly to a virulent sub population in 
the vaccine. Naylor and Jones [17] demonstrated, a virulent sub population in a 
prototype live-attenuated vaccine using in vitro and in vivo screening techniques 
and suggested that this could account for the occasional disease seen in young 
poults following multiple back passage of the vaccine. At the time of these 
studies it was difficult to determine if these virulent viruses were indeed vaccine 
derived. However, in a recent study Catelli et al. [205] have demonstrated the 
reversion to virulence and extended persistence of the same live-attenuated 
vaccine and confirmed its vaccine origin.
Studies have shown that good cross protection occurs following vaccination with 
subtype A and B vaccines against challenge with either subtype [23, 172, 201, 
206], Vaccines prepared from either A or B subtypes have been shown confer 
protection against the Colorado subtype C virus [20].
Vaccination with live attenuated vaccines alone will not provide complete 
protection in adult birds; therefore, an oil-adjuvanted inactivated vaccine is 
administered after the initial live vaccination. Gough and Jones [190] suggest a 
typical vaccination programme in turkeys as: live subtype A or B or both at day- 
old using a coarse spray, repeated at 7-10 days and again at 4-6 weeks. 
Breeding stock would also receive inactivated vaccine at 16-20 weeks.
Studies in turkeys on the immunity to an APV vaccine following in ovo vaccination 
have also been reported [207] and the results indicated that this route of 
vaccination has several advantages over conventional methods including, more 
accurate administration of the vaccine that can be done in the hatchery, possible
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multi vaccination in a single dose and less handling of the birds resulting in 
reduced stress. A recent preliminary study has indicated that inoculation of 
poults with a single dose of a cold-adapted subtype C strain of APV at 1 week of 
age has provided protection until 15 weeks of age [208], However, the authors 
stress that trials using larger sample numbers would be needed to determine the 
application of these results in the field.
As mentioned earlier the genetic instability of RNA viruses and the minimal 
coding sequence changes that result from passage [205] means that they can 
readily revert. The recent developments of recombinant subunit and deletion 
mutant viruses [72] mean that reversion is much less likely. Whether these 
recombinant viruses provide protection and become useful vaccines is yet to be 
established. Other recombinant vaccines that incorporate specific immunogens, 
such as the F protein, in fowl pox virus [143] have had some success. This 
vaccine was shown to induce APV antibodies and provided some protection in 
experimental turkeys when challenged [143]. Another interesting approach was 
the development of an APV virosome vaccine [209] which also conferred 
protection in experimental conditions. These types of vaccines are designed to 
contain viral membrane proteins within a liposome complex but do not possess 
genetic nucleic acid. Therefore they are as safe as inactivated vaccines and are 
still able to attach and fuse with host cells [209],
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General materials and methods
This section describes routine procedures undertaken during this work. Details of 
specialized procedures are given in the relevant chapters.
3.1 Glassware
All items of glassware were cleaned as follows before use.
3.1.1 Treatment of contaminated glassware
Glassware was machine washed using detergent (Neodisher GK, Chemische 
Fabrik Dr. Weigert, Hamburg, Germany) then rinsed twice with tap water then 
three times in ultra pure water. Sterilisation was by autoclaving at 121°C for 30 
minutes. Flasks and measuring cylinders were closed with aluminium foil and 
sterilized in a hot air oven at 160°C for 2 hours.
After use all glassware contaminated with infectious material was soaked 
overnight in Virkon (ANTEC International Sudbury, Suffolk, England), washed 
and autoclaved as above.
3.2 Overview of cloning, expression and purification using a 
prokaryotic system
Genes were amplified using PCR techniques, ligated into various plasmid vectors 
and inserted into E.coli by heat shock transformation. After bacterial culture DNA 
was extracted. The exact nucleotide sequence of constructs was determined 
before sub-cloning into specialized E.coli expression cells.
Chapter 3
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Foreign genes were placed under the control of an inducible phage-based T7 
promoter which prevented expression of potentially toxic proteins, which might 
affect E Coli replication, prior to induction by IPTG. Binding of IPTG to a 
repressor induced conformation changes which lead to its dissociation followed 




DNA sequences coding for a polyhistidine tag were added to genes to enable 
proteins to be purified using matrices containing immobilized Ni 2+ ions.
3.3 Construct development and analysis
3.3.1 Polymerase Chain Reaction (PCR)
Pfu polymerase (Stratagene, Amsterdam, Netherlands Cat no. 600250) was used 
to amplify genes for cloning and expression and was added at 80°C to the
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reaction mixture to avoid mispriming and subsequent extension from unintended 
regions of sequence. For general diagnostic PCRs taq polymerase (Promega, 
Southampton, UK Cat no. M1861) was used. Both followed current 
recommended protocols.
Pfu PCR reaction mixture 50ul in 500pl PCR-tube
5pl Pfu 10x buffer
0.5pl dNTP solution (10mM per nucleotide)
5 pmols each oligonucleotide primer
40pl double processed tissue culture water (Sigma W3500)
0.1 pg template
50pl mineral oil (Sigma M-8410)
1 pi Pfu Enzyme
Taq PCR reaction mixture 25ul in 500pl PCR-tube
2.5pl Taq 10x buffer
1.75pl magnesium chloride solution
0.5pl dNTP solution (10mM per nucleotide)
0.25pl Taq DNA polymerase (5U/pl)
17pl double processed tissue culture water (Sigma W3500)
5 pmols each oligonucleotide primer 
0.1 pg template
50pl mineral oil (Sigma M-8410)
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3.3.2 Site-directed mutagenesis (SDM)
This was used to correct any nucleotide sequence errors or to introduce specific 
sequence changes to developing constructs, details of which are dealt with in the 
relevant chapters.
(i) Theory
DNA replicated in most E Coli strains used for cloning is methylated while DNA 
copied from it using available polymerases is not. Restriction endonuclease Dpn 
1, (Invitrogen cat no. 15242-019) digests only methylated DNA, so after digestion, 
the desired copied DNA construct can be used without contamination with the 
original template (See Figure 6).
(ii) SDM reaction
5pl 10x PfuTurbo buffer (see 3.2 above for product information)
20pmols each oligonucleotide primer
1pl dNTP solution (10mM for each nucleotide)
0. 1.pg template
38pl double processed tissue culture water (Sigma W3500)
1 pi PfuTurbo (2.5U/pl) added at 80°C
(iii) SDM PCR cycle
1. 80°C hot start
2. 95°C 30 seconds
3. 95°C 30 seconds
4. 55°C 1 minute (temperature varied depending on the Tm Values [210])
5. 68°C at 2 minutes / kilobase (Kb) of template
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Steps 3-5 were repeated between 12 and 18 times 
Hold temperature was 8 °C
(iv) Dpn 1 digestion








PCR product tem plate
Figure 6. Site-directed mutagenesis using the methylated DNA specific 
restriction endonuclease, Dpn 1.
3.3.3 Ligations
Circularizing of blunt ended PCR products and ligation of inserts into vectors 
were carried out using Fermentas ligase (T4 DNA ligase # EL0013) using the 




Transformations of library efficiency DH5a competent cells (Invitrogen # 18263- 
012, stock cells for maintaining plasmids) and BL21 (DE3) (Invitrogen # C6060- 
10 expression cells) were done following supplier’s protocols.
A volume of 50-100^1 of transformed cells was plated on LB agar (Sigma, Poole, 
UK #L.2897) plates containing antibiotic appropriate to the vector. Either 
ampicillin was used (Sigma # A.0166) at a concentration of 100pg/ml or 
kanamycin (Invitrogen, UK) at a concentration of 15pg/ml. Plates were incubated 
at 29-30°C.
3.3.5 Plasmid preparations
Where a high level DNA purity was not needed a crude method was used. In all 
other situations an appropriate Qiagen kit was used..
Minipreps using commercial Qiagen miniprep kit Cat. No. 27104
Preparations followed the recommended protocol using a 5 ml starter culture. 
DNA was eluted with water (Sigma W3500)
Crude Standard technique
Individual E.coli colonies were picked from agar plates into 3ml of LB broth 
(Invitrogen # 1085521). Cultures were incubated overnight at 30°C with agitation. 
1.5ml of culture was placed into a 1.5ml centrifuge tube and spun at 13.2 x 
1000rpm for 30 seconds. The pellet was re-suspended in 300pl of TENS buffer 
(see Appendix) and vortexed until the suspension was viscous. A volume of 
150p.l of NaAC pH5.2 3M was added, vortexed and centrifuged at 13.2 x 1000rpm
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for 2minutes. The resultant supernatant (400p.l volume) was mixed with 900pl of 
100% ethanol and incubated at -20°C for approximately 15 minutes. The 
samples were centrifuged at 13.2 x 1000rpm for 6 minutes and the supernatant 
discarded. Pellets were washed in 70% ethanol, air dried and re-suspended in 
50pJ of double-processed tissue culture water (Sigma W3500) containing RNase 
(Sigma # R-4642) at a concentration of 60|a.g/ml. Preparations were kept at -  
20°C and thawed for use as required.
3.3.6 Restriction Endonuclease (RE) digestions
Digestions were used to prepare plasmids and inserts for ligations and after 
cloning to map new constructs to check their identity. In general digestions 
followed supplier’s protocols.
3.3.7 Sequencing
Plasmid and PCR DNA was sequenced by Advanced Biotechnology Centre 
(ABC), Imperial College, London. PCR DNA templates were treated with 
exonulease 1 and shrimp alkaline phosphatase (Exo / Sap Appendix) 
respectively to remove PCR primers and excess dNTPs, which would otherwise 
interfere with sequencing reactions. Nucleotide sequence data were analysed 
using Chromas version 1.45, Generunner version 3.05 and Bioedit version 5.0.9.
3.3.8 Agarose gel electrophoresis
Agarose gels of concentrations between 0.8 and 2% w/v were prepared in TBE 
buffer.
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Three parts of sample were mixed with one part of DNA load buffer (see 
Appendix) in a suitable volume prior to loading. Following electrophoresis, gels 
were stained with ethidium bromide solution (see Appendix). A molecular weight 
(MW) standard was used at all times (Appendix)
3.4 E.coli protein expression
3.4.1 Expression
Three derivatives of the E.coli strain DE3 were used for expression: 1. BL21 
(DE3), 2. BL21 (DE3) pLysS and 3. BL21 (DE3) pLysE were obtained from 
Invitrogen, UK.
Colonies that contained the desired plasmids cultured in LB broth (Invitrogen # 
1085521) overnight at 30°C. These cultures were used to seed fresh cultures in 
LB broth, at a dilution of 1:50 and then incubated again at 30°C until after 
approximately 3 hours reaching mid-log phase at a reading of 0.4 OD60o- Cultures 
were induced with IPTG at concentrations between 0.5mM-1mM and incubated 
for an additional 1-4 hours. Induced cells were analysed for the expression of 
desired proteins.
3.4.2 E.coli cell lysis
50ml of Cell culture was centrifuged at 1,500 x g for 10minutes




20pl protease inhibitor (Sigma, P 8849)
150pl triton x (Sigma, T8787) (10% in PBS)
30pl (100mg/ml in distilled water) lysozyme (Sigma, L6876)
7.5pl DNAse (Sigma, D5025)
Made up to 1 ml in the following buffer:
Lysis buffer
0.535g NaH2P04 + 2H20  
3.07g Na2HP04 
8.77g NaCI
0.7g Imidazole (Sigma 10250)
Made up to 500ml with distilled water.
3.4.3 Protein purification
Proteins were purified using Ni-NTA Spin columns (Qiagen Crawley, UK 
catalogue number 31314) using supplier’s protocols. However, all cell lysates 




When linear baculovirus DNA lacking certain essential sequence is transfected 
into insect cells together with a transfer plasmid containing those sequences, 
homologous recombination occurs and virus is produced In this study, Sf9
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insect cells (Invitrogen, UK) were transfected with plasmid vector pBlueBacHis2 
(Invitrogen , UK) to which genes of interest (GOI) had been added.
Baculovirus 
linear DNA










Figure 7. The generation of recombinant baculovirus DNA.
3.5.2 Insect cell cultures
Sf9 cells were maintained in various sized cell culture flasks (NUNC, Denmark) 
following Invitrogen’s recommended protocols (Insect cell lines manual, version K 
25-0127).
3.5.3 Baculovirus plasmid vectors
pBlueBacHis2 (Invitrogen, UK) plasmids were used. Methods described under 
section 3.3 were used to develop these vectors.
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3.5.4 Transfections and plaque purifications
Invitrogens Bac-N-Blue transfection and expression instruction manual (version 
M, 25-0109) was followed throughout.
3.6 Protein analysis
3.6.1 Polyacrylamide gel electrophoresis (PAGE)
Expressed proteins were analyzed using sodium dodecyl sulphate PAGE (SDS- 
PAGE) as described by Laemmli [211]. Gels were stained with coomassie 
brilliant blue (see appendix).
Electrophoresis apparatus was the SCIE-PLAS (Warwickshire, UK) V10-WCDC 
with 1mm combs.
(i) Gels
Gels are formed by polymerizing an acrylamide monomer into long chains and 
cross linking these chains using N, N’-methylene bisacrylamide (bis). The 
percentage of SDS-PAGE gels depends on the ratio of acrylamide monomer to 
bis. Applications are as follows:
3% gels- isoelectric focusing, 5-30% - molecular sieving and
gels at 30% can be used for molecules with a relative molecular mass (Mr) as
small as 2000. Gel preparation and recipes are described in the appendix.
(ii) Protein sample preparation and loading
See Appendix




These were used for serological identification of captured proteins.
Following SDS-PAGE proteins were transferred electrophoretically onto a 
nitrocellulose (NC) membrane by virtue of the negatively charged SDS that was 
bound to the proteins. Captured proteins were then probed with antibodies. 
Bound antibodies can be detected using an enzyme-conjugate which catalyses a 
reaction with diamino benzidine (DAB, Sigma, D5905) substrate to give an 
insoluble stain. Molecular weights (MW) were determined by comparing relative 
mobilities with known standard markers.
(i) Electrophoretic protein transfer
After running a standard SDS-PAGE gel the positions of the molecular weight 
markers and the bromophenol front was measured. This allowed molecular 
weights of unknown samples to be calculated post western blot.
One of the glass plates covering the gel was removed and NC paper and filter 
papers were cut to the exact size of the relevant section of the gel.
Filter papers were stacked into three lots of six and soaked from one end in 
relevant buffer, these were either the anode 1, anode 2 or the cathode buffer 
(Electrode transfer buffers Appendix).
The western blot sandwich was constructed as follows:
Gloved hand
Anode 1 Cathode
Anode2 Anode 2 gel
NC NC NC NC
Gel -> Gel -> Gel -> Gel ->invert Anode 2
Glass Glass Glass Glass Anode 1
Naylor, [212]
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The above assembly was then placed onto the lower cathode plate followed by 








Figure 8 Western blot sandwich.
Gels were blotted for 2 hours at 80 milliamps (mA)
(ii) Development of nitrocellulose membranes
Small sealable 16mm x 10mm polythene bags were used for the development of 
NC membranes immersed in relevant solutions. Bags were agitated every 10-15 
minutes over a 1 hour incubation period to prevent local starvation of 
constituents. Between solutions the membranes were washed a minimum of 3 
times in phosphate buffered saline (PBS, see Appendix) containing 0.05% 
Tween80 detergent (Sigma, Poole, UK).
The sequence of solutions used was as follows:
5 8
APV western blot
1. Overnight blocking step at 8°C of 1% bovine serum albumin (BSA Sigma, 
Poole, UK) in PBS containing 0.05% Tween80(PBS/Tween).
2. Polyclonal serum diluted 1/100 in PBS/Tween for 1 hour
3. Goat anti turkey (GAT) horse radish peroxidase conjugate (ISL, immune 
systems limited, Paignton, UK) diluted 1/5000 in PBS/Tween for 1 hour
4. Substrate buffer (see Appendix) for 1 minute
5. DAB solution (see Appendix) until bands appear, usually between 5-15 
minutes.
6. Reaction stopped by immersing in distilled water for 30 minutes.
His tag western blot
1. Same as 1. above
2. Monoclonal, anti His, horse radish peroxidase (HRP) conjugated antibody 
(Alpha Diagnostics Cat no. HISP12-HRP) diluted 1/10,000 in PBS/Tween for 1 
hour.
3. Follow steps 4-6 above.
3.6.3 ELISAs
Some aspects of these procedures were consistent throughout the thesis, 
however many parameters were changed depending on the application. 
Therefore, ELISAs are explained in relevant chapters. Details of the antisera 
used in these tests are given below.
(i) Subtype A antiserum: At 75 days, SPF chickens were inoculated with a 
virulent subtype A APV and then again at 96 days by ocular route. Birds were
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bled seven days post second infection. Each bird received 0.1ml of 5.5 log10CD50 
(Kindly provided by Dr Kanan Ganapathy, Liverpool University)
(ii) Subtype B antiserum: At 49 days, SPF chickens were inoculated with a 
virulent subtype B APV by ocular route and birds were bled ten days later. Each 
bird received 0.1 ml of 4.0 log10CD50 (Kindly provided by Dr Kanan Ganapathy, 
Liverpool University)
(iii) Subtype C antiserum: Day old chicks were inoculated with a Colorado strain 
subtype C APV by ocular route and then again at 3 weeks by intravenous route. 
Birds were bled 24 days later (Kindly provided by Dr Fengsheng, Intervet UK)
(iv) IBV antiserum: This was generated using the same method described for 
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Development of a prokaryotic expression vector: Design, cloning and 
expression of APV genes N, P and F and the GFP gene
Chapter 4
4.1 Introduction
At Liverpool several plasmid vectors have been designed which readily accept 
APV genes and were designed for the first rescue of an APV from recombinant 
DNA [72], The plasmid developed from pUC18 in that work, became the chosen 
vector for the prokaryotic expression work described herein. Although this 
plasmid was an efficient acceptor of APV genes it required some extra elements 
(see Figure 9) to enable expression of his tagged proteins in E.coli. The new 
plasmid was named p18smahis.
pUC18 derivative
I
Add 6 x  His tag  stop 
sequence
l
Add a T 7
term ination
sequence
Figure 9. Manipulations of a plasmid derived from pUC18, to generate 
a new expression vector: p18smahis.
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All genes were amplified from existing clones using new PCR primers which 
introduced a T7 promoter followed by a ribosomal binding site (RBS) sequence to 
the start of the gene, and removed the stop codon from the trailer (Figure 10).
Sene of interest N, P, F or GFP
Start codon Stop codon
I
~ Reading frame = multiples of three bases » TTA TCC ff’Â jf*TG
Positive primers 





primers start at 
in frame codons 
up stream of 
TA&
PCR
New T7 driven DNA products without a stop codon 
but in the same reading frame as the start 
template
Figure 10. Amplification of GFP and APV genes: Removing the stop 
codons and adding T7 and RBS sequences.
New stop codons and his tag regions were introduced to these PCR products by 
ligating (Section 3.3.3) into p18smahis (Figure 11).
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T7 m s ATS Gene of interest
T7 IRBS AT& Gene of interest IS StOP T7 terminator
Figure 11. Generation of GFP or APV transcripts that contain a his tag region.
Clones that contained the exact sequence and reading frame of a particular 
inserted gene were sub-cloned into specialised E.coli cells for expression. These 
genes had been placed under the control of a T7 promoter and therefore required 
T7 polymerase for transcription. E.coli strain BL21 (DE3) express T7 polymerase 
following induction with IPTG and can therefore transcribe such genes. However, 
because some proteins may be toxic to E.coli control measures were needed 
which included lowering the concentration of IPTG and reducing the time scale 
over which expression is induced.
GFP was sub cloned first because expression could be rapidly detected. Slides 
were prepared using induced and non induced wet culture and fluorescence / 
expression was compared using a UV microscope.
65
F, N and P constructs used the same system and expression was determined 
using SDS-PAGE. These recombinant proteins all contained a his tag region for 
capture and purification using Ni-NTA spin columns. Again SDS-PAGE was used 
for analysis.
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4.2 Materials and methods part 1: Development of a prokaryotic 
expression vector
Primers P18es2.6- 5’-GGGGGAATTCTGCGCGGAAC-3’ and p18es800+
5’ GGGGAATTCGCAGGAAAGAACATG 3’ were used to amplify a pUC18 
derivative in a Pfu PCR. This generated a blunt ended linear product which, 
when circularized using T4 DNA ligase (see 3.3.3), produced a vector containing 
desired restriction enzyme sites. The ligated DNA was treated with Dpn 1 
restriction enzyme to digest the original template then used to transform library 
efficiency DH5a competent cells (see 3.3.4). Subsequent bacterial colonies were 
screened using the standard Taq PCR protocols (see 3.3.1). Products from this 
procedure were analysed using agarose gel electrophoresis (see 3.3.8). 
Plasmids were extracted from positive colonies using a Qiagen miniprep kit as 
described in section 3.3.5 then prepared for sequencing. Those with the correct 
sequence were digested with a Sma1 restriction enzyme (see 3.3.6) and ligated 
with a double stranded DNA segment containing a his tag region followed by a 
translational stop codon. This segment was generated by annealing 
approximately 1pg of primer sma-his-pos 5’-GGGCATCACCATCACCATCACTA 
G-3’ and 1 jag of primer sma-his-neg 5’-CTAGTGATGGTGATGGTGATGCCC-3’ 
in a PCR block using the following program: 94°C for 3 minutes then 40°C 
>30minutes. The transformation, screening, plasmid preparation and sequencing 
procedures described above were repeated.
Adding the T7 termination sequence
Mfe1 and EcoR1 restriction endonucleases have different recognition sequences 
but leave the same 5’ AATT overhang. After digestion the 2 sites can be ligated 
and because both recognition sequences are lost, it will not be recognized by
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either enzyme. These properties were pivotal in the T7 termination cloning 
strategy illustrated in Figure 12.
Figure 12. Adding a T7 termination sequence to p18smahis.
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A kanamycin resistant plasmid (Ctpe) that had been developed by Naylor et al. 
[72] was ligated with a blunt ended, T7 termination PCR product. This contained 
Mfe1 sites at both the 5’ and 3’ ends (Figure 12. step 1.). Transformed DH5a 
colonies were cultured in LB broth containing 100pg/ml of kanamycin and 
plasmids were extracted using a Qiagen plasmid miniprep kit. The T7 
termination sequence was excised from the purified plasmid by digesting with 
Mfe1 leaving a product with complementary end sequences to that of EcoR1 
(Figure 12. step 2). This product was ligated with EcoR1 digested p18smahis 
with 0.5pl of Mfe1 (10U/pl) and 0.5pl of EcoR1 (10U/pl) in the ligation mixture. 
This prevented unwanted ligations (Figure 12. step 3) and improved the success 
rate of the desired ligation (Figure 12. step 4). DH5a cells transformed with 
ligation mixture were cultured on LB agar plates containing ampicillin at a 
concentration of 100pg/ml (see 3.3.4). Plasmids were screened using standard 
taq PCR and agarose gel electrophoresis, purified using qiagen miniprep kits and 
sequenced.
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4.3 Results part 1: Vector development
Amplification of a pUC18 derivative using P18es2.6 (5  GGGGAATTCTGCGCG 
GAAC-3) and P18es800+ (5 GGGGAATTCGCAGGAAAGAACATG 3) produced 
a PCR product of 1.8Kb
Figure 13 PCR product amplified from a pUC18 derivative, size ~1.8kb 
on an agarose gel, stained with ethidium bromide.
Bacterial colonies transformed with the above, were screened using primers that 
gave a product of 300 base pairs (bp). Figure 14 shows an example of two 
colonies that contained plasmid with the desired insert.
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Figure 14. Example of two E.coli clones containing the vector shown 
in Figure 13. Identified via PCR screening. Product size ~300bp on 
an agarose gel, stained with ethidium bromide.
In total, five clones contain the vector. Two of these were shown to have the 
correct nucleotide sequence (Figure 15).
Sequence Name: CNLQ1 Run ended: Jul 17, 2003 ____________
580 590 _____600
T T  C C G C G C A  < ^C ^~ G ^G ^X ^A ^A /T JT ^) G C A G G A A A C
E coR l s ite  S m a l s ite  E eoR l s ite
Figure 15. Sequence of introduced RE sites EcoRl and Smal in pl8smahis
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These two vectors were used for the second stage of development in which a his 
tag stop region was added. Again colonies were screened using PCR. Primers 
were designed to produce products of 320bp as shown in 7 of the 25 samples 
screened in Figure 16.
Figure 16. Seven E.coli clones containing the desired vector P18sma-his 
(lanes 6, 8, 9, 14, 15, 19 and 22). Identified via PCR screening. Product 
size ~320bp on an agarose gel, stained with ethidium bromide
Sequence analysis of the above showed that five of the seven clones had the 
correct sequence (Figure 17).
03.ab 1 Sequence Name: CNQ2 Run ended: Aug 3, 2003____________
2 90 30 0  3 1 0  320
G G G C A T C A C C A T C A C C A T C A C  T A G  G G G  G A A T T C  T G C
' H i s  + a g  s t o p  s e q u e n c e
Figure 17. The his tag stop sequence in pl8smahis.
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Addition of the T7 termination sequence illustrated in Figure 12 involved several 
steps; Figure 18 shows two Mfe1 digests that extracted the T7 termination 
sequence from Ctpe and this was then ligated into EcoR1 digested p18smahis
Colonies containing the insert were identified by PCR and the resulting DNA was 
sent for sequencing analysis. All samples had the correct, entire T7 termination 
sequence. The start of this sequence is shown in Figure 19.
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File: PB05 03 abl Sequence Name: PB05 Run ended: Jun 2, 2004______________
4 3 0  4 4 0  __ 4 5 0 ^ ^  4 6 0
G C A T C A C C A T  C A  C C A T  C A C T  A G G G G (C A  A T  T G ) G  A T G G C T A A G




Figure 19. Addition of a T7 termination sequence to p18smahis: the combination of 
EcoRl and Mfe1 restriction enzyme recognition sequences.
4.4 Materials and methods part 2: Amplification of APV genes and 
GFP: ligation with p18smahis
APV genes F, N, and P were amplified in a standard Pfu PCR from existing 
clones using the PCR primers listed below. Each oligo pair introduced a H  
promote| followed by a RBS sequence to the start of the gene, and removed the 
stop codon from the trailer.
Nucleocapsid primers
N-T7 5’-fTTAAT AC G ACT C ACTAT AGQTT AA|AAGQì|G  AGT C AAAAAT GT CT CTT G-3’ 
with N-no-Stop 5’-CT C AAATTT GG AT GAT CT CT CAT C- 3’
Phosphoprotein primers
P-T7 5’ -TTAATACGACTCACT ATAGGTT AAGAAGGAG AAGT AAC AAT GT CTTT CC-3’ 
with P-no-Stop 5’-CAGATCAAGATTGTATATGTCGCTC -3’
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Fusion protein primers
F-T7 5’ -TTAATACGACT CACTATAGGTT AAGAAGG AG AT ATAC AT AT GG AT GTAAG
AATCTGT-3’ with F-no-stop 5’-ACTGACATAAGCCATGCTGCTATG-3’
GFP gene amplification
GFP was amplified from a plasmid kindly provided by Mathew Davis (University
of Leeds) with primers T7-GFP
5’H B ^ TACGACTCAC^ ^ B ^ TAAGAAG^ i GACGCCACCATGGTGAGCAAGGGC"
3’ and GFP no stop 5’- CTTGTACAGCTCGTCCATGCC -3’
4.4.1 Ligations with p18smahis, generating clones for expression
Blunt end PCR products were ligated into the Sma1 site of p18smahis with 0.5pl 
(10U/pl) of Sma1 in the ligation mixture. Ligations were used to transform DH5a 
competent cells which were grown on LB agar plates containing 100pg/ml of 
ampicillin. Subsequent colonies were prepared using the crude standard 
miniprep technique (section 3.3.5) for plasmid analysis. These were screened 
using EcoR1 restriction endonuclease digestion. Regions of interest were 
amplified using standard Taq PCR for sequencing.
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4.5 Results part 2: APV and GFP gene amplification
Pfu PCR amplification of genes N, P, F and GFP produced blunt end products of 
1.2Kb, 800bp, 1.6Kb and 700bp respectively as shown in Figures 21 and 22.




EcoR1 digestion of p18smahis plasmids that had accepted the genes shown in 
Figures 21 and 22 resulted in excision of the insert producing the following sized
products:
N-p18smahis = 1.8Kb + 1 2Kb
P-p18smahis = 1.8Kb + 800bp
F-p18sma-his = 1.8Kb + 1.6Kb
GFP-p18sma-his = 1.8Kb + 700bp
These are demonstrated in Figures (23, 24, 25 and 26)
Figure 22. EcoR1 digest of three individual, N-p18smahis plasmid 
preparations. One produced the expected sizes of 1.8Kb and a 1.2Kb on 
an agar gel stained with ethidium bromide.
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Figure 23. EcoR1 digest of four individual, P-p18smahis plasmid preparations. 
All produced the expected sizes of 1.8Kb and 800bp on an agar gel stained with
ethidium bromide.
Figure 24. EcoR1 digest of six individual, F-p18smahis plasmid preparations, 
five produced the expected sizes of 1.8Kb and 1.6Kb on an agar gel stained 
with ethidium bromide.
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Figure 25. EcoR1 digest of five individual, GFP-p18smahis plasmid preparations. 
Two produced the expected sizes of 1.8Kb and 700bp on an agar gel stained
with ethidium bromide.
4.5.2 Sequence analysis
Many sequences had two or more nucleic acid point mutations or deletions 
however; several clones of each construct had the correct sequence. Figure 26 
shows the electroencephalogram of a GFP clone with the correct sequence.
T 7  p r o m o t e r  R B S
Figure 26. A GFP construct with an up stream T7 promoter and an RBS sequence.
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4.6.1 Transformations
E.coli BL21 (DE3) cells were transformed using ~1ng of N, P, F or GFP- 
p18smahis plasmid DNA according to the supplier’s protocol (3.3.4)
4.6.2 PCR screening
Taq PCRs were used to screen BL21 (DE3) cells that had been transformed with 
N, P, F or GFP-p18smahis plasmid DNA. Colonies were screened directly from 
agar plates without the need for plasmid purification as shown in Figure 27. 
Products were analysed using agar gel electrophoresis (3.3.8)
4.6 Materials and methods part 3: Gene expression and purification
Figure 27. Direct PCR screening of E.coli colonies 
4.6.3 Induction
Colonies that contained the desired plasmids were induced as described in 
section 3.4.1 using 1mM IPTG and an induction time of 3hours.
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4.6.4 E.coli cell lysis
Cells were lysed as decribed in section 3.4.2
4.6.5 Protein purification
APV his tag recombinant proteins were purified under native conditions using Ni- 
NTA spin columns as described in section 3.4.3
4.6.6 Wet culture slides
0.5pl of induced and non-induced GFP cultures were placed onto 76 x 26 mm 
microscope slides, overlayed with cover slips then viewed using a UV microscope 
using a filter optimized for observing Fluorescein..
4.6.7 SDS-PAGE
APV recombinant proteins were analysed under none-reducing conditions as 
described in section 3.6
4.6.8 Western blot
APV western blots were used to detect recombinant proteins in cell lysates and
purified samples as described under section 3.6.2
Positive and negative controls for these blots were prepared as follows:
Positive control
1x107 (75cm cell culture flask) of Vero cells containing APV 
Cell sheet re-suspended in 2ml PBS 
Two cycles of freeze thawing 
Centrifuged for 1min at 13.2 x 1000rpm
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Supernatant discarded
Pellet re-suspend in none reducing sample buffer (Appendix) for SDS-PAGE 
Negative control
A standard E.coli cell culture was generated and lysed following the same 
procedures as described for those containing expression vectors. These were 
then prepared for SDS-PAGE (section 3.6).
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4.7 Results part 3: Expression and purification
4.7.1 Direct PCR screening of E.coli colonies containing N, P or F- 
p18smahis
BL21 (DE3) cells that had been transformed with F-p18smahis, were screened 
with internal and external primer combinations (see Figure 28, 1. and 2.). Those 
transformed with P-p18smahis or N-p18smahis were screened using external 
primer combinations. For F-p18smahis these were anticipated to give 420bp 





Figure 28. Internal and external PCRs for direct screening of 








Figure 29.' One BL21 (DE3) clone containing the F-p18smahis 
plasmid. 420bp and 2.0Kb PCR products on an agar gel 
stained with ethidium bromide.
Cells transformed with either N or P-p18smahis were screened using the external 
primer combination shown in Figure 28, 2, giving 1.8Kb and 1.4Kb products 
respectively as shown In Figures 30 and 31.
N-pl8sm ahis 
1. 2 . 3 . 4 .
----600bp
Figure 30. Four positive BL21 (DE3) clones containing the N-p18smahis 
plasmid. A 1.8Kb PCR product on an agarose gel stained with ethidium 
bromide
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Figure 30. Two positive BL21 (DE3) clones containing the P-p18smahis 
plasmid. A 1,4Kb PCR product on an agarose gel stained with ethidium
bromide.
4.7.2 GFP p18smahis expression
BL21 (DE3) cells that had been transformed with GFP-p18smahis were induced, 
prepared as wet culture slides and analysed directly by simple UV microscopy 
utilizing the inherent fluorescent properties of the GFP protein. Figure 31 shows 
induced E.coli cells (right) fluorescing compared with none-induced negative 
control (left). Thus: construct was functional and expression was induced.
Figure 31. Wet culture slides of none-induced (left) and induced (right) E.coli 
cells containing GFP-P18sma-his construct viewed using UV microscopy.
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APV constructs N-p18smahis, P-p18smahis and F-p18smahis employed the 
expression system validated by GFP above. None reducing SDS-PAGE was 
used for visualizing expression, comparing none-induced and induced samples. 
Expected sizes for the N and P proteins were as follows.
N = 38-43 KDa [14-16]
P = 35-40 KDa [14-16]
The F protein of APV has a cleavage site towards the amino terminal of the 
protein at an arginine-lysine rich sequence [48] and can be cleaved into two sub­
units F2 (amino-terminal) and F1 (carboxy-terminal). In none-reducing conditions 
disulphide bonds link these sub-units but in reducing conditions the bonds are 
broken and the sub-units are separated. Therefore cleavage activity and 
conditions used in SDS-PAGE will determine the size of the product seen.
None cleaved F protein (F0) = 68 KDa [16]
Cleaved, none-reducing conditions = 59 KDa [16, 212]
Cleaved, reducing conditions F1 = 45-54 KDa F2 = 15 KDa [14-16].
F-p18smahis
The cell lysates of two F-p18smahis E.coli colonies (both induced and none 
induced) were compared using none reducing SDS-PAGE analysis. Figure 32 
demonstrates bands (circled) in both induced samples which were absent in the 
none-induced samples indicating that these products were proteins resulting from 
induction i.e expression of F-P18sma-his. The approximate size of these 
products, 59 KDa, could represent sub-units F1 and F2, linked by disulphide 
bonds, as suggested by Cavanagh and Barrett 1988 [16] and Naylor [212],
4.7.3 Expression of APV constructs
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F-P18sma-his





hv)X X N X  X
|s|X= none-induced 
X= Induced
Figure 32 None-reducing, SDS-PAGE analysis of 
Cell lysates from two E.coli samples (Both, induced 
and none-induced) containing F-P18sma-his construct.
4.7.4 N and P-p18smahis
No differences were observed between the induced and none-induced cell 
lysates of these constructs via SDS-PAGE suggesting that expression had not 
been induced, however expressed N or P could have been masked by E.coli host 
proteins of the same molecular weight. Therefore, Ni-NTA purification using the 
his tag region was attempted.
4.7.5 Protein purification
Any expressed APV protein from p18smahis vectors would be fused with a his 
tag (Figure 12) which would allow purification using immobilized metal Ni2+. 
Fractions that were taken at three separate stages of purification for F, N and P 
are shown in Figures 33 and 34. These were analysed by SDS-PAGE. The third 
fraction represents purified his tagged protein.
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F-pl8smahis purification 
Sample 1KD «w Sample 2 Sample 3






Figure 33 SDS-PAGE analysis of three induced and purified 
F-P18sma-his samples. Ly = cell lysate, W = wash fraction, 
el = purified sample.
No product could be seen in the purified sample for F in this gel or in other 
instances when IPTG concentration and/or time allowed following induction were
altered.
Figure 34. SDS-PAGE analysis of N and P-P18sma-his samples after 
induction and purification. Ly = cell lysate, W = wash fraction, 
el = purified sample. Ringed bands highlight faint bands seen in the 
purified sample.
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Purified products of both N and P were larger than the expected sizes of P 35- 
40KDa, N 38-43Kda and most likely represented E.coli contaminants however, 
these could also have represented multimers (aggregates held together with 
none-covalent bonds) of each purified protein.
4.7.6 Western blot analysis
The lysates and purified samples of F, N and P (Figure 32, 33 and 34) together 
with APV virus culture and E Coli without insert were probed using polyclonal 
APV positive turkey serum to produce the blot shown in Figure 35.
Figure 35. Western blot analysis of F, N and P recombinant proteins Ly -  cell lysate 
and el = purified sample. Ringed bands highlight proteins that gave the strongest
reaction
A graph plotting the relative frontal mobility (Rf) value of each MW marker (Table 
1) against the log10 of its MW was used to determine the size of the bands 











Rf values ringed 
samples Figure 35
Log10 MW markers
0.018 N = 0.38 5.34
0.086 P = 0.38 5
0.164 F = 0.19 4.78





Figure 36. Log10 MW of samples N, P, F and APV following western blot analysis.
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Western blot results and conclusions
Both the N and P lysate samples gave a 36.3KDa band. This size could have 
represented the P protein however; as both lysates produced the same size 
product, it was unlikely. Furthermore the purified samples of both N and P in 
Figure 34 did not show N or P bands and therefore they were considered to be 
E.coli proteins and not N or P multimers.
Both the F lysate and virus lysate gave a 57KDa band. This figure was close to 
the 59KDa published size for cleaved F protein [16, 212] in none reducing 
conditions. No products were seen in purified F samples.
It appeared from these results that the F protein was being expressed but not 
purified. One possibility may have been due to concealment of the his tag by the 
protein itself, which would render it inaccessible for capture, using Ni2+. A 
simple experiment to linearise the protein and expose the his tag regions before 
Ni2+ capture was attempted.
4.8 Linearising expressed protein
(i) Method
To disrupt hydrogen bonding and yield a linearised protein 8M urea was added to 
200pl of the F cell lysates shown in Figures 32, 33 and 35. Mixtures were 




No F protein was purified from lysates treated with urea (Figure 37)
W6i F-pl8smahis pu rifica tio n  (denatured) K|Da MW 
Sample 1 Sample 2 90— Î
65— m
0  4 0 —  B
i
I ■■
H |  Ly W  el Ly W  el
Figure 37. SDS-PAGE analysis of purified F protein following treatment 
with 8 M urea Ly = cell lysate, W = wash fraction, el = purified sample.
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4.9 Discussion
Many proteins have been successfully expressed in and purified from E.coli cells, 
including glycoproteins of infectious laryngotracheitis virus (ILTV) [213] and APV 
N and M subtype C proteins [2, 3]. Here potentially antigenic subtype A APV 
proteins, the fusion protein (F), the nucleocapsid protein (N) and the 
phosphoprotein (P) were tagged with 6 histidine amino acids and selected for 
expression in E.coli. In addition to these proteins GFP was expressed as a 
direct visual reporter of gene expression and purification.
A plasmid, known to readily accept APV genes was modified so that it could be 
used as a prokaryotic expression vector. Although many commercial plasmids 
are available for expression, certain APV genes were known to be difficult to 
clone (C. J. Naylor., D. R. Kapczynski., personal communication); therefore, the 
rational was to make necessary changes to a plasmid with known cloning 
characteristics. The methods adopted for making these changes were effective 
and generated some flexible cloning strategies that proved useful in future work. 
In particular the strategy outlined in Figure 12 produced a method that was highly 
selective for desired ligations. The T7 terminator was added by ligation of 2 
dissimilar RE sites in the presence of both restriction endonucleases as 
previously described. This proved to be an efficient method whereby 90 % of 
screened colonies contained the desired insert.
Figures 22-25 demonstrated p18smahis plasmids that had accepted the genes N, 
P, F and GFP although the plasmid yields were low. As a convenient alternative 
to further bacterial culture and DNA purification when the inserted genes were 
sequenced, plasmid DNA was amplified by PCR. Only a small number of these
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clones contained the correct sequence, emphasizing the importance of 
sequencing the constructs, in their entirety, before taking them onto the next 
stage. For a gene to be expressed it must be “in frame” (multiples of three 
nucleotide bases from the start codon to the stop codon), therefore, just one base 
deletion will eliminate desired protein expression beyond that point in the gene.
The GFP was useful for readily determining protein expression and showing that 
the developed vector was functional. While expression generally increases over 
time, over expression can lead to accumulation of insoluble protein in inclusion 
bodies. When bacteria package highly expressed protein in this manner, strong 
dénaturants are required for their extraction. Unfortunately such strong 
dénaturants can affect a proteins antigenic property; therefore if a protein is to be 
used as antigen it is desirable to extract it in soluble form. Optimal conditions for 
this can vary from protein to protein and are often achieved empirically.
The cell lysates of induced E.coli containing the F gene (Figure 32) showed 
products of 57KDa following western blot analysis as did the APV virus culture. 
This was close to the published size 59KDa [16] and may have represented sub­
units F1 and F2, linked by disulphide bonds, however IMAC Ni-NTA purification 
yielded no protein. This may have been because too little was being expressed 
to allow purification but another possibility was concealment of the his-tag within 
the protein itself, which would render it inaccessible for capture, using Ni2+. 
However, by adding a strong dénaturant to the cell lysate, hence linearising at 
least a percentage of the protein, the His-tag should have been exposed and 
accessible for purification. These changes had no impact on purification 
efficiency. As consistent bands of the correct size were seen in cell lysates of
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induced F samples, it is likely that expression levels were insufficient for 
purification.
Purification from N and P lysates yielded several products, yet these were larger 
than expected (Figure 34). It was thought that these could have represented N 
and P multimers yet, none of these proteins reacted in a western blot when 
probed using an APV positive serum. This suggests that the proteins observed by 
SDS-PAGE were E.coli contaminants purified non-specifically on the Ni-NTA 
columns.
Generally, a low level of expression was considered to be the reason for the 
inability to purify the proteins and this led to exploration of methods that 
increased expression levels.
It is known that different RBS and their position relative to the to the downstream 
transcribed gene can affect translation, as can other factors within the plasmid 
vector [214, 215]. Flowever, to introduce these changes to existing clones would 
be time consuming and may only improve expression levels minimally. An 
alternative approach was to use a commercial vector. In addition it was decided 
that fusion proteins of APV and GFP would be made to enable simple UV 
visualization of APV protein expression and tracking of the different stages of 
purification. A baculovirus expression system was also explored.
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GFP and APV N, P and F genes were cloned into a commercial, prokaryotic 
expression vector p-ET 30 (kindly provided by Dr Richard Birtles, Liverpool 
University). This vector is shown in Figure 38.
B p u l 102 I;SO)
X h o  1(158)
N o t 1(166) 
Eag 1(166) 
H in d  111(173) 
Sal 1(179) 
Sac 1(190) 
E coR  1(192) 
Bam H  1(198) 
E coR  V(206) 
M eo 1(212 ) 
K p n  1(238) 




P V U  1 (4 4 7 » )  .  / / / ^
S g f  1 ( 4 4 7 0 )  ^ - V / /  V  
/ / /Sm a 1(4353) V / /
B s p L U It 1(3277} /
Sap 1(3161) 
3SÎ1107 1(3043) 
T th 1 11 1(3022)
V yM lu  1(1176)
|Y iY —Bd  1(1 ISO)
CO Iro I l I BstE 11(1357)
T / K A pa 1(1387)
?
if
a 3 ssH 11(1587)





Figure 38. Petao vector map
Like p18smahis it placed genes under the control of a T7 promoter and had the 
potential to provide either or both amino (N) and carboxy (COOH) terminal his 
tagged proteins following expression. N-terminal his tags were generated for the 
N and P proteins and dual N / COOH terminal his tags for the F protein. In 
addition, APV genes N, P and F were each combined with the GFP gene to
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produce new N-GFP, P-GFP and F-GFP proteins, when expressed (Figure 39). 
For each of the 3 fusion constructs, single and duel his tags were made. The 
GFP region of these new recombinant APV proteins enabled tracking of 
expression and purification. It was important to place the GFP gene after AVP 






New N, P or F-GFP 
reading frames
I tac
Fluorescent N, P or F-GFP protein
Figure 39. Generating F-GFP recombinant proteins.
(ii) Baculovirus
Baculoviruses have been used to express many different viral proteins in insect 
cells [1, 4-6, 63]. These systems have been shown to produce high levels of 
correctly folded recombinant proteins when expressed under the control of the 
Autographa califomica multiple nuclear polyhedrosis virus (AcMNPV) polyhederin 
promoter [216-219]. Insect cells recognise signals for phosphorylation and N- 
linked and O-linked glycosylation amongst others and are therefore capable of
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producing biologically active proteins. As the APV F protein is known to be one 
of the major immunogenic, glycosylated proteins it was selected over N and P to 
be expressed in this system along with GFP. These genes were inserted into 
baculovirus transfer vectors for transfection of Sf9 insect cells with linear 
baculovirus DNA. Expressed recombinant proteins would have an N terminal his 
tag.
5.2 Materials and methods part 1: Developing clones
5.2.1 Amplification of APV, GFP and APV-GFP genes for E.coli
expression
N, P, F and GFP genes were initially designed to produce an N-terminal his 
tagged protein following expression from p-ET 30. Genes required amplification 
using oligo pairs that started in frame with the gene start codon and finished at 
the translational stop codon. (Figure 40)
S tart codon Stop codon
I
|T*6| IN , P, F or GFP gene
Positive primers 
start in frame up 
stream of the 
gene start codon
Negative 
primers start at 




New DNA products with fo r ligation with p-ET 30
Figure 40. Generating new N, P, F and GFP genes for ligation with Pet30
1 0 0
Several templates were used for amplifying APV genes: (i) The full length clone 
developed by Naylor et al 2004 [72] using oligos listed in Table 2 (ii), existing N 
and P clones in PCi (Promega, UK) using N and P oligos listed in Table 2 and (iii) 
the F-p18smahis clone developed in Chapter 4 using oligos listed in Table 3. 
Use of this clone for amplification of the F gene produced a gene that coded for 




Sequence 5’ to 3’
N




Pstop CATAACTAC AG AT C AAG ATT G
F
Fstart plus 3 AGGAT GGAT GTAAGAAT CT GT CTCC




Sequence 5’ to 3’
F
Fstart plus 3 
Sma His neg
AGGAT GGAT GTAAGAAT CT GT CT CC 
CTAGT GATGGT GATGGT GAT GCCC
1 0 1
The GFP gene was amplified from GFP-p18smahis developed in Chapter 4 using 




Sequence 5’ to 3’
GFP
GFPstart 2 AT GGT GAGCAAGGGCGAGGAGC
GFP stop 1 TTTACTT GTACAGCT CGT CC
APV-GFP fusion genes were developed as illustrated in steps 1-4, Figure 41, 
using oligos listed in Table 5. However, these products were only developed 
after the GFP gene and each APV gene had been individually cloned into p-ET 
30. This PCR product was circularized (step 5 Figure 41) producing a viable 
plasmid vector and therefore did not require further development.
All PCRs followed the standard Pfu PCR protocol. However the overlap PCR in 
step 3 Figure 41 had no oligos in the reaction mixture.
Table 5.
Oligo Names
Sequence 5’ to 3’
GFPstart 1 AT GGT GAGCAAGGGCGAGG
p-ET 30, 777 - C AGT CGT C ACT CAT GGT G ATTT CT C
p-ET 30, 5227 + GAGCT CCGT CGAC
N nostop CTCAAATTTGGATGATCTCTCATC
P nostop CAG AT CAAG ATT GTATAT GT CGCT C
Fnostop ACT GACATAAGCCATGCTGCTAT G
1 0 2
1. The GFP and APV genes were amplified from  p-ET 3 0  constructs producing PCR 
products with regions of complementary, overlapping sequence
Positive oligo (GFP Negative Negative oligo (N , P Positive plasmid oligo
start 1+) includes plasmid oligo or F nostop-) (p-ET 30 ,5227+)
GFP start codon (d-ET  3 0 .7 7 7 -) removes the stop i
Complementary, overlapping p-ET 30  
sequence
2. These were treated with exo 1 (Exo Appendix) to remove oligos: 
GFP start 1 +, p-ET 3 0 ,7 7 7 -, p-ET 30 ,52 2 7 +  and N , P or F nostop
x E x o lx
ft
3. PCR products were mixed and run in an overlap Pfu PCR
■
ft
GFP p-ET 30 ¿TGjjg N , P or F
T _ r
4. GFP start 1. and N , P or F nostop oligos were added to 
amplify these products in a Pfu PCR
8
I H  P-ET 30~
8
A ren a  N . P o r F
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5 . Blunt end PCR products were circularised using 
DNA Ligase
V
6 .  Dpnl Restriction endonuclease was added to
remove the original p -E T  3 0  templates (see iv 
Dpnl digestion, 3.3.2). Products were then 
cloned.
Figure 41. The generation of p-ET 30 plasmid vectors carrying APV-GFP genes
Vectors that coded for both N and COOH his tagged N and F-GFP proteins were 
also developed using the above vectors as templates in a SDM reaction (3.3.2). 
Oligos for these reactions are listed in Table 6
Table 6.
Oligo Name Sequence 5’ to 3’
S DMgf p-cterm-h is-pos CGAGCT GTACAAGAAAT CGGAT CCGAATT CG
SDMgfp-cterm-his-neg CGAATT CGGAT CCGATTTCTT GTACAGCT CG
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5.2.2 Amplification of the APV F gene and the GFP gene for 
Baculovirus expression
Both genes were amplified in a standard Pfu PCR from F and GFP-p18smahis 
vectors developed in Chapter 4 using oligos that introduced Mfe 1 RE recognition 
sites to both the 5’ and 3’ ends. The sequence of these oligos is shown in Table 





Sequence 5’ to 3’
Fmfelpos CGTTCCAATTGGATGTAAGAATCTGTCTCCTATTG
Fmfel neg CAAGCCAATTGCAGACT GACATAAGCCAT GCTGC
GFP mfe1 pos CTTATCAATTGGTGAGCAAGGGCGAGGAGCTG
GFPmfelneg ATAGGCAATT GCG ACTTGTACAGCT CGT CCAT GCCG
5.2.3 E.coli and Baculovirus transfer vectors: Ligations and cloning
Blunt ended GFP, N, P and F PCR products were ligated into the EcoRV site of 
p-ET 30 using the Fermentas protocol but with the addition of 0.5pl (10U/pl) of 
EcoRV in the ligation mixture. Ligations were used to transform DH5a competent 
cells which were grown on LB agar plates containing 15pg/ml of Kanamycin.
Blunt ended N, P and F-GFP PCR products were circularized using T4 DNA 
ligase according to the recommended protocol. After an overnight incubation at
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14°C, 0.5(jl (2-8U/|jl) of RE Dpn1 was added. This mixture was incubated for a 
period of 6 hours at 37°C then used to transform DH5a competent cells. These 
were again grown on LB agar plates containing 15pg/ml of Kanamycin.
Ligation of F and GFP genes into pBlueBacHis2 followed procedures used for 
inserting the T7 termination sequence into p18smahis (4.2). F and GFP replaced 
the T7 terminator and pBlueBacHis2 plasmids replaced p18smahis in the 
strategy illustrated in Figure 12. Ligations with pBlueBacHis2 were in the 
presence of EcoR1 only but all other constituents were the same. However, the 
APV F gene contained two internal Mfe 1 sites in addition to those introduced to 
the start and end of the gene (5.2.2) and therefore when excised from Ctpe using 
RE Mfe1, was digested into three sections, (Figure 42) each of which having 
complementary end sequences to that of EcoR1 digested pBlueBacHis2. GFP 
and all three sections of the F gene were ligated with EcoR1 digested 
pBlueBacHis2 with 0.5pl of EcoR1 (10U/pl) in the ligation mixture. DH5a cells 
transformed with ligation mixture were cultured on LB agar plates containing 
ampicillin at a concentration of lOOpg/ml (3.3.4).
5.2.4 RE digestions
Digestions using EcoRV, EcoR1, Mfe 1 and Dpn 1 followed suppliers protocols.
5.2.5 Screening and sequencing
Restriction endonuclease (3.3.6) and PCR techniques (3.3.1 and 4.6.2) were 
used to screen E.coli colonies for desired plasmids. All products were analysed 
using agar gel electrophoresis. Those that were positive were sequenced.
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Qiagen miniprep kits were used for all plasmid preparations (3.3.5)
5.2.6 Plasmid preparation
Generation of 3 APV F sections 
a fter digestion with RE M fe 1






F2 section including 1 /3  
o f  th e  sequence coding 
fo r  th e  fusion re la te d  
domain
F I section  including 2 /3  
o f  th e  sequence coding 
fo r  th e  fusion re la te d  
domain
F I  /  Tail region  
including th e  
sequence coding fo r  
th e  transm em brane  
domain
Figure 42. The F gene digested into three sections using RE Mfe1. Each section had 
Mfe1 5’ AATT overhangs, complementary to EcoR1 5’ AATT overhangs of pBlueBacHis2.
5.3 Materials and methods part 2: Expression in E.coli
5.3.1 Transformations
E.coli BL21 (DE3), BL21 (DE3) pLysS and BL21 (DE3) pLysE cells were 
transformed using ~1ng of N, P, F, GFP, N-GFP or F-GFP p-ET 30 plasmid DNA 
according to the supplier’s protocol (3.3.4). pLysS and pLysE cells contain 
plasmids that express T7 lysosyme (more so in pLysE than pLysS). This reduces
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expression of T7 driven genes until induced and can be useful if proteins are 
suspected of being toxic to bacteria.
5.3.2 PCR screening
Taq PCRs were used to screen BL21 (DE3) cells that had been transformed with 
the above. Colonies were screened directly from agar plates as described in 
section 4.6.2 and Figure 27.
5.3.3 Induction
Colonies that contained desired plasmids were induced as described in section 
3.4.1 using either or both 0.5mM andlmM IPTG and induction times of 1-4hours.
5.3.4 E.coli cell lysis
Cells were lysed as described in section 3.4.2
5.3.5 Protein purification
APV his tag recombinant proteins were generally purified under standard native 
and denaturing conditions using Ni-NTA spin columns as described in section 
3.4.3. In addition to the standard purification protocols the following modifications 
were made : 1. Addition of 2-Mercaptoethanol (2ME) (10mM final concentration) 
to denatured lysates. 2. Addition of 10% ethanol in denaturing wash buffers. 3. 
Addition of 25% glycerol in denaturing wash buffers and 4. Addition of 8M urea to 
native lysates and wash and elution buffers.
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5.3.6 Wet culture slides
0.5|jl of induced GFP and N, P and F-GFP cultures were placed onto 76 x 26 mm 
microscope slides, overlayed with cover slips then viewed using a UV microscope 
using a filter optimized for observing Fluorescein.
5.3.7 SDS-PAGE
All recombinant proteins were analysed under none-reducing conditions as 
described in section 3.6
5.3.8 Western blot
APV and his tag western blots were used to detect recombinant proteins in cell 
lysates and purified samples as described under section 3.6.2
5.3.9 ELISAs
Flexible, 96 well, flat bottomed ELISA plates (Becton Dickinson, UK) were used. 
Wells were coated with 50pl of antigen which had been previously diluted 1/50 in 
ELISA CBC (carbonate-bicarbonate) buffer (Appendix). Plates were incubated at 
8°C overnight. Antigens included cell lysates, purified products and a Liverpool 
developed whole virus APV antigen. The details of where each antigen was 
placed in a particular ELISA, is given along side the relevant plates in the results 
section.
The procedures for APV and his tag ELISAs are given below.
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APV ELISA
1. Incubated plates washed 5 times with ELISA wash buffer (Appendix).
2. 50pl / well of polyclonal APV positive or negative serum, diluted 1/100 in wash 
buffer incubated for 1 hour at 37°C.
3. Washed 5 times with wash buffer.
4. 50pl / well of GAT conjugate diluted 1/1000 in wash buffer incubated for 1 
hour at 37°C.
5. Washed 5 times with wash buffer.
6. 100pl / well of OPD activated with 30% H20 2 (Sigma, UK H-1009) (Appendix) 
incubated at room temperature in the dark for a maximum of 15 minutes.
7. 50pl / well of 2.5M H2S04 (Appendix)
his tag ELISAs
1. Same as step 1 above
2. Monoclonal, anti his, HRP conjugated antibody diluted 1/10,000 in 
PBS/Tween for 1 hour.
3. Same as steps 5-7 above.
5.4 Materials and methods part 3: Baculovirus expression
5.4.1 Insect cell lines
Sf9 insect cells were grown and maintained as described in 3.5.2
5.4.2 Transfection
GFP and F2-BlueBacHis2 constructs were transfected as described in 3.5.4. 
using the following controls:
1. Transfection with all constituents except the transfer plasmid
1 1 0
2. Transfection with all constituents except the linear baculovirus DNA
3. Transfection with media only.
5.4.3 UV microscopy
Sf9 cell sheets were analysed for recombinant GFP baculovirus by viewing 
infected cell sheets using a UV microscope equipped with a Fluorescein filter.
5.4.4 Light microscopy
Sf9 cell sheets were analysed for recombinant F2, baculovirus by viewing 
infected cell sheets using an inverted light microscope.
5.4.5 Plaque purification
GFP and F2 recombinant baculovirus were plaque purified as described in 
section 3.5.4
5.4.6 PCR analysis of plaque purified virus
DNA was extracted using the Qiagen blood sample protocol supplied with QiAmp 
DNA extraction kits (Qiangen, UK 51304 ). DNA was analysed using standard 
Taq PCRs (3.3.1)
5.4.7 Insect cell lysis and his tag purification
Sf9 cells were lysed and purified as follows:
Approximately 3.3 x 106 cells (1 x 25cm2 cell culture flask) were re-suspended in 
600pl of lysis cocktail (see below) followed by 5 cycles of freeze thawing. 
Unclarifed lysates were centrifuged at 1000 x g for 10minutes, separating 
insoluble material. Clarified lysates were filtered using 0.2pm syringe filters 
before his tag purification. Native his tag purification was used as described in
1 1 1
section 3.4.3. Insoluble material was re-suspended in 1ml of CBC buffer 
containing 8M urea.
Lysis cocktail
1Opl protease inhibitor (Sigma, P 8849)
15pl triton x (Sigma, T8787) (10% in PBS)
7.5pl DNAse (Sigma, D5025)
Made up to 1 ml in the following buffer:
Lysis buffer
0.535g NaH2P04 + 2H20  
3.07g Na2HP04 
8.77g NaCI
0.7g Imidazole (Sigma 10250)
Made up to 500ml with distilled water.
5.4.8 ELISAs
Sf9 insect cell lysates and his tag purified products were prepared and tested in 
his tag ELISAs as described in section 5.3.9
1 1 2
5.5 Results part 1: Developing clones
5.5.1 Amplification of APV, GFP and APV-GFP genes
Figures 43, 44 and 45 show N, P, F and GFP Pfu PCR products that had been 
amplified from the full length clone, N and P-PCI clones, F-p18smahis and GFP- 
p18smahis using newly designed oligos given in tables 2, 3 and 4.
Figure 43. N, P and F, amplified from an APV full length 
clone and GFP from the GFP-p18smahis clone developed 
in Chapter 4. (agarose gel, stained with ethidium bromide)
Figure 44. Duplicate N and P PCR products amplified from 
N and P PCi clones (agarose gel, stained with ethidium bromide)
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Figure 45. F amplified from F-p18smahis (agarose 
gel, stained with ethidium bromide)
Figure 46, shows N, P and F-GFP Pfu PCR products. These represent products 
illustrated at stage 4, Figure 41.
Figure 46. N, P and F-GFP PCR products (agarose gel, stained 
with ethidium bromide
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Figure 47, shows N and F-GFP Pfu PCR products that were generated in a 
’’Quick Change” SDM reaction. These constructs contained genes that would 
produce both N and COOH terminal his tagged recombinant proteins.
N-GFP MW F-GFP
9.4Kb
F ig u r e  4 7 .  N, P and F-GFP, PCR products produced in an SDM 
reaction (agarose gel, stained with ethidium bromide)
5.5.2 Amplification of the APV F gene and the GFP gene for 
baculovirus expression
Figure 48 shows PCR products that represent both the F gene and the GFP 
gene. These had been amplified from F and GFP-p18smahis vectors using 
oligos listed in table 7. Each oligo introduce specific Mfe 1 RE recognition sites 
to both the 5’ and 3’ ends.
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F ig u r e  4 8 .  F and GFP PCR products amplified in a Pfu PCR using oligos that 
introduced specific Mfe 1 RE recognition sites to both the 5’ and 3’ ends (agarose gel, 
stained with ethidium bromide)
5.5.3 Identification of clones with the correct sequence
After ligating the products shown in Figures 43-48 with specific plasmid vectors 
(see 5.2.3) and subsequent transformation of E.coli cells, Taq PCR and 
restriction endonucleases screening methods (3.3.1 and 4.6.2) (3.3.6) identified 
several positive clones. Plasmid ligations with APV gene products amplified from 
p18smahis and PCI produced successful clones; however, no success was 
achieved using products amplified from the full length clone of Naylor et al. [72] 
Extracted plasmids were then sent for sequencing and those with the correct 
nucleotide and predicted amino acid sequence were used for E.coli and insect 
cell expression. Several clones of each construct were identified with the 
exception of P-GFP in p-ET 30, and F1, and F1/tail in pBlueBacHis2. Figures 49 
and 50 are examples of N and P p-ET 30 clones containing the correct sequence 
(analyse using Generunner 3.05).
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F ig u r e  4 9 .  Nucleic and predicted amino acid sequence of the APV N gene in p-ET 30 
with an N terminal his tag region
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F ig u r e  5 0 .  Nucleic and predicted amino acid sequence of the APV P gene in p-ET 30 
with an N terminal his tag region
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5.6 Results part 2: E.coli expression
-95% of transformed BL21 (DE3), BL21 (DE3) pLysS and BL21 (DE3) pLysE 
E.coli cells, yielded clones of each construct. These were identified using the 
Taq PCR method (4.6.2). However, colonies containing the GFP construct could 
be identified visually without the need for PCR analysis. Figure 51 shows 
fluorescent, BL21 (DE3) pLysE GFP colonies viewed over a UV transilluminator.
F ig u re  5 1 . Un-induced, fluorescing BL21 (DE3) pLysE 
cells that contained the GFP-pET30 construct. Plate was 
viewed over a UV transilluminator.
5.6.1 GFP and N expression
The first clones N and GFP in BL21 (DE3) pLysE cells were induced with 1mM of 
IPTG for a total of 3 hours. A non-induced control and 3 samples, taken at 1 hour 
intervals from the GFP clones, were analysed using UV microscopy. Figure 52 
demonstrates an increase in GFP expression over time.
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Induced expression o f QFP
Wet culture slides x 200
2hrs post induction 3hrs post induction
F ig u re  52. Un-induced and induced GFP cultures. An increase in GFP expression 
over a period of 3 hours, viewed using UV microscopy.
Samples taken at 3 hours post induction for both N and GFP were used in 
denaturing and native Ni-NTA purification. The products following purification 
were analysed on SDS-PAGE gels shown in Figures 53 and 54
F ig u re  53. SDS-PAGE analysis of induced N and GFP clones, purified 
under denaturing conditions N l = non-induced control, L y  = cell lysate, 
FI = flow through, e l = purified sample.
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F ig u re  5 4 . SDS-PAGE analysis of induced N and GFP clones, purified 
under native conditions L y  = cell lysate, FI = flow through, wash fraction, 
e l = purified sample.
Under denaturing conditions purified N produced a band of ~44KDa (highlighted 
Figure 53) which was close to published sizes 38-43KDa [16]. However, a 
protein of the same size was observed in the purified GFP sample (Figure 53). 
As this was too large to represent GFP and appeared in both samples, it most 
likely represented an E.coli contaminant. Absence of similar bands in a western 
blot of these samples, using polyclonal APV positive turkey serum confirmed this 
(data not shown). No reactions were observed with any test samples.
Purified GFP produced two bands under denaturing conditions: the fore 
mentioned 44KDa band and a band of ~31KDa (Figure 53). This 31KDa band 
correlated with the published GFP size of Ormo et al [220]. Under native 
conditions the 44KDa band did not appear, only the expected 31KDa GFP band 
was observed (Figure 53). In addition, GFP fluoresced at each stage in the 
purification procedure. No purified N protein was observed under native 
conditions.
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These gels showed GFP successfully his tag purified under standard native and 
denaturing conditions and native purification producing less contaminants. 
Purification of N protein from BL21 (DE3) pLysE under standard native and 
denaturing conditions failed. In addition, a general observation when using 
standard denaturing conditions was the increase of contaminating protein in 
purified samples.
5.6.2 Expression and purification of N, P and F from BL21 (DE3) cells
As previous attempts to purify N protein using BL21 (DE3) pLysE cells had failed 
the next set of clones analysed were BL21 (DE3) cells. Expression levels are 
higher in these cells and therefore may have been beneficial to purification. Each 
construct had been induced using 0.5mM IPTG for a period of 3 hours. All had 
been purified under both standard native and denaturing conditions. In addition 
to the standard purification was a modified native purification protocol; 8M urea 
was added to native lysates and native wash and elution buffers. This would 
determine if native soluble protein was being expressed but not captured due to 
concealment of his tag regions. Essentially, a high concentration of urea would 
linearise soluble native protein and expose any concealed his tag regions that 
may have been hindering Ni2 + capture.
Before purified products were analysed, native and denatured cell lysates of 
induced N, P and F clones (three separate clones for each) were examined by 
SDS PAGE (Figure 55). A comparison of these lysates revealed a significant 
difference in the P clone. This clone produced a highly concentrated, 37KDa 
band in both native and denatured samples (highlighted in Figure 55) which fell
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between the published sizes of 35-40KDa for APV P protein [16]. No significant 
differences could be observed for N, and F lysates.
N clones
2 3~l £ 2 3~
P clones mm j
1 2 3 1 2 3
Native Denatured Native Denatured
1 2  3
F clones
1 2  3
-30
Native Denatured
Induced E.coli cell lysates
F ig u re  5 5 . SDS-PAGE analysis of native and denatured cell lysates of 
induced N, P and F clones.
Figure 56 shows products that were purified from N, P and F lysates shown 
above using standard native and denaturing purification techniques (3.4.3).
F ig u re  56. SDS-PAGE analysis of N, P and F purified products 
following native and denaturing his tag purification. Numbers 1 and 2 
represent individual clones
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A 37KDa protein (highlighted figure 56) was observed in both purified native P 
samples. This protein was absent in N and F purified samples, as it was with cell 
lysate analysis (Figure 55) and therefore probably represented recombinant APV 
P protein. No recombinant N or F proteins were observed in native samples and 
all denatured samples were again, highly contaminated. Contamination could 
have resulted from proteins associating with his tag regions and co-purifying as a 
result. To address this, a modified purification protocol was applied. In this 
experiment a denatured lysate (number 1, N clone Figure 55) had been purified 
in the presence of constituents that would prevent such associations; namely, 
2me, ethanol and glycerol (modification 1, 2 and 3. section 5.3.5.). Comparisons 
were made against a standard purification using SDS PAGE. None of these 
changes improved the clarity of the purified sample. It was considered that some
E.coli proteins may have had internal regions of consecutive histidine amino 
acids which were only exposed under denaturing conditions. This would allow 
them to bind specifically with Ni2+ charged columns, creating a binding site 
competition with recombinant proteins. As a result a range of unwanted proteins 
would be purified.
A modified native purification (modification 4. section 5.3.5.) of N, P and F 
resulted in the SDS PAGE gel shown in Figure 57. Both N and P produced 
bands of expected sizes in purified samples (~43KDa and 37KDa respectively) 
(highlighted Figure 57) under these conditions and appeared to have a low level 
of contamination. As postulated, native recombinant N and P protein was being 
expressed, but capture was hindered due to concealment of his tag regions. No 
purified F protein was observed. Samples suspected of containing recombinant
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proteins were tested in APV and his tag ELISAs (5.2.4).
N  clone P clone
M W M W
"45 -------------- H  ■"— ..
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Ly f l  el! e l2 Ly f l  elj e l2
F clone
M W
Ly fj ^ e l i  el2
F ig u re  57. SDS-PAGE analysis of N, P and F; purified under modified 
native conditions: L y  = cell lysate, F I = flow through, e h  = first fraction 
of the purified sample e l2 = second fraction of the purified sample
5.6.3 Expression and purification of APV-GFP constructs
N-GFP and F-GFP clones (N-terminal his tagged) in BL21 (DE3) cells that had 
been induced with 0.5mM of IPTG for a total of 4hours were first analysed using 
UV microscopy. Figures 58 and 59 show wet culture slides of N-GFP and F- 
GFP. An increase in fluorescent intensity was observed over the four hour 
induction period for both. However, cells appeared to be losing structural 
integrity and fluorescence was diffused compared with the same cells expressing 
GFP alone (Figure 60). E.coli appeared to have a low tolerance of these 
proteins.
N-GFP and F-GFP clones (N, and COOH-terminal his tagged) produced the 
same images.
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Induced expression of N-GFP
W et culture slides x 400




F ig u re  58. Induced N-GFP cultures. An increase in expression over a period of 4 
hours, viewed using UV microscopy.
Induced expression of F-GFP
W et culture slides x 400
3hrs post induction 4hrs post induction
F ig u re  59. Induced F-GFP cultures. An increase in expression over a period of 4 
hours, viewed using UV microscopy.
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Comparisons between Induced E.coh cells either containing N- 
GFP, F-GFP or GFP alone. x400
E.coHcells expressing GFP
E.coli cells expressing N-GFP
E.cofi cells expressing F-GFP
F ig u re  6 0 . Induced N-GFP, F-GFP and GFP cultures viewed using UV microscopy. 
Cells expressing N or F-GFP appeared to be losing their structural integrity and 
fluorescence was diffused compared with those expressing GFP alone.
Each APV-GFP fluorescent culture was used for standard native purification and 
analysed using SDS PAGE. No proteins of correct sizes were observed in 
purified samples. However, his tag western blot analysis of N-GFP and F-GFP 
(his tagged at both the N and COOH terminal) cell lysates, produced N-GFP 
specific bands that correlated to the approximate size of N plus GFP = 76KDa 
(highlighted Figure 61). F-GFP lysates produced 32KDa bands (highlighted 
Figure 61) however; the approximated size for F-GFP was 90KDa. The 32KDa 
band may have represented the GFP section following proteolytic cleavage from
F. This section would retain the COOH his tag for detection. Sizes were 
calculated by plotting the Rf values of highlighted samples against known 
standards as described in section 4.7.6.
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His tag western blot
F ig u re  6 1 . his tag western blot of native N-GFP and F-GFP cell lysates 
N-GFP highlighted bands = 76KDa and F-GFP = 32KDa
his tag Western blot demonstrated specific his tagged proteins in cell lysates of 
dual tagged N-GFP and F-GFP however, native his tag purification was 
unsuccessful. Concealment of his tag regions was again suspected.
5.6.4 APV and his tag ELISAs of E.coli expressed products
Denatured N protein and native N protein purified in the presence of 8M urea 
were tested in conjunction with native P protein and native P protein purified in 
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F ig u re  62. APV ELISA of E.coli expressed N and P
Each antigen reacted with APV positive serum (row A lanes 1, 3, 5, 8 and 10 
Figure 62). However; N and P reactions with negative control serum were also 
apparent (row F lanes 1, 3, 5 and 8 Figure 62). Reactions with negative serum 
were stronger with N antigens and N products purified under denaturing 
conditions in particular. Samples purified under denaturing conditions contained 
consistent high levels of contaminating proteins when observed by SDS PAGE 
analysis so were also anticipated to effect ELISAs. It was considered that E.coli 
specific antibodies in test serum, reacting with E.coli contaminants in test 
samples, were responsible. Compared with APV standard control antigen, all 
test antigens had increased background.
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To confirm the presence of recombinant his tag protein, the above antigens were 
tested in conjunction with native F (purified in the presence of 8M urea) in a his 
tag ELISA. Native GFP (Figure 54) was used as a positive control and E.coli 
lacking recombinant his tag protein was used as a negative control. Results of 
this ELISA are shown in Figure 63.
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Figure 63. his tag ELISA of E.coli expressed N, P, F and GFP
Both controls functioned as anticipated and clear positives were observed with 
each antigen purified in the presence of 8M urea (lane 1, 3 and 5 Figure 62) and 
with native P protein (lane 7 Figure 5). N protein purified under denaturing 
conditions gave a negative result. In agreement with SDS PAGE analysis it 
appeared in these assays that native N, P and F proteins purified in the presence
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of 8M urea yielded an increased amount of purified protein. However as linear 
proteins they were not suitable APV antigen candidates as previously discussed.
5.7 Results part 3: Baculovirus expression
5.7.1 Identification of recombinant baculovirus
Between days 4 and 7 post transfection, Sf9 insect cells were analysed for 
recombinant GFP and F2 baculovirus. GFP cell sheets were viewed using UV 
microscopy and F2 cell sheets were viewed using light microscopy. Under light 
microscopy cells containing recombinant baculovirus are free of occlusion bodies 
which appear as refractive crystals in cell nuclei. In cells infected with wild type 
virus there is a general increase in cell diameter. The results of these analyses 
are shown in Figures 64 and 65.
F lu o re s c e n t S f9  in s e c t c e lls  a t  7  days 
p o s t t r a n s fe c t io n  x too
C ell on ly  c o n tro l C e lls  c o n ta in in g  GFP
re c o m b in a n t b a cu lo v iru s
Figure 64. Transfected Sf9 insect cells containing GFP recombinant baculovirus. 
Intense fluorescence observed at 7 days post transfection compared with cell only 
control.
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transfection x200
Occlusion body-free 
cells with increased 
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Figure 65. Transfected Sf9 insect cells containing F2 recombinant 
baculovirus. Cells with and without occlusion bodies were observed at 7 
days post transfection, indicating presence of both recombinant and wild type 
virus. Transfected cells had increased diameter compared with the cell only 
control and were beginning to detach from the adherent monolayer.
Cells containing occlusion bodies (wild type virus) had been expected as 
transfected material was unlikely to produce 100% recombinant virus. GFP cell 
sheets also reviled areas of occlusion bodied cells when viewed using light 
microscopy. Importantly these areas were not fluorescent under UV light.
Recombinant GFP and F2 were analysed in the same way following plaque 
purification (Figure 66).
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S f9  insect cells infected with 
plaque purif ied F2 and GFP 
recombinant baculovirus x200
Cell only control
Plaque purified F2 recombinant 
baculovirus
Plaque purified GFP recombinant 
baculovirus
F ig u re  66. Sf9 insect cells infected with plaque purified GFP and F2 recombinant 
baculovirus. No occlusion bodied cells were observed and both infected cell sheets 
contained detached cells with increased diameter compared with the cell only control.
Plaque purification appeared to be successful as no cells were observed with 
occlusion bodies in either GFP or F2 infected Sf9 cell sheets and signs of 
infection were retained. This was confirmed by PCR analysis for F2 and by UV 
microscopy for GFP. Only DNA extracted from plaque purified F2 baculovirus 
infected cells (absent of occlusions) produced the expected 137bp band (Figure 
67) when compared to extracts of cells containing occlusion bodies (wild type 
virus) and from uninfected cells. Plaque purified GFP produced fluorescent cells 
identical to those shown in Figure 64 and therefore did not require PCR analysis.
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F ig u re  67. PCR analysis of DNA extracted from Sf9 cells infected with 
plaque purified F2 recombinant baculovirus, cells with occlusion bodies 
and uninfected cells.
5.7.2 his tag purification
His tag ELISAs were used to analyse F2 native purified samples and F2 and GFP 
native lysates. These are shown in Figures 68 and 69
his tag ELISA o f F2 purified products.
(A n ti h is tag monoclonal 1/lOK)
F ig u re  6 8 . his tag ELISA of native F2 purified products that were 
prepared from F2 infected Sf9 insect cell lysates shown in figure 66.
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his tag ELISA of Sf9 insect cell
lysates. (Anti his tag monoclonal 1/lOK)
CBC b u ffer only
Figure 69. his tag ELISA of native F2 and GFP lysates prepared from 
infected Sf9 insect cells.
Only the positive controls and the GFP lysates reacted in these ELISAs (C +ve 
control Figure 68 and lane 3 and 7 Figure 69) and no his tag protein was 
detected in the F2 lysate or purified samples. It was considered that the 
hydrophobic signal peptide at the start of F2 may have resulted in its association 
with other hydrophobic proteins in the expression cells, thus making it insoluble 
under native conditions. Immediate N-terminal signal peptide regions (as in the 
full length F protein) are usually removed by signal peptidases however, as the 
signal peptide of F2 recombinant protein was preceded by a his tag region, it 
would remain intact.
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Insoluble pellets that remained following native lysis were re-suspended using the 
method given in section 5.4.7. This material was then analysed for the presence 
of recombinant F2 protein in a his tag ELISA (Figure 70). Insoluble material (re­
suspended in the same way) from non infected cells was used as a negative 
control.
his tag ELISA of insoluble material, re-suspended
using CBC + 8M urea. (Anti his tag monoclonal 1/10K)
-ve
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Figure 69. his tag ELISA of F2 his tag recombinant 
protein prepared from the insoluble material of lysed, 
F2 baculovirus infected Sf9 insect cells.
Both F2 samples (extracted from insoluble cellular material) were positive by his 
tag ELISA and the negative control functioned accordingly. As postulated 
baculovirus expressed F2 recombinant protein was insoluble under native 
conditions; an implication that would render any purified protein ineffective as 
antigen due to the denaturing processes needed to extract them.
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5.8 Discussion
Commercial expression vector p-ET30 readily accepted APV and GFP genes into 
its sequence and produced stable clones in DH5a. However, successful clones 
were only identified from ligations involving gene products amplified from existing 
clones that had different antibiotic resistance to that of p-ET30 (p18smahis and 
PCi). This suggested that many cells following transfection actually contained 
unwanted or original template plasmids. pBlueBacHis2 baculovirus transfer 
vector appeared to be less efficient as only one of three F sections and GFP 
were successfully cloned. This observation demonstrates the empirical nature of 
identifying plasmids that readily accept a chosen gene. The strategy illustrated in 
Figure 41 produced N and F-GFP fusion constructs efficiently with all of the 
clones screened containing the correct nucleotide sequences. In contrast, all P- 
GFP sequences contained at least one coding base substitution. These were 
distributed randomly throughout the gene.
Significant increase in expression of recombinant proteins were observed using 
P-ET30 compared to the developed p18smahis vector (Chapter 4) and this was 
best demonstrated by GFP. Fluorescence was observed pre-induction in a 
selection of clones (Figure 51) which was attributed to “leakage”. BL21 (DE3) 
pLysE cells contain plasmids that express T7 lysosyme which digest T7 
polymerases reducing basal level expression; however, some cells lose these 
plasmids during growth and therefore the property is lost and basal level 
expression can occur. Following IPTG induction of GFP an increase in 
fluorescent intensity was observed over a period of 3 hours and cells appeared 
structurally sound. In contrast, although an increase in fluorescent intensity of 
induced N and F-GFP was also seen, fluorescence was somewhat diffused.
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Moreover, cells expressing N or F-GFP appeared to be losing structural integrity 
(Figure 60) which could suggest problems with APV protein toxicity in E.coli. 
Native GFP protein was successfully his tag purified and had low levels of 
contaminating proteins. However when purified under denaturing conditions 
contaminating proteins were observed (a later finding with all denatured 
samples). It was considered that some E.coli proteins may have had internal 
regions of consecutive histidine amino acids which were only exposed under 
denaturing conditions. This could have lead to specific E.coli protein purification 
using his tag capture. Purification of N and F-GFP was less successful. No 
purified N-GFP and F-GFP were identified; however a band that correlated with 
the calculated size of N-GFP was detected in native N-GFP lysates using a his 
tag western blot. As no protein was purified from this fluorescent lysate it was 
highly likely that concealment of its his tag regions was responsible. APV-GFP 
fusion proteins were useful for visual conformation of expression and may have 
provided an indication of APV protein toxicity problems in E.coli; however, 
purification was not improved whether tagged at the N terminal or both the N and 
COOH terminal.
Expression of N, P, and F was more difficult to assess visually by SDS PAGE 
compared to simple UV analysis of APV-GFP however, purification was more 
successful with these proteins. N, P and F proteins were purified using modified 
native conditions and a minimal amount of P protein was purified using standard 
native conditions. Although modified native purification produced linear protein 
which rendered them inappropriate as APV ELISA antigen candidates (as 
observed in Figure 62), it provided conformation that recombinant proteins were 
being expressed and that his tag purification could be achieved if his tag regions 
were exposed. His tag ELISAs used to detect these proteins were extremely
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quick and efficient and would be used as a primary screening method for future 
detection.
Recombinant baculoviruses were developed and demonstrated a good level of 
expression as shown by GFP. However, recombinant F2 protein could not be 
purified under native conditions and was only demonstrated when insoluble 
material was re-suspended using a strong dénaturant. Its insoluble properties 
were considered to be a result of the continued presence of a hydrophobic signal 
peptide region. This was not cleaved by signal peptidases due to the his tag 
making it inaccessible. PCR manipulations could be employed to remove this 
sequence generating new transfer vectors for new recombinant baculovirus 
production, however the generation of recombinant baculovirus is extremely time 
consuming compared with the generation of new E.coli clones therefore was not 
under taken.
A marked improvement in expression levels was generally observed using newly 
developed E.coli clones. However, APV-GFP clones produced visible changes in 
E.Coli morphology so suggesting problems with APV protein toxicity. In addition, 
purification procedures demonstrated concealment of his tag regions in native 
proteins. It was considered that expressing small regions of individual proteins 
might prove less toxic to E.coli and reduce concealment problems whilst retaining 
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Expression and purification of sections of subtype-A APV fusion 
protein: Their use in ELISAs and potential importance in virus
neutralization
6.1 Introduction
An indication of APV protein toxicity to E.coli (5.2.3, Chapter 5) and concealment 
of his tag regions in native protein following expression, led to the following 
hypothesis: If different regions of an individual protein were expressed 
separately: (i) problematic hydrophobic areas could be removed and (ii) reduced 
protein sizes could minimize his tag concealment issues. Moreover, this could 
allow identification of subtype-specific epitopes or epitopes common to all 
subtypes recognized by antibodies reacting in ELISAs and possibly those 
involved in virus neutralization as reported for RSV fusion protein by Lounsbach 
et al and Werle et al [188, 221],
The subtype A APV fusion protein was divided into 6 sections using the published 
F sequence of Naylor et al 1998 [48] as a design template. This is shown in 
Figure 70 along with one subtype B sequence and one subtype C sequence. 
Two sections were designed in the F2 region of the full length (F0) protein, three 
in the F1 region and one incorporating the entire cytoplasmic tail. The 
hydrophobic regions highlighted by Naylor et al 1998 [48] were excluded. Each 
section was amplified using oligos that maintained the same reading frame as 
shown in Figure 70 and incorporated an N-terminal his tag when cloned into 




This chapter describes the use of these six regions of the F protein as ELISA 
antigens and also investigates whether they could be targets for neutralizing 
antibodies in the sera of infected birds.
F section 1 * F section 2
A type I »VRICLLLF LISNPSSCIQ EÎYNEESCST VTRGYKSVLR TGWYTNVFNL EIGNVEHITC SDGPSLIDÏE LVLTKHÀLRB LKIVSÂDQVÀ KESRLSSPRR
B type .YLKLL.IIY .WGA.GK........S .. . . . ...................................................................S.. .S..Q...Q. .R.........IT ..N.IL.H.K
C type .SWKW...V .LAT.TGGLE .S.L..................L.................... T. .V.D...L.. T.........R.. .E.........! ................L. ..Â.IH...K
- - - - - - - - - - - - - - - - - - - ► F section 3 ♦- - - - - - - - - - - - - - - -
A type RRPVLGAIAL GVAIAAAVIA GVALAKTIRL EGEVKAIKNA LPHTNBAVST LGKGVRVLAT AVNDLKBFIS KKLTPAINQN KCHIADIKHA ISFGQNNRRF
B type K.....................T....... [ .............................. L. . .S ..|................. I .................................................... R....................
C type A............................. .1................ A...G. ..K....................................... D.................. R. ..D.S.L... V....Y.
- - - - - - - - - - - - - - - - - - - - - - - - - - - *• F section 4 ^- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
A type LNWRQFSDS AGITSAVSID UITDDEIVRA INRJIPTSSGQ ISLHLHHRAH VRRKGFGILI GVYDGTWYH VQLPIFGVIE TPCWRWAAP LCRKKKGNYA
B type ........................................ A...K............................................................ G...................................................HERBS,.
C type .............N .. . ,P ,I............A.......VSN...............H...E..............................GSS...I..............D ,,..K,K.........SG.D....






CTNAGSIAYY PHKDDCEVRD DYVFCDTAAG INVALEUDQC NYNISTSKYP CKVSTGRHPV SHVALTPLGG LVSCYESVSC SIGSHKVGII 
F ..................S E .0....... T................................. F..............G......................
. t ....... .Q...... V.. ..EE.......S .H... .............. K.SEE. .R....T.................... I ....... S...A ..A..DGH....................
A type KQLGK6CTHI PNNEADTITI DNTVYQLSKV VGEQRTIKGA PMNFHPIL FPVDQFHVAL DQVFBSIDRS QDLIDKSHDL LGADAKSKAG
B type ...N................................ I ......................................... L. . .E . .. . I ..............V.R. K.................MW ..SI. A.L..TI..
J...Q..KI .DSIE.GH.. P O ..11.C type RP.......SY. S.QD...V. .. E...H....K ..SS..D..E . .B . . . . I .............VEK.




A type LGIFPLLAVI YÎCSRVRKTK PKHDYPAITG HSSHAYVS
B type .SHSIIVGIA . .WKK..A. APHG..K... Q.H.G.I.
C type .I1LAAVGVGV FFWKK..AA ., FPHEI0JGV MGFIP
Figure 70. Predicted amino acid sequence of subtype A, B and C (A type, B type and C 
type) APV F protein. Six sections were designed for individual expression in E.coli. No 
sections incorporated the hydrophobic areas (Grey shaded segments). Two sections 
were designed in the F2 region of the FO protein three in the F1 section and one 
incorporating the entire cytoplasmic tail.
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6.2 Materials and methods part 1: Developing clones
6.2.1 Gene amplification
F sections 1, 3, 4 and 5 were amplified from F-p18smahis vector (developed in 
Chapter 4) using oligos designed to maintain the same reading frames as shown 
in Figure 70 and incorporate N-terminal his tags when cloned into E.coli 
expression vector p-ET30. A list of these oligos is given in table 8. Standard pfu 
PCR was used and the following cycle was applied: (i) 80°C hold (hot start) (ii) 
94°C for 30 seconds (iii) 54°C for 30 seconds (iv) 72°C for 40 seconds (v) repeat 
(ii) -  (iv) x 20, (vi) 8°C hold temperature. F sections 2 and 6 were generated by 
annealing complementary oligos (shown in table 8) using the following PCR 








G AAG AAT CCTG CAGTACT G




GCTTT GAGGGAGCT CAAAACAGT GT CAGC 
T GAT CAAGT GGCTAAGG AAAGCAG ACTAT CCTAA 
TTAGGATAGT CT GCTTT CCTTAGCCACTT 
GAT CAGCT GACACT GTTTT GAGCT CCCT CAAAGC
F section 3
F 448 pos 
F 610 neg
GAGGCAGTAT CCACATTAGGG
TTACCTT CT GTTATTTTGGCCAAAACTAATT GCC
F section 4
F 634 pos 
F 943 neg
GCAGGTATCACATCAGCTGTGTCTC 
TTAGTACCACCCTT GAT CTT CT CT CAG
F section 5
F 1018 pos 
F 1450 neg
GACACAGCAGCTGGCATTAAT G
TTAGT CGTTAG ACTTAT CTATTAAGT CCT GAG
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F section 6
Fcyto-tailpos T GTT CCAGAGT CCGGAAGACCAAACCAAAGCAT
GATTACCCGGCCACGACAGGT CATAGCAGCAT G 
GCTTATGTCAGTTAA
Fcyto-tailneg TTAACT GACATAAGCCAT GCTGCTAT G ACCT GT C
GTGGCCGGGTAATCATGCTTTGGTTTGGTCTTC
CGGACTCTGGAACA
6.2.2 Ligations and cloning of APV F sections with p-ET30
F sections were ligated into the EcoRV site of p-ET 30 using the Fermentas 
protocol but with the addition of 0.5pl (10U/pl) of EcoRV in the ligation mixture. 
Ligations were used to transform DH5a competent cells which were grown on LB 
agar plates containing 15pg/ml of Kanamycin. Resulting colonies were screened 
using the PCR technique described in section 4.6.2. Plasmids from colonies that 
were positive were extracted using Qiagen miniprep kits (3.3.5) and sent for 
sequencing. All products were analysed using agarose gel electrophoresis 
(3.3.8).
6.2.3. RE digestions
Digestions using EcoRV followed supplier’s protocols.
6.3 Materials and methods part 2: Expression
6.3.1 Transformations
E.coli BL21 (DE3) cells were transformed using ~1ng of each F section/p-ET 30 
plasmid construct according to the supplier’s protocol (3.3.4). Colonies were 
grown on agar plates containing 15pg/ml of Kanamycin.
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6.3.2 PCR screening
Taq PCRs were used to screen BL21 (DE3) cells that had been transformed with 
the above. Colonies were screened directly from agar plates as described in 
section 4.6.2 and Figure 27. Expected sizes for these PCRs were as follows:
F section 1 (237bp), F section 2 (420bp), F section 3 (262bp), F section 4 
(400bp), F section 5 (532bp) and F section 6 (179bp).
6.3.3 Induction
Colonies that contained desired plasmids were induced as described in section
3.4.1 using 0.5mM IPTG and induction times of 1-3hours.
6.3.4 E.coli cell lysis
Cells were lysed as described in section 3.4.2. The efficiency of lysis was 
checked by gram staining (Appendix).
6.3.5 Protein purification
F section his tag recombinant proteins were purified under standard native 
conditions using Ni-NTA spin columns as described in section 3.4.3.
6.3.6 SDS-PAGE
Recombinant proteins were analysed under none-reducing conditions as 
described in section 3.6
6.3.7 Western blot
His tag western blots were used to detect purified recombinant proteins 3.6.2
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6.3.8 his tag ELISAs
His tag ELISAs were performed as described in section 5.3.9 for general 
detection of purified recombinant proteins.
6.4 Materials and methods part 3: Development of ELISAs
6.4.1 ELISAs
Flexible, 96 well, flat bottomed ELISA plates (Becton Dickinson, UK) were used. 
Wells were coated with 50pl of antigen which had been previously diluted in 
ELISA CBC buffer (Appendix), dilutions are given along side the relevant plates 
in the results section. Plates were then incubated at 8°C overnight. Antigens 
included his tag purified products and a Liverpool developed whole virus APV 
antigen. The details of where each antigen was placed in a particular ELISA, are 
given alongside the relevant plates in the results section.
All test antisera were hyperimmune with the exception of subtype B APV (See 
section 3.6.3 for details). The procedures are given below.
(i) ELISA procedures
1. Incubated plates washed 5 times with ELISA wash buffer (Appendix).
2. 50pl / well of test serum (given along side the relevant plates in the results 
section) previously diluted 1/100 in wash buffer, incubated for 1 hour at 37°C.
3. Washed 5 times with wash buffer.
4. 50pl / well of GAT conjugate diluted 1/1000 in wash buffer incubated for 1 
hour at 37°C.
5. Washed 5 times with wash buffer.
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6. 100|jl / well of OPD activated with 30% H20 2 (Sigma, UK H-1009) (Appendix) 
incubated at room temperature in the dark for a maximum of 15 minutes.
7. 50pl / well of 2.5M H2S04 (Appendix)
6.4.2 Adsorption of E.coli antibodies from test serum
E.coli antibodies were removed from test serum using the techniques illustrated 
in Figure 71. These were adapted from Islam 1988 [222]
C e n tr ifu g e  
1 0 ,0 0 0  xg  f o r  1 
m inute
I
lml o f E.coli 
culture
C o lle c t ce ll p e lle ts  
and r e -
su sp end /w ash  in 
lm l o f  PBS
J=L
V
C o lle c t cell 
p e lle ts  and r e ­
suspend in 
0 .5 m l o f  t e s t  
serum
C e n tr ifu g e  
1 0 ,0 0 0  xg  f o r  
10 m in u tes
In c u b a te  a t  3 7 °C  
f o r  1 hour. 
V o r te x  e v e ry  10 
m inutes
C e n tr ifu g e  
1 0 ,0 0 0  x g  f o r  5  
m inutes
C o lle c t th e  
s u p e rn a ta n t/  
a d so rb ed  
serum
Figure 71. Adsorption of E.coli antibodies from serum
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6.4.3 Agar gel precipitation (AGP)
AGP was used to analyse the efficiency of E.coli antibody adsorption from test 
serum. In these tests both antigen and antibody diffuse through an agarose 
matrix and precipitate at equivalence points. Lines of precipitation can then be 
observed using a dark background and oblique illumination. 10 ml of molten agar 
(1% in PBS) was poured into a plastic Petri dish and allowed to solidify at room 
temperature. Wells were cut in each plate using a template which produced one 
center well surrounded by six outer wells in a daisy pattern. Wells were 7mm in 
diameter and 4mm apart. Plugs were carefully removed using a hypodermic 
needle. Lysed E.coli cells (antigen) were placed into the centre well and test sera 
were placed in surrounding wells. Plates were placed into small sealable 16mm 
x 10mm polythene bags and incubated at 37°C for 24 hours. Details of test sera 
used in each particular AGP is shown in the relevant results section.
6.4.4 IP staining
In common with ELISAs and western blot, IP staining demonstrates antigen- 
antibody interactions. It is used to detect antigens in microscopic preparations 
(smears, tissue sections, cell cultures). The anti-globulins are tagged with an 
enzyme which, following the application of a chromogen substrate, produce a 
detectable colour in positive areas.
Here, IP staining of uninfected and APV infected vero cell sheets (grown in 48 
well cell culture plates) was used to test for APV specific antibodies in SPF serum 
of 12 week old (12wk) and 80 week old (80wk) chickens. An APV positive serum 
was used as a control. The protocol used was as follows:
(i) Remove medium form cell sheets with pastettes
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(ii) Fix in 70% ethanol for 10 minutes (~ 500|jI / well)
(iii) Wash gently x 3 with PBS
(iv) Add 300jjI of test serum (diluted 1/500 in PBS) to each well and incubate for 
1 hour at 37°C (Figure 72 details each test serum)
(v) Wash gently x 3 with PBS
(vi) Add 300|jl of GAT conjugate (diluted 1/500 in PBS) to each well and incubate 
for 1 hour at 37°C
(vii) Wash gently x 3 with PBS and x1 with DAB substrate buffer (Appendix)
(viii) Add 300pl of DAB substrate solution (Appendix) to each well and incubated 
in the dark.





Figure 72. IP staining of APV infected and uninfected vero cell sheets using APV + 
and SPF serum from 12wk old and 80wk old birds.
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6.5 Materials and methods part 4: Virus neutralization
A two part, virus neutralization test was designed to identify potential neutralizing 
epitopes within the expressed regions of the fusion protein:
1. Standard neutralization tests were performed in vero cells using a SH-G 
deletion recombinant, subtype-A APV [72] and subtype A, B and C antiserum to 
identify end point dilutions. Use of SH-G deletion recombinant (ASH-G) APV 
eliminated any virus neutralizing properties of antibodies previously shown to 
target the G protein [91].
2. Neutralization test were then repeated following adsorption of the same 
Subtype A, B and C antiserum with each of the antigenic F sections. Thus, if 
neutralizing antibodies were absorbed by a particular F antigen then endpoints at 
lower dilutions would be expected. Those with two log2 dilutions or greater 
compared to the control value, would be considered significant. Therefore, the 
relative contributions of the different regions of the F protein in eliciting 
neutralizing antibodies could be assessed.
6.5.1 Standard virus neutralization test
50pl of tissue culture media without serum (appendix) was added / well of an 8 X 
12, 96-well tissue culture plate (NUNC international Denmark). This was followed 
by 50pl of pooled, APV subtype-A, B or C positive anti sera (previously diluted to 
1/16) to the first column of wells (specific placement of each antiserum is given 
along side the results). Next a series of doubling dilutions were made up to 
column 10 giving a Log2 5-14 range of dilutions. 50pl of ASH-G virus suspension 
at a Log 102 /50pl concentration was then added and thoroughly mix to columns 
1-11 leaving column 12 as a cell control. Plates were then incubated at 37°C for 
3 hours. Each 100pl suspension was transferred to a corresponding well
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containing a fully confluent vero-cell monolayer. Following a second 3hr 
incubation at 37°C each well received 50|jl of tissue culture medium containing 
serum (appendix). CPE was examined daily using light microscopy.
6.5.2 Novel virus neutralization test
25pl of tissue culture media without serum (appendix) was added / well of an 8 X 
12, 96-well tissue culture plate (NUNC international Denmark). This was followed 
by 25pl of pooled, APV subtype-A, B or C positive anti sera (previously diluted to 
1/64 for subtype A and B and 1/16 for subtype C) to the first column of wells 
(specific placement of each anti sera is give in the results). Next a series of 
doubling dilutions were made up to column 8. Tests using subtype-A and B 
antisera had a Log2714 range of dilutions with subtype C range at Log2 5-12. Next 
25pl of F antigen 1, 2, 3, 4, 5, 6 or control Ni-NTA elution buffer (appendix) plus 
glycerol at the same concentration as purified F antigens (previously diluted 1/50 
in tissue culture medium) was added. Again details of their position in a 
particular test are given in the relevant results section. Plates were incubated for 
3hrs. 25pl of ASH-G virus suspension at a Log 102 /50pl concentration was then 
added to columns 1-11 leaving column 12 as a cell control. Plates were again 
incubated at 37°C for 3 hours. Each 100pl suspension was transferred to a 
corresponding well containing a fully confluent vero-cell monolayer. Following a 
final, 3hr incubation at 37°C each well received 75pl of tissue culture medium 
containing serum (appendix).
CPE was examined daily using light microscopy.
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6.6 Results part 1: Developing clones
Figure 73 shows F sections 1, 3, 4 and 5 that had been amplified from F- 
p18smahis. Each band correlated with the calculated size of each f section 
(F section 1 = 138bp, F section 3 = 162bp, F section 4 = 309bp and F section 5 =
432bp.
F section F section 
1 3




Figure 73. Pfu PCR amplification of F sections 1,3,4 and 5 (agarose gel 
stained with ethidium bromide)
F sections 2 and 6 were not analysed prior to ligation with p-ET30.
All six F sections were cloned into p-ET30. Sequences of these constructs are 
shown in Figures 74-79.
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61 7 1 81 91
* H H H H H H S S G L U P R G S G
ATGCfiCCATC ATCa t c a t ò A'sJTCTTCTGGT CTGGTGCCAC GCGGTTCTGG
TACGTGGTAG TAGTAGTAGT S t a r t  -  his  tag CGCCAAGACC
H K E T A A A K F E R Q H D S
TATGAAAGAA ACCGCTGCTG CTAAATTCGA ACGCCAGCAC ATGGACAGCC
ATACTTTCTT TGGCGACGAC GATTTAAGCT TGCGGTCGTG TACCTGTCGG
P D L G T D D D D K A I  A D A' E ) E S
CAGATCTGGG TACCGACGAC GACGACAAGG CCATAGCAGA t!c a a Ig a a t c c
GTC1 f  section 1 start, in fram e with the  start -  his tag AbfTCTTAGG
C S T U T R G V K S U L R T G U V
TGCAGTACTG TAACTAGGGG TTATAAGAGT GTGTTAAGGA CAGGGTGGTA
ACGTCATGAC ATTGATCCCC AATATTCTCA CACAATTCCT GTCCCACCAT
T N U F N L E I  G N U E N I  T C
TACGAATGTA TTTAACCTCG AAATAGGGAA TGTCGAGAAC ATCACTTGCA
ATGCTTACAT AAATTGGAGC TTTATCCCTT ACAGCTCTTG TAGTGAACGT
N D G P
ATGATGGACC
TACTACCTGG
S L I  
CAGCCTAATT 
GTCGGATTAA
t  E / T 7 y -
GACACTGAGJ AAf 
CTGTGACTCffM f T ___
Stop codon
cH iff
F ig u r e  7 4 .  Nucleic and predicted amino acid sequence of F section 1 in p-ET 30 with 
an N terminal his tag region









H H H H
ATCATCATCA
TAGTAGTAGT
S S G 
T^CTTCTGGT























D D K A A D  / a \ L  R 
_ _  GACGACAAGG CCATGGCTJ»HGC1ITGAGG
GJ1 F section 2 start, in frame with the start - his tag ApGhAACTCC







T U S A 
CAGTGTCAGC 
GTCACAGTCG






S R L S 
GCAGACTATC 
CGTCTGATAG
/ T N I  R S F F 
(ÌTABinTStop codon fCG
gW t a g c c t  AGGCTTAAGC
E L R R
AGCTCCGTCG
TCGAGGCAGC






F ig u r e  75. Nucleic and predicted amino acid sequence of F section 2 in p- ET 30 with
an N terminal his tag region
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H H H H S S G L U P
CTGGTGCCAC 
t a g  G
R G S G 
GCGGTTCTGG 
CGCCAAGACC





AI S t a r t  -  his
K E T 8 8 A K F E R Q H D S
TATGAAAGAA ftCCGCTGCTG CTAAATTCGA ACGCCAGCAC ATGGACAGCC
ATACTTTCTT TGGCGACGAC GATTTAAGCT TGCGGTCGTG TACCTGTCGG
P D L G T D D D D K A A D y ? \ A  u
CAGATCTGGG TACCGACGAC GACGACAAGGI CCATGGClfifl" ^GAOGCAGTA
GT F  section 3  start, in fra m e  with the  start -  his tag ACfCCGTCAT
S T L G N G U R U L A T A U N D L
TCCACATTAG GGAATGGTGT GAGGGTACTA GCAACTGCAG TCAATGACCT
AGGTGTAATC CCTTACCACA CTCCCATGAT CGTTGACGTC AGTTACTGGA
K E F I  S K K L T P A 1 N Q N K
CAAAGAATTT ATAAGTAAAA AATTGACTCC TGCTATTAAC CAGAACAAAT
GTTTCTTAAA TATTCATTTT TTAACTGAGG ACGATAATTG GTCTTGTTTA
Figure 76. Nucleic and predicted amino acid sequence of F section 3 in p-ET 30 with an 
N terminal his tag region
t  View Analysis Tables Graph Options Window Help
P r e d i c t e d  a a  
N u c le ic  a c id  
s e q u e n c e
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H H H H H H S S G L U P R G S G
ATGCACCATC ATCATCATCA "WCTTCTGGT CTGGTGCCAC GCGGTTCTGG
TACGTGGTAG TAGTAGTAGT Al S t a r t  -  h is  t a g  G CGCCAAGACC
K E T A A A K F E R Q H D S
TATGAAAGAA ACCGCTGCTG CTAAATTCGA ACGCCAGCAC ATGGACAGCC
ATACTTTCTT TGGCGACGAC GATTTAAGCT TGCGGTCGTG TACCTGTCGG
P D L G T D D D D K A A D / a \ g I
CAGATCTGGG TACCGACGAC GACGACAAGG CCATGGCTGAr*' a g c aJg g t a t c
GTC F  section 4  start, in f ra m e  with th e  start -  his tag A t t n  CC AT AG
T S A U S L D L T D D E L U R A
ACATCAGCTG TGTCTCTTGA TTTAATGACA GATGATGAAC TTGTTAGAGC
TGTAGTCGAC ACAGAGAACT AAATTACTGT CTACTACTTG AACAATCTCG
I  N R M P T S S G Q I  S L M L N
AATTAACAGA ATGCCAACTT CATCAGGACA GATTAGTTTG ATGTTGAACA
TTAATTGTCT TACGGTTGAA GTAGTCCTGT CTAATCAAAC TACAACTTGT
i s s s s s a s s i s s a s s s ^ s a n s s ^ s a
F ig u r e  77. Nucleic and predicted amino acid sequence of F section 4 in p- ET 30 with
an N terminal his tag region
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i ls llE J H
DOpC
100 XOC.XKCX
_ U _ 21 i*1
* H H H H H H S S G L Ü P R G S G
ATGCACCATC ATCATCATCA N CTTCTG G T CTGGTGCCAC GCGGTTCTGG
TACGTGGTAG TAGTAGTAGT A S t a r t - h i s  tag TG CGCCAAGACC
K E T A A A K F E R Q H D S
TATGAAAGAA ACCGCTGCTG CTAAATTCGA ACGCCAGCAC ATGGACAGCC
ATACTTTCTT TGGCGACGAC GATTTAAGCT TGCGGTCGTG TACCTGTCGG
P D L  G T D D D D K A A D A
CAGATCTGGG TACCGACGAC GACGACAAGG CCATGGCTitf' to a c/a c a g c a
GTC1 F  section 5 start, in frame with the start - his tag a c Tg t g t c g t
A G I N U A L E U D Q C N V N I  S
GCTGGCATTA ATGTGGCCCT AGAAGTTGAC CAGTGCAACT ATAACATATC
CGACCGTAAT TACACCGGGA TCTTCAACTG GTCACGTTGA TATTGTATAG
T S K V P C K Ü S T G R H P U S
GACTTCTAAA TACCCATGCA AAGTCAGCAC AGGTAGACAC CCTGTCAGTA
CTGAAGATTT ATGGGTACGT TTCAGTCGTG TCCATCTGTG GGACAGTCAT
Figure 78. Nucleic and predicted amino acid sequence of F section 5 in p- ET 30 with 
an N terminal his tag region
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F ig u r e  79. Nucleic and predicted amino acid sequence of F section 6 in p- ET 30 with
an N terminal his tag region
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F sections 1, 2 and 6 can be seen in their entirety (from start to stop codon) in 
figures 74, 75 and 79. The subsequent sections of 3, 4 and 5 remained in frame 
to the designed stop codons. Each predicted aa sequence correlated with those 
highlighted in Figure 70.
6.7 Results part 2: Expression
6.7.1 PCR screening
100% of screened BL21 (DE3) E.coli cells, yielded clones of each F section that 
correlated with expected sizes (section 6.3.2). These were identified using the 
Taq PCR method (4.6.2). Products are shown in Figure 80.
Figure 80. PCR screen of BL21 (DE3) E.coH colonies. A, B and C 
represent individual colonies of the particular F section listed above it 
(agarose gel stained with ethidium bromide)
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6.7.2 E.coli cell lysis
Lysis of F section clones induced for 1-3hours was as demonstrated by gram 
stain (Figure 81).
Gram stain of E.coli ce I Is and lysed E.coli cells
E.coli cells lysed E.coli ce I Is
Figure 81. Analysis of E.coli cell lysis using gram staining
6.7.3 his tag ELISAs
His tag ELISAs demonstrated recombinant F section proteins in purified samples 
following native his tag purification as shown in Figure 82. An increase in protein 
yield was observed over the three hour induction period for both A and B clones 
of each F section. F section 2 gave the weakest signal and was only detectable 
in the sample purified from a culture taken at 3 hours post induction in this ELISA.
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his tag ELISA (Anti his tag monoclonal 1/lOK)
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Figure 82. his tagged, recombinant F section proteins, detected 
in purified samples following native his tag purification. The his tag 
epitope of recombinant proteins was detected in this ELISA using 
an anti his tag monoclonal antibody.
6.7.4 SDS-PAGE and Western blot analysis
F section samples purified after 3 hours induction, and positive by his tag ELISA, 
(Figure 82) were analysed by SDS-PAGE and his tag Western blot. SDS-PAGE 
analysis of F sections 2 and 6 produced strong bands of approximately 11 6KDa 
and 10KDa respectively. F section 5 produced a weak band of approximately 
25KDa and F sections 1, 3 and 4 were undetectable as shown in Figure 83. 
However, when tested in a his tag western blot as shown in Figure 84, all were 
positive with the exception of F section 2. A standard curve (Figure 85) 
generated in the same way as described in 4.7.6 was used to determine the band 
sizes shown in Figure 83. F section 1 gave a band of 13 KDa, F section 3, 12.5 
KDa, F section 4; 15 KDa, F section 5; 25KDa and F section 6; 11 KDa. All
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absorbance were close to expected sizes however; F section 3 gave a band that
was 2KDa smaller than expected.
F sec tio n s
Figure 83. SDS-PAGE analysis of his tag purified F sections.
Expected ___  ̂ 13 8 10  14.8 15.5 24.8 11.6
Size Kda
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F section 6
4 2  4.3
log 10 M W
F section 1
F section 5
Figure 85. Log10 MW of F sections 1,4,5 and 6 following Western blot analysis
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6.8 Results part 3: Development of ELISAs
The samples tested by his tag ELISA, SDS-PAGE and Western blot (Figures 82, 
83 and 84) were used in APV ELISAs. Each was tested alongside a Liverpool 
developed whole virus subtype-A APV antigen with SPF serum from 12 wk old 
chickens as controls. Sections were tested at 1/50 and 1/100 dilution with 
subtype-A antiserum producing the ELISA shown in Figure 86. In view of their 
antigenicity, F sections were referred to as F antigens from this time. 
Subsequently, antigens were tested with subtype A, B and C APV positive serum 
and with two negative controls (i) IBV positive serum and (ii) SPF serum from 12 
wk old chickens (6.7.1)











Figure 86. F antigens tested with subtype-A antiserum.
Absorbances were measured at 492nm. Absorbances for the test serum were 
divided by negative readings to give the ratios shown in Table 9. Ratios showed
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that at 1/100 dilution, all six F sections produced higher absorbance ratios than 
the Liverpool whole virus antigen.
Table 9. Absorbencies at 492nmF Ag 4 2 2 1 1 3 3 4 4 5 5 Virus AgAPV pos serum 1 .2 1.1 0 .9 1 .1 1 1.1 0.9 1 .1 1 0.8 0 .8 0.8SPF serum 12 wl 0 .1 0 .09 0.0 7 0.08 0 .0 7 0 .0 7 0.08 0.1 0 .1 0 .0 7 0.0 7 0 .1ratio 12 12.2 12.9 13.8 14.3 1 5 .7 15 11 10 11.4 11.4 8
Following these results F antigens were stored at -20°C for subsequent ELISA 
tests (6.7.1) however, after thawing, precipitates had formed. As a result, new 
batches of purified F antigens were generated (as previously described) and 
each was mixed at a ratio of 50:50 with glycerol to maintain their solubility. 
Because glycerol may be detrimental to antigen performance however; ELISAs 
were repeated and results were found to be similar to those found previously 
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Figure 87. F antigens with and without 50% glycerol, tested with subtype-A antisera.
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ELISAs testing each F antigen and subtype-A APV whole virus antigen against 
six pools (10 birds / pool) of positive subtype A, B or C chicken antisera, IBV 
positive antisera and SPF sera are given below. Each serum, F antigen and 
whole virus antigen was used at a 1/100 dilution. Tables 10-15 show duplicate 
and mean absorbance readings at 492nm for each F antigen. Tables 16-18 show 
duplicate and mean absorbance readings at 492nm for whole virus antigen.
6.8.1 F antigens tested against subtype A, B and C antisera
Table 10. Subtype-A antiserum with F antigens 1 - 3
A + sera
F Ag1 F Ag 1 Mean F Ag 2 F Ag 2 Mean F Ag 3 F Ag 3 Mean
pool
1 0.75 0.53 0.64 0.47 0.5 0.485 0.54 0.53 0.54
2 0.98 0.9 0.94 0.84 0.82 0.83 1 1.1 1.05
3 0.71 0.63 0.67 0.6 0.6 0.6 0.68 0.67 0.68
4 1.02 1.04 1.03 0.94 0.95 0.945 1.51 1.45 1.48
5 1.95 1.8 1.87 1.6 1.6 1.6 2.29 2.2 2.25
6 0.84 0.76 0.8 0.71 0.67 0.69 1.03 1.04 1.04
spf 0.18 0.12 0.15 0.12 0.12 0.12 0.12 0.12 0.12
IBV 0.15 0.17 0.16 0.13 0.12 0.12 0.19 0.15 0.17
Table 11. Subtype-A antiserum with F antigens 4 -6
A + sera
F Ag 4 F Ag 4 Mean F Ag 5 F Ag 5 Mean F Ag 6 .F Ag 6 Mean
pool
1 0.62 0.6 0.61 0.63 0.6 0.62 0.68 0.9 0.79
2 1.1 1.1 1.1 1.1 0.98 1.04 1 1.2 1.1
3 1.3 1.2 1.25 1.1 1 1.05 0.78 0.93 0.86
4 1.5 1.5 1.5 1.5 1.4 1.45 1.7 1.9 1.8
5 2.2 2.2 2.2 2.3 2.1 2.2 2 2.03 2.02
6 1.02 0.96 0.99 1 0.96 0.98 1.04 1.04 1.04
spf 0.14 0.14 0.14 0.14 0.16 0.15 0.15 0.3 0.23
IBV 0.18 0.12 0.15 0.13 0.15 0.14 0.18 0.18 0.18
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Table 12. Subtype-B antiserum with F antigens 1 -3
B + sera
F Ag1 F Ag 1 Mean F Ag 2 F Ag 2 Mean F Ag 3 F Ag 3 Mean
pool
1 0.2 0.12 0.16 0.11 0.11 0.11 0.12 0.12 0.12
2 0.71 0.66 0.68 0.62 0.62 0.62 0.78 0.76 0.78
3 0.53 0.43 0.48 0.41 0.4 0.41 0.48 0.45 0.47
4 0.23 0.21 0.22 0.18 0.17 0.18 0.21 0.21 0.21
5 0.32 0.29 0.31 0.29 0.27 0.28 0.35 0.33 0.34
6 0.147 0.117 0.13 0.1 0.1 0.1 0.11 0.11 0.11
spf 0.12 0.08 0.1 0.06 0.07 0.07 0.08 0.07 0.08
IBV 0.1 0.12 0.11 0.13 0.13 0.13 0.12 0.15 0.14
Table 13. Subtype-B antiserum with F antigens 4 -6
B + sera
F Ag 4 F Ag 4 Mean F Ag 5 F Ag 5 Mean F Ag 6 F Ag 6 Mean
pool
1 0.18 0.17 0.18 0.16 0.17 0.17 0.13 0.25 0.19
2 0.95 0.95 0.95 0.85 0.85 0.85 0.69 0.78 0.74
3 0.72 0.67 0.70 0.58 0.63 0.61 0.5 0.64 0.57
4 0.72 0.7 0.71 0.47 0.43 0.45 0.24 0.33 0.29
5 0.38 0.37 0.38 0.28 0.35 0.32 0.32 0.32 0.32
6 0.14 0.15 0.15 0.15 0.13 0.14 0.14 0.27 0.21
spf 0.12 0.08 0.1 0.06 0.07 0.07 0.08 0.07 0.08
IBV 0.18 0.13 0.16 0.2 0.14 0.17 0.12 0.16 0.14
Table 14. Subtype-C antiserum with F antigens 1 -3
C + sera
F Ag1 F Ag 1 Mean F Ag 2 F Ag 2 Mean F Ag 3 F Ag 3 Mean
pool
1 1.76 1.7 1.73 1.58 1.6 1.59 2 2.1 2.05
2 2 1.9 1.95 1.75 1.85 1.8 2.3 2.3 2.3
3 1.7 1.74 1.72 1.71 1.49 1.6 2.1 2.02 2.06
spf 0.15 0.11 0.13 0.09 0.085 0.09 0.11 0.1 0.10
IBV 0.13 0.13 0.13 0.16 0.19 0.18 0.11 0.15 0.13
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Table 15. Subtype-C antiserum with F antigens 4 -6
C + sera
F Ag 4 F Ag 4 Mean F Ag 5 F Ag 5 Mean F Ag 6 F Ag 6 Mean
pool
1 2.2 2.3 2.25 2.2 2 2.1 1.7 1.7 1.7
2 2.5 2.5 2.5 2.3 2.3 2.3 1.8 1.8 1.8
3 2.3 2.1 2.2 2.1 2.11 2.12 1.6 1.6 1.6
spf 0.1 0.13 0.12 0.12 0.11 0.12 0.13 0.1 0.12
IBV 0.17 0.12 0.15 0.13 0.11 0.12 0.15 0.16 0.16
Table 16. Subtype-A antiserum with subtype-A whole virus antigen
A+ sera
Liverpool whole virus antigen
pool mean
1 0.63 0.6 0.66
2 0.73 0.68 0.71
3 0.72 0.7 0.71
4 0.53 0.58 0.56
5 0.55 0.52 0.54
6 0.52 0.49 0.51
spf 0.18 0.1 0.14
IBV 0.08 0.1 0.9
Table 17. Subtype-B antiserum with subtype-A whole virus antigen
B+ sera
Liverpoo whole virus antigen
pool mean
1 0.3 0.31 0.31
2 0.41 0.39 0.4
3 0.32 0.4 0.36
4 0.21 0.23 0.22
5 0.2 0.2 0.2
6 0.14 0.18 0.16
spf 0.2 0.1 0.15
IBV 0.12 0.1 0.11
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Table 18. Subtype-C antiserum with subtype-A whole virus antigen
C+ sera
Liverpool whole virus antigen
pool mean
1 0.39 0.33 0.36
2 0.3 0.28 0.29
3 0.4 0.32 0.36
spf 0.17 0.15 0.16
IBV 0.16 0.09 0.13
Table 19 summarizes the above data providing an average of the given mean 
results minus SPF negative control readings for each F antigen and whole virus 
antigen, with each particular APV antiserum. All six F antigens gave higher 
absorbance readings than whole virus antigen with all antisera but especially C.
Table 19.
Subtype A fusion protein sections Subtype A
Whole
virusF Ag 1 F Ag 2 F Ag 3 F Ag 4 F Ag 5 F Ag 6
Mean Mean Mean Mean Mean Mean Mean
Subtype A anti sera 0.84 0.74 1.05 1.15 1.07 1.05 0.46
Subtype B anti sera 0.23 0.22 0.26 0.42 0.35 0.25 0.12
Subtype C anti sera 1.67 1.6 2.03 2.2 2.05 1.58 0.17
Relative antigenicities were calculated as percentages of the highest recording 
(antigen 4) with subtype A and B antisera these are shown in Tables 20-21. 
Table 22 shows amino acid homologies for each F antigen between subtypes A, 
B and C.
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Table 20. Relative antigenicity of F antigens 1, 2, 3, 5 and 6 to antigen 4 with 
subtype A antiserum
F Ag 1 F Ag 2 F Ag 3 F Ag 4 F Ag 5 F Ag 6
Mean Mean Mean Mean Mean Mean
Subtype A antisera 0.85 0.74 1.05 1.15 1.07 1.05
Relative % toAg4 74 67 92 100 93 91
Table 21. Relative antigenicity and of F antigens 1, 2, 3, 5 and 6 to antigen 4 
with subtype B antiserum
FAg
1
FAg 2 FAg 3 F Ag 4 FAg 5 FAg 6
Mean Mean Mean Mean Mean Mean
Subtype B antisera 0.23 0.22 0.26 0.42 0.35 0.25
Relative % toAg4 55 52 61 100 83 60
Table 22. Amino acid homologies of F antigens, between Subtypes A, B and C
Subtype A F antigen 1 2 3 4 5 6
% amino acid homology with Subtype B 98 65 96 91 90 46
% amino acid homology with Subtype C 87 85 87 84 •78 14
At this time, F antigens were sent to Biochek, ltd (Hounslow, UK) for commercial 
APV ELISA analysis. Initial testing produced desired results but when further 
tested against SPF serum from 80wk old chickens all produced very high 
background absorbances. Similar testing of the serum in Liverpool produced the 
similar high absorbencies when compared to absorbencies of SPF serum from 12 
wk old chickens. Moreover, absorbencies were higher than those for APV 
positive serum against three F antigens, namely 1, 2 and 6 as show in Table 23.
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Figure 88. APV ELISA of F antigens and an APV whole virus control 
(virus Ag). SPF 80wk serum gives high background.
Table 23. Absorbencies at 492nm
F Ag 1 2 3 4 5 6 virus Ag
APV pes serum 1 6 1.7 1 1 1 1.3 0.6
SPF serum (12wk) 0.05 0.08 0.03 0.03 0.03 0.03 0.04
SPF serum (80wk) 1.9 1.8 0.8 0.7 1 1.5 0.2
To determine whether unwanted, interactions between specific E.coli antibody 
and E coli antigen in the antigen preparations were the cause, the SPF (80wk) 
serum was pre-adsorbed using an E.coli extract. APV positive and SPF 12 wk 
serum were also pre-adsorbed. The absorbed sera were assessed by AGP as 
shown in Figure 89. Subsequently adsorbed and non adsorbed sera were tested 
in an APV ELISA (Figure 90)
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A g a r ge l p re c ip ita t io n  te s t
N on  a d s o rb e d  s e ra  E.coli a d s o rb e d  s e ra
Serum: APV +, SPF 12wk and SPF 80wk 
Antigen: E .co li

















Figure 90. APV ELISA of F antigens and an APV whole virus control (virus Ag). E.coli 
adsorbed SPF 80wk (boxed) serum still gave high background.
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Table 24. Absorbencies at 492nm
F section 1 2 3 4 5 6 virus A g
non adsorbed SPF 80wk 1 .4 1 .8 0 .7 0 .7 1 .2 1 .3 0 .2
adsorbed 80wk 1 .3 1 .7 0 .9 0 .5 1 1 .2 0 .3
AGP removed all E.coli antibodies from SPF 12 wk and 80wk serum and partially 
removed them from APV positive serum. However, the comparative ELISA using 
F antigens and adsorbed and non adsorbed sera showed no improvements to 
background absorbances (Table 24) with SPF 80wk serum. In addition, high 
background was observed using the Liverpool developed whole virus antigen. It 
was considered that APV antibodies might be present in SPF 80wk serum and
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therefore an IP staining test was carried out (Figure 91). IP staining suggested 
that no APV antibodies were present in SPF serum because only APV positive 
control serum gave a positive reaction (Figure 91).
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Figure 91. IP staining of uninfected and APV infected vero cell sheets using three 
different sera (i) APV positive serum (ii) SPF serum fro 12 week old chickens and (iii) SPF 
serum from 80 week old chickens.
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6.9 Results part 4: Virus neutralization
6.9.1 Standard neutralization test
Ninety six-well plates were organized as shown in Table 25. At day 4 pi, CPE (+ 
Table 25) could be seen in all positive controls and at log2 13-14 dilutions for 
subtype A and B antisera. For subtype C antisera CPE was observed at log2 7- 
14 dilutions. Therefore, neutralization end points were as follows: (i) log2 13 for 
subtype A and B antisera and (ii) log2 7 for subtype C antisera.
Table 26. Standard virus neutralization test using a ASH-G deletion recombinant 








A + + -
A + + + -
B - - - - - - - - + + + -
B + + + -
C - - + + + + + + + + + -
C - - + + + + + + + + + -
These end point dilutions provided the basis for the range of dilutions used in 
subsequent tests (6.8.2) and indicated partial neutralization of a ASH-G subtype 
A APV with subtype C chicken antisera.
6.9.2 Novel neutralization test
Adsorption of the same Subtype A, B and C antiserum (above) with each of the 
antigenic F sections resulted in a reduction of neutralizing endpoints with subtype 
A antiserum from log2 13 (control value) to log2 10 with F antigen 5 and to log2 11
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with F antigen 4 (Table 26),indicating that neutralizing antibodies in the serum 
had been themselves neutralized by the those F sections. No change in 
neutralizing endpoints was observed with F antigens 1, 2, 3 or 6. A reduction in 
neutralizing endpoints was observed with subtype B anti sera to log2 12 with 
antigen 5 and antigen 4 but again no change was observed with F antigens 1, 2, 
3 or 6 (Table 27). No reductions in neutralizing endpoints was observed with 
subtype C anti sera with any F antigen (Table 28)
Table 26. Neutralization of ASH-G deletion recombinant subtype A APV with 
subtype A antisera, following adsorption with subtype A F antigens
log2 dilutions
Fantiqen 7 8 9 10 11 12 13 14
1 - - - - - - + +
1 - - - - - - + +
1 - - - - - + + +
1 - - - - - - + +
2 - - - - - - + +
2 - - - - - - + +
2 - - - - - - + +
2 - - - - - - + +
3 - - - - - - + +
3 - - - - - - + +
3 - - - - - - + +
3 - - - - - - + +
4 - - - - + + + +
4 - - - - + + + +
4 - - - - + + + +
4 - - - - + + + +
5 - - - + + + + +
5 - - - + + + + +
5 - - - + + + + +
5 - - - + + + + +
6 - - - - - - + +
6 - - - - - - - +
6 - - - - - - + +
6 - - - - - - - +
control - - - - - - + +
control - - - - - - + +
control - - - - - - + +
control - - - - - - + +
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Table 27. Neutralization of ASH-G deletion recombinant subtype A  APV with
subtype B antisera, following adsorption with subtype A F antigens
log2 dilutions
Fantiqen 7 8 9 10 11 12 13 14
1 - - - - - - + +
1 - - - - - - + +
1 - - - - - - - +
1 - - - - - - + +
2 - - - - - - + +
2 - - - - - - + +
2 - - - - - - - +
2 - - - - - - + +
3 - - - - - - + +
3 - - - - - - + +
3 - - - - - - + +
3 - - - - - - + +
4 - - - - - + + +
4 - - - - - + + +
4 - - - - - + + +
4 - - - - - - + +
5 - - - - - + + +
5 - - - - - + + +
5 - - - - - + + +
5 - - - - - + + +
6 - - - - - - + +
6 - - - - - - + +
6 - - - - - - + +
6 - - - - - - + +
control - - - - - - + +
control - - - - - - + +
control - - - - - - + +
control - - - - - - + +
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Table 28. Neutralization of ASH-G deletion recombinant subtype A  APV with
subtype C antisera, following adsorption with subtype A F antigens
log2 dilutions
Fantigen 5 6 7 8 9 10 11 12
1 - - + + + + + +
1 - - + + + + + +
1 - - + + + + + +
1 - - - + + + + +
2 - - - + + + + +
2 - - + + + + + +
2 - - + - + + + +
2 - - + + + + + +
3 - - + + + + + +
3 - - + + + + + +
3 - - + + + + + +
3 - - + + + + + +
4 - - - + + + + +
4 - - + + + + + +
4 - - + - + + + +
4 - - + + + + + +
5 - - + + + + + +
5 - - + + + + + +
5 - - + + + + + +
5 - - - + + + + +
6 - - + + + + + +
6 - - + + + + + +
6 - - - + + + + +
6 - - + + + + + +
control - - + + + + + +
control - - - + + + + +
control - - + + + + + +
control - - + + + + + +
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6.10 Discussion
Six regions of the F protein were successfully amplified, cloned, his tagged and 
expressed from p-ET30 as recombinant proteins in E.coli cells, so justifying the 
decision to divide it into six smaller sections. Each one yielded detectable levels 
of protein in his tag ELISAs and Western blots with the exception of F section 2, 
which was only detected as a weak signal by his tag ELISA. However, only F 
sections 2, 6 and 5 were detectable by SDS-PAGE, moreover SDS-PAGE 
suggested that F section 2 was expressed and his tag purified more efficiently 
than other sections. This posed the question as to how it had it been purified 
using its his tag but not detected using the his tag monoclonal antibody. It was 
hypothesisied that following expression, one or more histidines may have been 
lost. Whilst not interfering with purification, this might have sufficiently altered the 
tag to leave it unrecognized by the monoclonal antibody. Another suggestion 
might be that the amino acid combinations in section 2 were able to bind to nickel 
ions in a similar fashion to a His tag. Although SDS-PAGE analysis 
demonstrated that F-sections 1, 3 and 4 had been purified at lower levels than 2, 
5 and 6, their performances in APV ELISAs were similar. This might indicate that 
antibodies produced during infection by a natural route preferentially recognized 
these sections of the F protein. However quantification of each section would be 
required before such an assertion could be fully justified.
All six antigens tested in ELISAs using subtypes A, B and C APV-positive sera or 
SPF serum from 12 week old chickens, gave higher absorbances than those 
using the Liverpool subtype A whole virus as antigen and especially so in ELISAs 
using subtype C antiserum. Several ELISAs have been developed by others 
using recombinant subtype C proteins, namely the SH, N and M proteins [2, 3,
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59, 63], all of which have been documented as subtype-specific with the 
exception of a chemically synthesized N protein section of 20 amino acids in 
length [59]. Alvarez et a.I [59] reported an 85% amino acid homology for this 
section between all subtypes which probably explained its cross reaction.
Comparison of each F section with equivalent sections in subtype B and C APVs 
showed amino acid identities to range between 78% and 98% with the exception 
of sections 2 and 6. These equate to 65% for section 2 with A and B, 46% for 
section 6 with A and B but only 14% for section 6 with A and C. These 
percentages made section 6 somewhat of an anomaly with respect to its cross 
reactivity with C antiserum and suggest the binding may be non-specific 
However, it was not recognised similarly by monospecific IBV antiserum so it 
seems likely that this small protein might share common antigenicity with some 
other region of APV or a host protein upregulated during APV infection.
Relative ELISA absorbancies with subtype B antiserum showed a reduction for 
antigen 3 from 92% to 61% and from 91 to 60% with antigen 6. This might have 
been expected for antigen 6 with which it shares only a 46% amino acid identity. 
However the identity for antigen 3 is 96% and suggests that those small numbers 
of amino acid changes between A and B subtypes are antigenically important. 
Relative ELISA absorbances for subtype C antiserum were not calculated 
because such absorbance readings were so high that they were beyond the 
linear range and probably also taking the ELISA into a plateau region.
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In ELISAs using SPF serum from 80 week old chickens high background was 
observed with F antigens and to some degree the Liverpool developed whole 
virus antigen. This was unexpected but it should be borne in mind that it was a 
test serum maintained by a commercial ELISA company precisely because only 
highly optimized antigens and purified antigens have proved capable of yielding 
acceptably low absorbances. Furthermore, the history of such old birds can 
never be totally known so it seems unnecessary to speculate about these 
apparently anomalous findings.
Based on the results in this chapter, F antigens 1 -5  and in particular 4 appear to 
be useful diagnostic ELISA antigens for detection of antibodies to all APV 
subtypes in the sera of infected birds (but unresolved concerns with F antigen 6 
would eliminate it for recommendation). However the hyperimmune sera tested 
would have broader specificity than convalescent sera so caution in need in 
drawing definite conclusions. That said, broader specificity of hyperimmune 
subtype C antiserum did not result in cross reactivity with subtype A whole virus 
antigen.
Following adsorption of sera with each F antigen, neutralization tests identified 
two regions within the F protein that removed that neutralized neutralizing 
antibodies, F antigen 4 (amino acids 220 -  310 of full length F protein) and F 
antigen 5 (amino acids 336 -  479 of the full length F protein). These antigens 
reduced the neutralizing end point dilutions of homologous subtype A antiserum 
by 2 and 3 log2 dilutions respectively and by 1 log2 dilution with subtype B 
antiserum. No reductions were observed using F antigens 1, 2, 3 and 6. 
Interestingly, Lounsbach et al. [221] and Werle et al. [188] using F protein
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fragments of RSV expressed in E.coli and baculovirus respectively demonstrated 
neutralizing epitopes in amino acids 190 -  289 of the full length RSV F protein, a 
region that overlaps with the region chosen for APV F antigen 4 here. Other 
regions of the APV ectodomain did not neutralize and this suggests that the 
equivalent regions of the F proteins in the two related viruses may continue to 
share similar functions.
In conclusion, problems expressing hydrophobic membrane proteins in E.coli 
have been documented and it has been suggested that they are most likely due 
to association of the protein with or incorporation into vital membrane systems 
[223], The work described in this chapter promotes a novel approach for 
addressing these problems. Use of this approach enabled expression and 
purification of five F antigens that in these studies appeared to be useful in 
ELISAs for the detection of subtypes A, B and C antibodies. Furthermore F 
protein fragments enabled the identification of two regions targeted by 
neutralizing antibodies, one of which is also within an equivalent region identified 
for RSV F protein [188, 221]. This is the first report identifying regions within 




This chapter reviews the results of experimental work undertaken in this thesis 
and gives suggestions for possible future work.
ELISA is the most commonly used serological method for detection of antibodies 
to viruses, including APV [23, 135, 137, 138, 152, 168, 169]. ELISAs can be 
performed rapidly, require only tiny volumes of serum and can be automated, 
enabling many sera to be examined quickly. ELISA is therefore the method of 
choice for monitoring seroconversion of chickens and turkeys to APV field or 
vaccine virus. Many commercial and in-house ELISAs have been developed for 
APV [10, 135-138, 170, 171], Traditionally, ELISAs using antigens prepared 
from virus-infected cell cultures, generally work well but have some drawbacks. 
Antigen preparations generated in this way require virus that can easily be 
cultured in vitro but test specificities can be reduced by the presence of 
contaminating cellular proteins. Furthermore, Eterradossi et al.. [172] showed 
that for APV, a subtype A antigen detected subtype A antibodies with greater 
sensitivity than did a subtype B antigen and vice versa. These problems have 
been obviated to some extent by expression of recombinant viral proteins [1-7, 
63] which allowed individual epitopes to be used and have proven to be sensitive 
and specific antigens. These can be purified through the use of specifically 
designed affinity tags placed at the N or C termini of the protein.
In this thesis, three APV subtype A proteins, the nucleocapsid (N), the 
phosphoprotein (P) and the highly antigenic fusion (F) protein were selected for
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expression in an E.coli system. They were purified through Ni2+ capture of their 
fused his tags. Green fluorescent protein (GFP) was also used throughout the 
work as a visual reporter of gene expression and subsequent purification.
Many commercial plasmids are available for expressing his tag recombinant 
proteins in a variety of systems. However, certain APV genes only clone into 
bacteria with very low efficiency. In particular, using high copy plasmids under 
typical conditions, resultant purified DNA can be found to contain significant 
mutations in the APV insert or lack it entirely. In other situations the bacteria are 
killed by what are assumed to be toxicity effects (C. J. Naylor., D. R. Kapczynski, 
personal communications). A pUC18 derivative developed by Naylor et al. [72] 
had been modified to minimise such effects. It was decided to make modifications 
to this to allow recombinant protein expression in an E.coli system. Changes 
included adding a six his tag stop region to facilitate purification and a T7 
termination sequence. This approach was effective and 90% of screened 
colonies contained desired inserts. Moreover, these cloning strategies were 
flexible and useful throughout the thesis. Cloning characteristics of p18smahis 
were comparable with its progenitor plasmid in that it readily accepted APV 
genes. Nonetheless many resultant clones containing desired inserts had two or 
more point mutations or deletions, emphasizing the importance of complete 
sequence analysis.
Expression of GFP from p18smahis was demonstrated, although, expression of 
N, P and F was more complicated. Expression of F protein was indicated by a 
57KDa band (close to the published 59KDa size) [16] by SDS-PAGE and western 
blot, in a cell lysate of induced E.coli containing the F construct. However, 
purifications yielded no protein. A similar situation occurred when expressing N
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and P. It was considered that low levels of expression from p18smahis were 
responsible and needed improvement. A change of ribosomal binding site 
sequence and its position relative to the downstream transcribed gene was 
considered as these were known to affect translation [214, 215]. However, as 
these changes might have only marginally improved expression and would have 
been time consuming to implement, a new vector was selected. In addition 
because GFP can be detected by simple UV analysis, GFP-fusion proteins were 
made to allow tracking during induction and purification.
Cloning of APV genes and the GFP gene into commercial E.coli expression 
vector p-ET30 was relatively problem-free. However, it is important to note that 
successful clones were only identified when antibiotic selection could be used to 
eliminate original template plasmids and select newly developed p-ET30 
plasmids from ligation mixtures. Therefore, if clones developed in Chapter 4 
(ampicillin resistant) had not been available, p-ET30 (kanamycin resistant) 
construct development may well have been less efficient.
Expression levels from p-ET30 were significantly improved compared to 
expression levels from p18smahis. This was best demonstrated by UV 
microscopy of E.coli cells containing the GFP construct. Increasing fluorescence 
was observed over a three hour induction period and cells appeared structurally 
sound. Some concern was raised when APV-GFP constructs were analysed in 
the same way. Although an increase in fluorescent intensity was observed with 
these constructs, fluorescence was diffused and cells appeared to be losing 
structural integrity, suggesting problems with APV protein toxicity to E.coli. In
light of these observations, toxicity could have contributed to the minimal
?
expression of APV proteins experienced during the work documented in Chapter
4.
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Purifications of APV-GFP fusion proteins were not successful, although cell 
lysates were fluorescent. It was considered that concealment of his tag regions 
within the proteins themselves was responsible for the lack of capture on Ni2+ 
charged Ni-NTA matrices, a problem identified when purifying N and P proteins 
that were not fused with GFP. Those proteins were purified from a native 
extraction but only after they had been linearised by treatment with 8M urea. 
This confirmed N terminal his tag concealment in native N and P protein. 
Unfortunately, although this procedure permitted purification, it rendered them 
unsuitable as APV ELISA antigen candidates due to destruction of 
conformational epitopes.. The dual effects of both his tag concealment and 
protein toxicity led to the consideration that expression of small regions of 
individual proteins designed to exclude hydrophobic regions could prove less 
toxic to E.coli and reduce concealment problems.
Prior to expression of regions of the APV FO protein in E.coli, a baculovirus 
expression system was explored. Although E.coli expression has the ability to 
produce antigens rapidly, the main advantage of the baculovirus system is that 
recombinant proteins expressed in insect cells produce many of the post 
translational modifications of mammalian cells, including phosphorylation and N- 
linked and O-linked glycosylation [224] and are therefore capable of producing 
biologically active proteins. Plaque purified GFP and F2 recombinant 
baculoviruses were developed and a satisfactory level of GFP expression was 
demonstrated by UV microscopy. However, F2 protein expression was 
confirmed only after purification from insoluble material, which made it unsuitable 
as an ELISA antigen due to the destruction of conformational epitopes. 
Ultimately this meant that new baculovirus recombinants were required. As 
discussed above, this meant that lengthy procedures were required. In contrast,
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developments in E.coli expression would produce greater numbers of test 
antigens quicker and was therefore favoured.
As already discussed previous attempts to express and purify chosen APV 
proteins in E.coli had indicated problems of toxicity and/or concealment of his tag 
regions within the proteins being purified. It has been suggested that expression 
of hydrophobic membrane proteins have toxic effects due to their association with 
or incorporation into vital membrane systems [223]. A novel approach designed 
to exclude hydrophobic regions in the APV FO protein was to express six small 
regions as individual proteins. Exclusion of hydrophobic regions was designed to 
eliminate their incorporation into or association with membrane systems and 
ensuing toxicity effects. Moreover, their reduced size would reduce the chances 
of his tag concealment. Protein expression and purification improved significantly 
following these adaptations as each F section was expressed and his tag purified 
up to three hours post induction as native protein. SDS-PAGE analysis indicated 
differences in the amount of protein purified for each antigen and showed F 
antigens 1, 3 and 4 to be at undetectable levels. However, these three antigens 
were detected by western blot and antigenicity in APV ELISAs were very similar 
for all F antigens. These results appear to identify F antigens 1, 3 and 4 as 
regions of the FO protein with greater immunigenicity than regions 2, 5 and 6, 
although quantification would be required to accurately determine relative 
sensitivity.
All six antigens tested in ELISAs using subtypes A, B and C APV-positive sera or 
SPF serum from 12 week old chickens, gave higher absorbances than those 
using the Liverpool subtype A whole virus as antigen and especially so in ELISAs 
using subtype C antiserum. Prior to the work described in this thesis, only one
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other antigen has been reported as useful for detection of subtype A, B and C 
antibodies. This was a chemically synthesized N protein fragment of 20 amino 
acids in length from subtype C [59], Alvarez et al. [59] reported an 85% amino 
acid homology for this section between all subtypes which probably explained its 
cross reactivity. Comparison of each F section developed here with equivalent 
sections in subtype B and C APVs showed amino acid identities to range 
between 84% and 98 % with the exception of sections 2 and 6. These two 
equated to 65% for section 2 with A and B, 46% for section 6 with A and B but 
only 14% for section 6 with A and C. These percentages made section 6 
somewhat of an anomaly with respect to its cross reactivity with C antiserum and 
suggested that the binding may be non specific. However, like the other sections 
it was not recognised by monospecific IBV antiserum so it seems possible that 
this small protein might share common antigenicity with some other region of 
APV or a host protein up regulated during APV infection.
Relative ELISA absorbancies with subtype B antiserum showed a reduction for 
antigen 3 from 92% to 61% and from 91 to 60% with antigen 6. This might have 
been expected for antigen 6 with which it shares only a 46% amino acid identity. 
However the identity for antigen 3 is 96% and suggests that those small numbers 
of amino acid changes between A and B subtypes are antigenically important. 
Relative ELISA absorbances for subtype C antiserum were not calculated 
because such absorbance readings were so high that they were beyond the 
linear range and probably also taking the ELISA into a plateau region.
Commercial testing of F antigens in APV ELISAs initially produced desired results 
however when tested against SPF serum from 80week old chickens high
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background was observed. Testing of the serum in Liverpool produced the 
similar high absorbencies with F antigens and to some degree with the developed 
whole virus antigen. Although this was unexpected, it is important to note that it 
was a commercial test serum maintained precisely because only highly optimized 
antigens have proved capable of yielding acceptably low absorbances. 
Furthermore, the nature of sera from birds of such an age can never be totally 
known so it seems unnecessary to speculate about these apparently anomalous 
findings. Hence, F antigens 1 - 5 and in particular 4 appear to be promising 
diagnostic ELISA antigens for detection of antibodies to all APV subtypes in the 
sera of infected birds but unresolved concerns with F antigen 6 would eliminate it 
for recommendation. The hyperimmune sera tested are likely to have broader 
specificity than convalescent sera so caution is needed in drawing definite 
conclusions. That said, broader specificity of hyperimmune subtype C antiserum 
did not result in cross reactivity with subtype A whole virus antigen. It would be 
useful therefore to test F antigens against both hyperimmune and convalescent 
antisera of all subtypes to address these issues. Quantification of F antigens 
would also benefit the accurate determination of relative sensitivities.
When neutralization tests were conducted in cell culture following adsorption of 
sera with each F antigen, two regions were identified within the F protein that 
neutralized the activity of the antibodies, F antigen 4 (amino acids 220 -  310 of 
full length F protein) and F antigen 5 (amino acids 336 -  479 of the full length F 
protein). These antigens reduced the neutralizing end point dilutions of 
homologous subtype A antiserum by 2 and 3 log2 dilutions respectively and by 1 
log2 dilution with subtype B antiserum. No reductions were observed using F 
antigens 1, 2, 3 or 6. Interestingly, Lounsbach et al. [221] and Werle et al. [188]
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using F protein fragments of RSV expressed in E.coli and baculovirus 
respectively demonstrated neutralizing epitopes in amino acids 190 -  289 of the 
full length RSV F protein, a region that overlaps with the region chosen for APV F 
antigen 4 here. Other regions of the APV ectodomain did not neutralize and this 
suggests that the equivalent regions of the F proteins in the 2 related viruses may 
continue to share similar functions.
Significant progress was made throughout this work to express and his tag purify 
APV subtype A proteins for use as ELISA antigens. During development 
indications of APV protein toxicity to E.coli, as early as 1 hour post induction and 
N and C terminal concealment of his tag regions were demonstrated. In contrast, 
APV subtype C recombinant N protein was successfully purified 4 hours post 
induction and with no report of concealment of N-terminal his tag regions when 
expressed in and purified from the same strain of E.coli cells by Gulati et al.. [3], 
This demonstrates considerable differences between subtype A and C 
nucleocapsid proteins when expressed in E.coli, which might be partly explained 
by the relatively low amino acid identity of 69% [55] between the US subtype C 
and the European subtype A and B nucleocapsid proteins.
Problems expressing and purifying subtype A proteins were overcome by novel 
expression of regions of the full length F protein. F antigens 1-5 in these studies 
appeared to be useful in ELISAs for the detection of subtypes A, B and C 
antibodies, a finding that agrees with work of Tarpy et al. [176] who inadvertently 
identified the fusion protein as a potential antigen candidate for such purposes. 
Only one other universal APV ELISA antigen has previously been reported [59],
187
In addition to their use in ELISAs, F protein fragments enabled the identification 
of two regions targeted by neutralizing antibodies, one of which is within an 
equivalent region identified for the RSV F protein [188, 221] suggesting that the 
equivalent regions of the F proteins in the two related viruses share similar 
functions. This is the first report identifying regions within the subtype A F 
protein likely to be important in the protective immune response and it is 
reasonable to infer that these same regions may stimulate or enhance a 
protective immune response, either in their present form or after further narrowing 
down to constituent epitopes. Shorter F sections from within these regions could 
be used in identical tests with a view to identifying epitopes recognized by the 
neutralizing antibodies. These would be conveniently made by chemical 
synthesis and this technique would further allow convenient modification of 
individual amino acids to show their individual importance.
The importance of these epitopes might be further extended by introducing 
mutated epitopes into the ASH-G deletion virus using our reverse genetics 
system. If the mutation did not prevent virus rescue, absence of neutralization 
would be further evidence of the importance of the epitope. In addition it would 
be interesting to compare the protective capacity of such a virus with one not 
containing epitope modification.
Incorporation of F sections 4 and 5 as additions to the full length genome of 
recombinant APV vaccine candidates is also a possibility. Such rescued 
recombinants might have the potential to increase the stimulation of neutralizing 
antibody production due to the presence of increased F epitopes involved in virus 
neutralization. It is likely that the F section(s) would be positioned between M2
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• 20(jl dATP (100mM)
• 20|jl dCTP (100mM)
• 20pl dGTP (100mM)
• 20jjI dTTP (100mM)
• 120|jl double processed tissue culture water (Sigma W3500)
Miniprep TENS buffer
• 0.37g EDTA
• 5g SDS (Sigma L3771)
• NaOH
• 0.88g Tris HCL (sigma T-3253)
• 0.53g Tris base (sigma T-6066)
Agarose gel electrophoresis 1.4% (Agarose and buffer was adjusted 
accordingly to achieve a desired %) NB 10x TBE buffer was diluted 10 fold with 
distilled water for use. Gels were prepared in a conical flask.
• 0.5g Agarose powder (Promega v-3121)
• 35ml 1x TBE buffer (Invitrogen 10x TBE 15581-044)
• Swirl mix then heat for 40 seconds microwave power setting 100%
• Swirl cool under cold tap
• Pour into gel tank
• Allow the gel to set for « 15 mins then overlay with TBE buffer until buffer 
level is just below the surface of the tank
Molecular weight standards.
• 50pl Hind A (invitrogen, UK)
• 25pl <p x174 (invitrogen UK)
• 25|jl DNA load buffer (see below)
• 2pl / run was used
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DNA load buffer
• 0.25% Bromophenol blue (sigma B-0126)
• 30% Ficoll type 400 (Sigma catalogue number F4375)
• In a total volume of 10ml distilled water.
Ethidium bromide (sigma E-1510)
• 0.05% in 250ml distilled water
Exo / Sap
• 15 microlitres PCR product
• 1 microlitre SAP
• 0.15 microlitres Exo 1
• PCR Block 37°C for 30 minutes, 80°C for 10 minutes, hold at 4°C 
Exo
• 0.5pl / 50pl PCR product
• PCR Block 37°C for 30 minutes, 80°C for 10 minutes, hold at 4°C
SDS-PAGE recipes
Separating gels 10%
• 12.5ml of Acrylamide stock solution (40%) 37:1 (sigma #A6050)
• 0.5 ml of 10% SDS (Sigma L3771) in distilled water.
• 6.25ml of separating gel buffer (see below)
• 30.5ml of distilled water
• 25 pi of TEMED (sigma T-7024)
• 250pl of 10% APS made fresh each time (sigma L3771)
Stacking gels 5%
• 2.5 ml of Acrylamide stock solution (40%) 37:1
• 0.2 ml of 10% SDS in distilled water.
• 5 ml of stacking gel buffer (see below)
• 12.3 ml of distilled water
• 20 pi of TEMED
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100jal of 10% APS
Ammonium persulphate 10%
• 0.1g APS made up to 1ml in distilled water.
Electrode running buffer (concentrate)
• 30.3 g Tris base (sigma T-6066)
• g Glycine (sigma G-8898)
• Dissolved in distilled water and made up to 11tr (store at -4°c keep for 1 
month.
• For use, 200ml of concentrate plus 20ml of 10% SDS, make up to 2ltr.
Stacking gel buffer 0.5M pH 6.8
• 0.283g Tris base (sigma T-6066)
• 7.51 g Tris HCL (sigma T-3253)
• Dissolved in distilled water and made up to 100ml (store at -4°c keep for 
1 month.
Separating gel buffer 3M pH 8.8
• 30.21g Tris base (sigma T-6066)
• 7.96 g Tris HCL (sigma T-3253)
• Dissolved in distilled water and made up to 100ml (store at -4°c keep for 
1 month.
Protein Sample Buffers 
None reducing
• 10ml Stacking gel buffer
• 0.8g SDS
• 4ml Glycerol (sigma G-8773)
• 0.4mg bromophenol blue (sigma B-0126)
• Made up to 20ml with distilled water. Store room temperature.
Reducing
Same as above but add 1ml 2ME (sigma M-3148)
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Gel staining
Gels were stained overnight and de-stained as desired.
Stain
• 1g Coomassie blue (BDH G-250)
• 250ml Methanol
• 35ml Acetic acid (glacial)
• 215ml distilled water
• Filter and store at room temp
De-stain
• 100ml Methanol
• 35ml Acetic acid (glacial)
• 365ml distilled water
• Store at room temp
Gel preparation
• Separating gels were prepared in a buchner flask with the exception of 
the 10% APS solution
• Solution was de-gassed under reduced pressure for at least 10 mins. This 
reduced the risk of oxygen inhibition of acrylamide polymerisation.
• 10% APS was added to the de-gassed solution and then poured 
immediately between the glass plates.
• Gel solution was gently overlaid with water using a syringe.
• Gel was allowed to set.
• Stacking gel was prepared in the same way.
• Water was removed from the separating gel and a 24 well comb partially 
insert.
• The stacking gel was poured and the comb completely inserted.
• Gel was allowed to set.
• Comb was removed.
• Electrode running buffer applied to both sections of the gel apparatus.
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Protein Sample preparation/loading
• Samples were mixed 50:50 with sample buffer, 50p.l total volume.
• These were boiled for 5mins.
• Allowed to cool
• Centrifuged at 13.2 x 10OOrpm for 30 seconds
• 40pJ was loaded into the formed wells.
• Gels were run at either 75 mAmps (one gel) or 145mAmps (two gels) for 
1 hr 10mins
Molecular weight markers
Colour burst markers (Sigma C-4105) needed no preparation prior to loading. 
10nl was used per run.
Wide molecular weight markers (Sigma M-4038) were prepared and used 
according to Sigma recommended protocols
PBS 10x stock solution
• 80g sodium chloride (BDH 10241)
• 2g potassium chloride (BDH 10198)
• 11 5g Na2HP04 (BDH 10249)
• 2g KH2P04 (BDH 10203)
• Made up to 1 litre with distilled water
DAB substrate buffer (0.1 M phosphate pH 6.0)
• 2.12g Na2HP04 12H20
• 14.67g NaH2P04 2H20
• 0.5ml Tween8o
• Made up to 1 litre with distilled water 
DAB solution
• One DAB tablet (Sigma, D5905)
• 15ml of DAB substrate buffer
2 1 3
12pl 30% H20 2(H-1009)
Electrode transfer buffers
Anode 1 Anode 2 Cathode
pH 10.4 10.4 7.6
Tris base (Sigma T8524) 18.5 1.51g
6 amino hexonoic acid (Sigma A2504) 2.6g
Methanol 100ml 100ml
100ml




• 0.75g Na2C03 0.15g
• 1.47g NaHC03 0.29g
Make up to volume with distilled water. Store for 1 week at 0-4°C 




1.95g NaH2P04 (2H20) 0.78g
Tween 80 2.5ml 1ml
Tween 80 to be added last just before storing. Dilute 1 in 2 prior to use.
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Orthophenylene diamine (OPD) Substrate
0.2M Disodium hydrogen phosphate ( Na?HPQ4) anhydrous
• 28.4g Na2HP04 / Litre H20 
0.1M Citric Acid
• 21.01 g Citric acid ( C6H8O7.H20) / Litre
0.2M disodium hydrogen phosphate ~200ml added to 0.1 M citric acid (243ml) 
with stirring until the pH reaches 5.0.
Made up to 1 litre with deionised water.
0.4g of OPD, (20 tablets of 20mg -  Sigma p5412) added, mixed well in the dark 
and aliquoted into 12 or 24 ml amounts.
Stored at -20°C till required. Prior to use it is bought to room temperature (in the 
dark) and 20pl of 30% H20 2 (Sigma, UK H-1009) is added per 24ml.
2.5 M H2S 0 4
• 245g/Litre distilled water or 134ml/Litre distilled water 
Gram staining
• Place 0.5pl of lysate, mixed with an equal volume of distilled water onto a 
microscope slide, air dry and fix over a Bunsen flame.
• Flood Heat-fixed smear with crystal violet and leave for 1 minute
• Rinse with tap water
• Flood Heat-fixed smear with grams iodine and leave for 1 minute
• Rinse briefly with tap water
• Add acetone for 2-3 seconds
• Rinse immediately with tap water
• Add safranin for 30 seconds
• Rinse and blot dry
• Apply small drop of immersion oil and examine using an oil-immersion 
objective under light microscopy.
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Tissue culture medium
• 500ml Dulbecco’s modified eagles medium (sigma D6546)
• 5ml 200mM L-Glutamine (sigma G7513)
• 2ml Pen and Strep solution (see pen/strep below)
• 1ml Fungizone (Invitrogen 15290-026)
Tissue culture medium + serum
• Same as above plus 5% foetal bovine serum
Pen/Strep
• 600mg crystapen (Britannia pharmaceuticals ltd)
• 1g streptomycin (sigma S-9137)
• Made up in 40ml of tissue culture water (sigma W3500)
Ni-NTA elution buffer
• 0.61 g Na2HP04 anhydrous
• 0.11g NaH2P04 (2H20)
• 1.75g NaCI
• 2.1g imidazole (sigma I0250)
• Made up in 100ml of tissue culture water (sigma W3500)
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